Quarterlytics / Healthcare / Medical - Care Facilities / The Pennant Group, Inc.

The Pennant Group, Inc.

pntg · NASDAQ Healthcare
Claim this profile
Ticker pntg
Exchange NASDAQ
Sector Healthcare
Industry Medical - Care Facilities
Employees 7000
← All annual reports
FY2021 Annual Report · The Pennant Group, Inc.
Sign in to download
Loading PDF…
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_________________________________________________________________________________________________________________________________

FORM 10-K 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the fiscal year ended December 31, 2021. 

For the transition period from                      to                     .

Commission file number: 001-38900
_________________________________________________________

THE PENNANT GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

83-3349931
(I.R.S. Employer
Identification No.)

1675 East Riverside Drive, Suite 150, Eagle, ID 83616
(Address of Principal Executive Offices and Zip Code)
(208) 506-6100
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

_________________________________________________________________________________________________________________________________

Title of each class
Common Stock, par value $0.001 per share

Trading Symbol(s)
PNTG

Name of each exchange on which registered
Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act, or the Act.  ☐Yes ☒No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  ☐ Yes ☒ No

Indicate  by  check  mark  whether  the  registrant  (1)  has  filed  all  reports  required  to  be  filed  by  Section  13  or  15(d)  of  the  Securities  Exchange  Act  of  1934  during  the  preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of February 28, 2022, 28,529,556 shares of the registrant’s common stock were outstanding. The aggregate market value of the shares of common stock held by non-affiliates of
the registrant on the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2021) was approximately $1,143,039,000 based upon the closing
price of the common stock on such date. For purposes of this calculation, the registrant has excluded the market value of all common stock beneficially owned by all executive
registrant.
officers 

directors 

and 

the 

of 

Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement on Schedule 14A for the Registrant's

2022 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.

Note on Incorporation by Reference

THE PENNANT GROUP, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021
TABLE OF CONTENTS

Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures

Part I.

Part II.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
[Reserved]
Management's Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Part III.

Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters
Certain Relationships and Related Transactions and Director Independence
Principal Accountant Fees and Services

Exhibits, Financial Statements and Schedules
Form 10-K Summary

Part IV.

2
17
26
26
27
27

27
28
28
44
44
44
44
46
46

47
47
47
47
47

48
50

Item 1.
Item1A.
Item 1B.
Item 2.
Item 3.
Item 4.

Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.

Item 10.
Item 11.
Item 12.
Item 13.
Item 14.

Item 15.
Item 16.

Signatures

Table of Contents

Cautionary Note Regarding Forward-Looking Statements

Our reports, filings and other public announcements, including this Annual Report on Form 10-K may from time to time contain statements that do not
directly or exclusively relate to historical facts. Such statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform
Act  of  1995,  and  typically  include,  but  are  not  limited  to,  our  expected  future  financial  position,  results  of  operations,  cash  flows,  financing  plans,  business
strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Forward-looking statements can often
be  identified  by  words  such  as  “anticipate,”  “expect,”  “intend,”  “plan,”  “predict,”  “believe,”  “seek,”  “estimate,”  “may,”  “will,”  “should,”  “would,”  “could,”
“potential,”  “continue,”  “ongoing,”  similar  expressions,  and  variations  or  negatives  of  these  words.  Additionally,  many  of  these  risks  and  uncertainties  are
currently amplified by and will continue to be amplified by, or in the future may be amplified by, continued outbreaks of SARS-CoV-2, the virus that causes the
disease COVID-19 (“COVID-19”). The developments with respect to COVID-19 and its impacts have occurred rapidly, and because of the unprecedented nature
of the COVID-19 pandemic we are unable to predict the extent and duration of the adverse financial impact of COVID-19 on our business, financial condition and
results  of  operations.  These  statements  are  subject  to  the  safe  harbors  created  under  the  Securities  Act  of  1933,  as  amended  (the  “Securities  Act”),  and  the
Securities  Exchange  Act  of  1934,  as  amended  (the  “Exchange  Act”).  These  statements  are  not  guarantees  of  future  performance  and  are  subject  to  risks,
uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-
looking statements as a result of various factors, some of which are listed in Part I, Item 1A., Risk Factors, of this Annual Report on Form 10-K for the year ended
December 31, 2021. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak
only as of the date of this Annual Report, and are based on our current expectations, estimates and projections about our industry and business, management's
beliefs,  and  certain  assumptions  made  by  us,  all  of  which  are  subject  to  change.  We  undertake  no  obligation  to  revise  or  update  publicly  any  forward-looking
statement for any reason, except as otherwise required by law.

As  used  in  this  Annual  Report  on  Form  10-K,  the  words,  “Pennant,”  “Company,”  “we,”  “our”  and  “us”  refer  to  The  Pennant  Group,  Inc.  and  its
consolidated  subsidiaries.  All  of  our  independent  operating  subsidiaries,  and  the  Service  Center  (defined  below)  are  operated  by  separate,  wholly-owned,
independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities,
as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report are not meant to imply, nor should they be construed as meaning, that The
Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Pennant Group, Inc.

The  Pennant  Group,  Inc.  is  a  holding  company  with  no  direct  operating  assets,  employees  or  revenues.  In  addition,  certain  of  our  wholly-owned
independent subsidiaries, collectively referred to as the “Service Center,” provide centralized accounting, payroll, human resources, information technology, legal,
risk management, compliance oversight and other centralized services to the other independent operating subsidiaries through contractual relationships with such
subsidiaries.

The address of our headquarters is 1675 East Riverside Drive, Suite 150, Eagle, ID 83616, and our telephone number is (208) 506-6100. Our corporate
website is located at www.pennantgroup.com. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual
Report on form 10-K.

1

 
Table of Contents

Item 1.    Business

Overview

Part I.

The  Pennant  Group,  Inc.  is  a  leading  provider  of  high-quality  healthcare  services  to  patients  or  residents  of  all  ages,  including  the  growing  senior
population, in the United States. Through our innovative operating model, we strive to be the provider-of-choice in the communities we serve. On October 1, 2019,
we completed a spin-off from The Ensign Group, Inc. (“Ensign”) (NASDAQ: ENSG), our former parent company, which transferred all of its home health and
hospice agencies and substantially all of its senior living businesses to us.

As  of  December  31,  2021,  we  operate  multiple  lines  of  business,  including  home  health,  hospice  and  senior  living,  throughout  Arizona,  California,
Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. We provide home health and hospice services
through 88 agencies, and senior living services at 54 communities with 4,127 total units in our assisted living, independent living and memory care business. We
derive revenue from a diversified blend of payors including Medicare and Medicaid programs, private pay patients and residents and managed care payors.

We believe our key differentiators are our (1) innovative operating model that focuses on empowering and developing strong local leaders, (2) disciplined
growth strategy, and (3) ability to achieve quality care outcomes in cost effective settings. In our experience, healthcare is a local endeavor, largely dependent upon
personal and professional relationships, community reputation and an ability to adapt to the changing needs of patients, residents, partners and communities. As
our  operational  leaders  build  strong  relationships  with  key  partners  in  their  local  communities,  they  are  empowered  to  make  informed  and  critical  operational
decisions that produce quality care outcomes and more effectively meet the needs of our patients and residents.

We  believe  our  home  health  and  hospice  businesses  are  able  to  achieve  quality  outcomes—as  measured  by  multiple  industry  and  value-based  metrics
(such as hospital readmission rates)—in cost effective settings. We believe our senior living business is able to offer our residents a safe and tailored quality-of-life
at  an  affordable  cost,  thus  appealing  to  a  broad  population.  With  our  platform  of  diversified  service  offerings,  we  believe  that  we  are  well-positioned  to  take
advantage of favorable demographic shifts as well as industry trends that reward providers offering quality care in lower cost settings.

Our Innovative Operating Model

Our innovative operating model is the foundation of our superior performance and success. Our operating model is founded on two core principles: (1)
healthcare is a local business where providers are most successful when key operational decision-making meets local community needs and occurs close to patients
or residents and employees, and (2) peer accountability from operational and resource partners is more effective at driving excellent clinical and financial results
than traditional hierarchical or “top-down” accountability structures.

Our model is innovative because each operation has been and will continue to be an independent operating subsidiary that functions under the direction of
local  clinical  and  operational  leaders,  each  of  whom  are  empowered  to  make  decisions  based  on  the  unique  needs  of  the  patients  or  residents,  partners  and
communities they serve. This is in contrast to typical models where control and key decision-making is centralized at the corporate level. Moreover, we utilize a
“cluster model,” where every operation is part of a defined “cluster,” which is a group of geographically proximate operations working together to allow leaders to
communicate and provide support and accountability to each other. Clusters create incentives for leaders to share best practices and real-time data and benchmark
clinical and financial performance with their cluster partners. We believe this locally-driven data-sharing and peer accountability model is unique among healthcare
and senior living providers and has proven effective in improving clinical care, enhancing patient and resident satisfaction and promoting operational efficiencies.
This “cluster” operating model is the same model used by local leaders prior to our spin-off from Ensign in 2019 (further discussed below under Company History)
and is key to the success of our future operations.

Our organizational structure empowers our highly dedicated leaders and staff at the local level to make key decisions and creates a sense of ownership
over operational and clinical results and the overall employee experience. Each operation’s leader and his or her staff are encouraged to make their operations the
“provider of choice” in the communities they serve. To accomplish this goal, our leaders work closely with their clinical staff and our expert resources to identify
unique patient and resident needs and priorities in their communities and to create superior service offerings tailored to those needs. We believe that our localized
approach to program development and care leads prospective patients or residents and referral sources to choose or recommend our operations to others. Similarly,
our emphasis on empowering local decision-makers encourages

2

Table of Contents

leaders to strive to become the “employer of choice” in the communities they serve. One of our core values is the principle that the best patient care is provided by
employees who experience significant work satisfaction because they are valued as individuals. Our leaders work hard to embody this core value and to attract,
train and retain outstanding clinical staff by creating a work environment that fosters critical thinking, measurement, and relevance. Our local teams are motivated
and  empowered  to  quickly  and  proactively  meet  the  needs  of  those  they  serve,  without  waiting  for  permission  to  act  or  being  bound  to  a  “one-size-fits-all”
corporate strategy. In many markets, we attribute census growth and excellent clinical and financial outcomes to a healthy organizational culture built on these
principles. With strong employee satisfaction across the organization, we believe we can continue to attract and retain the best talent in our industries.

Lastly, while our teams are local, they are also supported by cutting-edge systems and our “Service Center”, which is staffed with teams of subject-matter
experts who advise regarding their respective fields of expertise, including information technology, compliance, human resources, accounting, payroll, legal, risk
management, education and other services. The partnership and peer accountability that exists between our local leaders and Service Center resources allows each
operation to improve while benefiting from the technical expertise, systems and accountability provided by our Service Center.

Partner of Choice in Local Healthcare Communities

We  view  healthcare  services  primarily  as  a  local  business,  driven  by  personal  relationships,  reputation  and  the  ability  to  identify  and  address  unmet
community  needs.  We  believe  our  success  is  largely  driven  by  our  ability  to  build  strong  relationships  with  key  stakeholders  within  the  local  healthcare
communities, leveraging our reputation for providing superior care.

We believe we are a partner of choice to payors, providers, patients, residents and employees in the healthcare communities we serve. As a partner, we
focus on improving care outcomes and the quality of life of our patients and residents in their home. Our local leadership approach facilitates the development of
strong  professional  relationships  within  communities,  which  allows  us  to  better  understand  and  meet  the  needs  of  our  partners.  We  believe  our  emphasis  on
working closely with other providers, payors, residents and patients yields unique, customized solutions and programs that meet local market needs and improve
clinical outcomes, which in turn accelerates revenue growth and profitability.

We are a trusted partner to, and work closely with, payors and other acute and post-acute providers to deliver innovative healthcare solutions in lower cost
settings. In the markets we serve, we have developed formal and informal preferred provider relationships with key referral sources and transitional care programs
that  result  in  better  coordination  within  the  care  continuum.  These  partnerships  have  resulted  in  significant  benefits  to  payors,  patients,  residents  and  other
providers, including reduced hospital readmission rates, appropriate transitions within the care continuum, overall cost savings, increased patient satisfaction and
improved quality outcomes. Positive, repeated interactions and data sharing result in strong local relationships and encourage referrals from our acute and post-
acute  care  partners.  As  we  continue  to  strengthen  these  formal  and  informal  relationships  and  expand  our  referral  base,  we  believe  we  will  continue  to  drive
revenue growth and operational results.

Company History

The  Pennant  Group,  Inc.  was  incorporated  as  a  Delaware  corporation  on  January  24,  2019,  for  the  purpose  of  holding  the  home  health  and  hospice
agencies and substantially all of the senior living businesses of Ensign, which was formed in 1999 with the goal of establishing a new level of quality care within
the skilled nursing industry. The name “Ensign” is synonymous with a “flag” or a “standard,” and refers to Ensign’s goal of setting the standard by which all others
in its industry are measured. The name “Pennant” draws on similar imagery and themes to represent our mission of becoming the “Ensign” to the home health,
hospice  and  senior  living  industries.  We  believe  that,  through  our  innovative  operating  model,  we  can  foster  a  new  level  of  patient  care  and  professional
competence at our independent operating subsidiaries and set new industry standards for quality home health and hospice and senior living services.

On October 1, 2019, Ensign completed the spin-off of Pennant effected through a tax-free distribution (except as to cash received in lieu of fractional
shares) of substantially all of Pennant’s issued and outstanding common stock to the stockholders of Ensign, as a result of which Pennant became an independent,
publicly-traded company (the “Spin-Off”). Following the Spin-Off, Ensign had no continuing ownership interest in Pennant.

Our independent operating subsidiaries are organized into industry-specific portfolio companies, which we believe has enabled us to maintain a local,
field-driven  organizational  structure,  to  attract  qualified  leaders  and  expert  resources,  and  to  effectively  identify,  acquire,  and  improve  operations.  Each  of  our
portfolio companies has its own leader. These experienced

3

Table of Contents

and  proven  leaders  are  generally  taken  from  the  ranks  of  our  operational  leaders  to  serve  as  resources  to  independent  operating  subsidiaries  within  their  own
portfolio  companies  and  have  the  primary  responsibility  for  recruiting  qualified  talent,  finding  potential  acquisition  targets,  and  identifying  other  strategic  and
organic growth opportunities. We believe this decentralized organizational structure will continue to improve the quality of our recruiting and facilitate successful
acquisitions.

We have two reportable segments: (1) home health and hospice services, which includes our home health, hospice and home care businesses; and (2) senior
living services, which includes our assisted living, independent living and memory care communities. We also report an “all other” category that includes general
and administrative expense. Our reporting segments are business units that offer different services and that are managed separately to provide greater visibility into
those operations. For more information about our operating segments, as well as financial information, see “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and Note 6, Business Segments, to the Consolidated and Combined Financial Statements.

Services

Home Health and Hospice. As of December 31, 2021, we provided home health and hospice services through 88 agencies. Our home health services
consist of providing a combination of clinical services including nursing, speech, occupational and physical therapy, medical social work and home health aide
services within a patient's home. Home health is often a cost-effective solution for patients and can also increase their quality of life by allowing them to receive
excellent clinical services in the comfort and convenience of the patient's home. Our hospice services focus on the physical, spiritual and psychosocial needs of
terminally ill patients and their families and consist primarily of clinical care, education and counseling. We generated approximately 70.0%, 70.3% and 68.6% of
our home health and hospice revenue from Medicare during the years ended December 31, 2021, 2020 and 2019, respectively.

Senior Living. As of December 31, 2021, we provided assisted living, independent living and memory care services in 54 communities with 4,127 total
units or rooms. Our senior living operations provide a variety of services tailored to our residents’ needs, including residential accommodations, activities, meals,
housekeeping and assistance in the activities of daily living to seniors who are independent or who require some support not at the level of clinical care provided in
a  skilled  nursing  facility.  We  generate  revenue  in  these  communities  primarily  from  private  pay  sources,  with  a  portion  earned  from  Medicaid  or  other  state-
specific programs. We derived approximately 71.3%, 73.2% and 77.4% of our senior living revenue from private pay sources during the years ended December 31,
2021, 2020 and 2019, respectively.

Our Growth Strategy

We believe that the following strategies are primarily responsible for our growth to date and will continue to drive the growth of our business:

Grow  Talent  Base  and  Develop  Future  Leaders.  Our  growth  strategy  is  focused  on  expanding  our  talent  base  and  developing  future  leaders.  A  key
component of our organizational culture is our belief that strong local leadership is a primary ingredient to operational success. We use a multi-faceted strategy to
identify and recruit proven business leaders from various industries and backgrounds. To develop these leaders, we have a rigorous “CEO-in-Training Program”
that includes significant in-person instruction on leadership, clinical and operational topics as well as extensive on-the-ground training and active learning with key
leaders  from  across  the  organization.  After  placement  in  a  local  operation,  our  leaders  continue  to  receive  training  and  regular  feedback  and  support  from
operational, clinical and Service Center peers. We believe our model of empowering local leaders and providing them a platform of support from expert resources
and systems will continue to attract and retain highly talented and entrepreneurial leaders.

Focus on Organic Growth. We believe that we have a significant opportunity to drive organic growth within our current portfolio, including recently
acquired operations. As we improve clinical outcomes, quality of care and operational results at each of our existing and newly acquired operations, we believe we
will  become  a  provider  of  choice  in  the  communities  we  serve,  which  leads  to  census  growth.  Through  this  census  growth,  and  as  we  continue  to  expand  our
service  areas  and  offerings,  we  believe  we  will  continue  to  translate  revenue  growth  into  bottom  line  success  with  rigorous  adherence  to  our  core  operating
principles. By effectively using data systems and analytics and embracing a culture of transparency and accountability, we tend to see our local leaders steadily
improving operational results. We believe our unique operating model will continue to cultivate steady and consistent organic growth in the future.

Pursue Disciplined Acquisition Strategy. The disciplined acquisition and integration of strategic and underperforming operations is a key element of our
past success and is integral to our future growth plans. We have historically successfully transitioned both turnaround and stable target businesses, transforming
them into top-quality operations preferred by referral

4

Table of Contents

sources. We plan to continue to take advantage of the fragmented home health, hospice and senior living industries by being disciplined in acquiring strategic and
underperforming operations within both our existing and new geographic markets. With experienced leaders in place at the local level and demonstrated success in
improving operating conditions at acquired businesses, we believe we are well positioned to continue expanding our footprint through disciplined acquisitions.

Leverage Our Operational Capabilities to Expand Partnerships. Our local leadership approach enables us to adapt to and efficiently meet the needs of
our partners in the communities we serve. Our clinical and data analytics capabilities foster solutions and allow us to optimize clinical outcomes. We use this data
to communicate with key partners in an effort to reduce overall cost of care and drive improved clinical outcomes. We will continue to expand formal and informal
partnerships  across  the  healthcare  continuum  by  strategically  investing  in  programs  and  data  analytics  that  help  us  and  our  partners  improve  care  transitions,
achieve better outcomes and reduce costs.

Growth and Acquisition History

Much of our historical growth can be attributed to our expertise in acquiring strategic and underperforming operations and transforming them into market
leaders in clinical quality, staff competency and financial performance. Our local leaders are trained to identify these opportunities for long-term organic growth as
we strive to become the provider of choice in our local communities. Accordingly, we plan to continue to drive organic growth and acquire additional operations in
existing and new markets in a disciplined manner.

From 2013 to 2021, we grew our home health and hospice services and senior living services revenue by 561.0% or a compounded annual growth rate of

26.6%.

From 2013 to December 31, 2021, we grew the number of our home health and hospice agencies and senior living units by 450.0% and 228.6%,

respectively.

5

 
Table of Contents

Agency and Unit Growth Since 2013

Home health and hospice agencies
Senior living communities
Senior living units
Total number of home health, hospice, and senior
living operations

2013

2014

2015

2016

16 
12 
1,256 

25 
15 
1,587 

32 
36 
3,184 

39 
36 
3,184 

December 31,
2017

2018

2019

2020

2021

46 
43 
3,434 

54 
50 
3,820 

63 
52 
3,963 

76 
54 
4,127 

88 
54 
4,127 

28 

40 

68 

75 

89 

104 

115 

130 

142 

We  aim  to  continue  to  grow  our  revenue  and  earnings  by  expanding  our  existing  operations  and  acquiring  additional  operations  in  existing  and  new

markets.

Industry Trends

The healthcare sector is one of the largest and fastest-growing sectors of the U.S. economy. According to the Centers for Medicare and Medicaid Services
(“CMS”), national healthcare spending increased from 8.9% of U.S. GDP, or $253 billion, in 1980 to an estimated 19.7% of GDP, or $4.1 trillion, in 2020. CMS
projects national healthcare spending will grow by an average of 5.4% annually from 2019 through 2028, accounting for approximately 19.7% of U.S. GDP, or
approximately $6.2 trillion, in 2028.

The home health and hospice segment is growing within the overall healthcare landscape in the United States. According to Grandview Research, Inc.’s
(“GVRI[‘s]”) research, the home health market is estimated at approximately $299 billion and is expected to grow at a compounded annual growth rate (“CAGR”)
7.88% from 2021 to 2028. The hospice industry is estimated at approximately $29 billion and is projected to grow at an estimated CAGR of 8.6%. The senior
living  market  is  estimated  at  approximately  $83  billion  and  is  expected  to  expand  at  an  estimated  CAGR  of  5.3%  between  2021  to  2027.  We  believe  that  the
industries in which we operate will continue to benefit from several macroeconomic and regulatory trends highlighted below:

Increased Demand Driven by Aging Populations. As seniors account for an increasing percentage of the total U.S. population, we believe demand for
home  health  and  hospice  will  continue  to  increase  and  demand  for  senior  living  services  will  improve  as  operating  conditions  impacted  by  the  COVID-19
pandemic return to normal. According to the U.S. Census Bureau in 2020, between 2016 and 2060, the number of individuals over 65 years old is projected to be
one of the fastest growing segments of the United States population, growing from 15% to 23%. The Bureau expects this segment to increase nearly 92% to 94.7
million  by  2060  (from  2016)  as  compared  to  the  total  U.S.  population  which  is  projected  to  increase  by  25.2%  over  that  same  time  period.  Furthermore,  the
generation currently retiring has access to less post-retirement benefits and accumulated less savings than in the past, creating demand for more affordable senior
housing and in-home care options. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.

6

Table of Contents

Shift of Patient Care to Lower Cost Alternatives. The growth of the senior population in the U.S. continues to increase healthcare costs, often at a rate
faster  than  the  available  funding  from  government-sponsored  healthcare  programs.  In  response,  government  payors  have  adopted  measures  that  encourage  the
treatment of patients in their homes and other cost-effective settings where the staffing requirements and associated costs are often significantly lower than the
alternatives.  With  our  emphasis  on  the  home  health,  hospice  and  senior  living  industries,  which  are  among  the  lowest  cost  settings  within  the  post-acute  care
continuum, we expect this shift to continue to drive our growth.

Transition to Value-Based Payment Models. In response to rising healthcare spending, certain markets’ commercial, government and other payors are
shifting  away  from  fee-for-service  payment  models  toward  value-based  models,  including  risk-based  payment  models  that  tie  financial  incentives  to  quality,
efficiency  and  coordination  of  care.  We  believe  that  payors  will  continue  to  emphasize  reimbursement  models  driven  by  value  and  that  our  clinical  outcomes
combined with our services in cost effective settings will be increasingly rewarded. Many of our home health agencies already receive value-based payments, and
we are well-positioned to capitalize on this trend as it unfolds across the markets we serve.

Significant  Acquisition  and  Consolidation  Opportunities.  The  home  health,  hospice  and  senior  living  industries  are  highly  fragmented  markets  with
thousands of small and regional providers and only a handful of large national players. There were over 11,000 Medicare-certified home health agencies operating
in 2020, with the top ten largest operators accounting for approximately 26% of the market. There are approximately 4,500 hospice agencies in the U.S. with the
top ten largest operators accounting for about 18% of the total market share. As with the home health and hospice industries, there is significant fragmentation in
the  senior  housing  industry,  with  the  top  25  operators  controlling  only  a  quarter  of  the  market.  We  believe  that  our  strategy  of  acquiring  strategic  and
underperforming operations in these highly fragmented markets will be an instrumental piece of our future growth.

Changing Regulatory Framework. Regulations and reimbursement change frequently in our industries. Our model is designed to successfully navigate
these regulatory and reimbursement changes. For example, effective January 1, 2020, CMS enacted additional changes to the Medicare home health prospective
payment system (“HH PPS”) with the implementation of the Patient Driven Groupings Model (“PDGM”). As discussed in greater detail below under Government
Regulation,  this  reimbursement  structure  involved  case  mix  calculation  methodology  refinements,  changes  to  low-utilization  payment  adjustment  (“LUPA”)
thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day period of care, and reduction in fiscal year
2020 and full elimination in fiscal year 2021 of requests for anticipated payments (“RAPs”). Beginning in fiscal year 2022, the CMS is replacing the RAP process
with  the  home  health  Notice  of  Admission  (“NOA”),  which  requires  a  single  NOA  filing  that  will  cover  continuous  30-day  periods  of  care  until  the  patient  is
discharged. This transition from RAP to NOA may cause delays in payment from CMS or even denial of payment, as the NOA process will be new for both CMS
and  the  Company.  Just  as  we  have  navigated  other  major  reimbursement  and  regulatory  changes,  we  believe  that  our  unique  operating  model  allowed  us  to
transition to PDGM as local operations and clinical leaders, supported by our expert resources, effectively adapted to the new reimbursement environment.

Payor Sources

We derive revenue primarily from Medicare and Medicaid programs, managed care and private payors.

Medicare. Medicare is a federal program that provides healthcare benefits to individuals who are 65 years of age or older or are disabled. The Medicare
home health benefit is available both for patients who need care following discharge from an inpatient facility and patients who suffer from chronic conditions that
require ongoing but intermittent care. The Medicare hospice benefit is also available to Medicare-eligible patients with terminal illnesses, certified by a physician,
where life expectancy is six months or less.

Medicaid. Medicaid is a program financed by state funds and matching federal funds administered by state agencies or managed care organizations on
their  behalf.  Medicaid  programs  generally  provide  health  benefits  for  qualifying  individuals  and  may  supplement  Medicare  benefits  for  the  disabled  and  for
persons  aged  65  and  older  meeting  financial  eligibility  requirements.  Medicaid  reimbursement  formulas  are  established  by  each  state  with  the  approval  of  the
federal government in accordance with federal guidelines.

Medicaid reimbursement varies from state to state and is based upon a number of different methodologies, including cost-based, prospective payment,
case mixed adjusted payments, and negotiated rates. Rates are subject to a state’s annual budgetary requirements and funding, statutory and regulatory changes and
interpretations and rulings by individual state agencies and State Plan Amendments approved by CMS.

7

Table of Contents

Managed Care and Private Insurance. Managed care patients consist of individuals who are insured by certain third-party entities, or who are Medicare
beneficiaries  who  have  assigned  their  Medicare  benefits  to  a  managed  care  organization  plan.  Another  type  of  insurance,  long-term  care  insurance,  is  also
becoming more widely available to consumers and is not expected to contribute significantly to industry revenues in the near term.

Private  and  Other  Payors.  Private  and  other  payors  consist  primarily  of  individuals,  family  members  or  other  third  parties  who  directly  pay  for  the

services we provide.

The following table sets forth our total revenue by payor source as a percent of revenue generated by each of our reportable segments and as a percentage

of total revenue for the year ended December 31, 2021:

Medicare
Medicaid

Subtotal
Managed care
Private and other

(a)

Total revenue

Home Health and Hospice Services

Year Ended December 31, 2021

Home Health Services
51.2 %
5.7 
56.9 
29.2 
13.9 
100.0 %

Hospice Services

89.7 %
8.0 
97.7 
2.1 
0.2 
100.0 %

Senior Living Services
— %

28.7 
28.7 
— 
71.3 
100.0 %

Total Revenue

49.3 %
13.3 
62.6 
11.2 
26.2 
100.0 %

Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Reimbursement for Specific Services

Historically, adjustments to reimbursement under Medicare and Medicaid have had a significant effect on our revenue and results of operations. Recently
enacted,  pending  and  proposed  legislation  and  administrative  rulemaking  at  the  federal  and  state  levels  could  have  similar  effects  on  our  business.  Efforts  to
impose  reduced  reimbursement  rates,  greater  discounts,  cost  sequestrations  in  federal  spending  bills  passed  by  Congress,  and  more  stringent  cost  controls  by
government  and  other  payors  are  expected  to  continue  for  the  foreseeable  future  and  could  adversely  affect  our  business,  financial  condition  and  results  of
operations. Additionally, any delay or default by the federal or state governments in making Medicare and/or Medicaid reimbursement payments could materially
and adversely affect our business, financial condition and results of operations.

Reimbursement for Home Health Services. Our home health business derives substantially all of its revenue from Medicare, managed care, and private
pay sources, which may vary in the markets we serve. Our home health services generally consist of providing some combination of the services of registered
nurses, speech, occupational and physical therapists, medical social workers and certified home health aides. Home health is often a cost-effective solution for
patients and can also increase their quality of life and allow them to receive quality medical care in the comfort and convenience of a familiar setting.

Reimbursement  for  Hospice  Services.  Hospice  revenues  are  primarily  derived  from  Medicare.  We  receive  one  of  four  predetermined  rate  categories
based on four different levels of care provided: routine home care, continuous home care, inpatient respite care and general inpatient care. This payment structure
is designed to include all of the services needed to manage a beneficiary’s care, consisting primarily of clinical care, education and counseling. These rates are
subject to annual adjustments based on inflation and geographic wage considerations.

Reimbursement for Senior Living Services. Assisted living, independent living and memory care community revenue is primarily derived from private
pay residents at rates we establish based upon the services we provide and market conditions in the area of operation. In addition, Medicaid or other state-specific
programs in some states where we operate supplement payments for board and care services provided in assisted living and memory care communities.

Competition

The post-acute care industry is highly competitive, and we expect that the industry will become increasingly competitive in the future. The industry is
highly fragmented and characterized by numerous local and regional providers, in addition to large national providers that have achieved geographic diversity and
economies of scale. Some of our independent operating subsidiaries also compete with skilled nursing facilities, inpatient rehabilitation facilities and long-term
acute care hospitals. Competitiveness may vary significantly from location to location, depending upon factors such as the number of

8

Table of Contents

competing  operations,  availability  of  services,  expertise  of  staff,  and  the  physical  appearance  and  amenities  of  senior  living  communities.  We  believe  that  the
primary competitive factors in the post-acute care industry are:

•

•

•

•

•

ability to attract and to retain qualified leaders and caregivers;

reputation and achievements of quality healthcare outcomes and patient and resident satisfaction;

attractiveness and location of senior living communities and other physical assets;

the expertise and commitment of operational leaders and employees; and

private equity and other firms with greater financial resources and/or lower costs of capital with similar asset acquisition objections.

We seek to compete effectively in each market by establishing a reputation within the local community as the “operation of choice.” This means that the
operation leaders are generally free to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local
community or market, and then create superior service offerings for that particular community or market that are calculated to encourage prospective customers
and referral sources to choose or recommend the operation.

Increased competition could limit our ability to attract and retain patients and residents, maintain or increase rates of reimbursement or to expand our
business. Some of our competitors have greater financial and other resources than we have, may have greater brand recognition and may be more established in
their respective communities than we are. Competing companies may also offer newer or more recently renovated communities or different programs or services
than  we  offer  and  may,  therefore,  attract  individuals  who  are  currently  patients  of  our  operations,  potential  residents  of  our  facilities,  or  who  are  otherwise
receiving our healthcare services. Other competitors may have lower expenses or other competitive advantages than us and, therefore, provide services at lower
prices than we offer.

There are few barriers to entry in the home health and hospice business in jurisdictions that do not require certificates of need or permits of approval. Our
primary competition in these jurisdictions comes from local privately and publicly owned providers and hospital-owned healthcare providers. We compete based
on the availability of personnel, the quality of services, expertise of visiting staff, and, in certain instances, on the price of our services. In addition, we compete
with a number of non-profit organizations that finance acquisitions and capital expenditures on a tax-exempt basis and charity-funded programs that may have
strong ties to their local medical communities and receive charitable contributions that are unavailable to us.

Our  senior  living  services  also  compete  with  local,  regional  and  national  companies.  The  primary  competitive  factors  in  these  businesses  include
reputation, cost of services, quality of clinical services, responsiveness to patient/resident needs, location and the ability to provide support in other areas such as
third-party  reimbursement,  information  management  and  patient  recordkeeping.  The  market  for  acquiring  and/or  operating  senior  living  communities  is  highly
competitive, and some of our present and potential senior living competitors have, or may obtain, greater financial resources than us and may have a lower cost of
capital.

Our Competitive Strengths

We believe that we are well positioned to benefit from the ongoing regulatory, reimbursement and demographic changes within the home health, hospice

and senior living industries. We believe that we will achieve clinical, financial and cultural success as a direct result of the following key competitive strengths:

Innovative  Operating  Model.  We  believe  healthcare  should  be  operated  primarily  as  a  local  business.  Our  local  leadership-centered  operating  model
encourages our leaders to make key operational decisions that meet the individualized needs of their patients, residents and community partners. Recognizing the
local nature of our business, our leaders develop each operation’s reputation at the local level, rather than being bound by a traditional organization-wide branding
strategy. In addition, our local leaders work closely with their cluster partners to share data and improve clinical and financial outcomes. Moreover, we do not
maintain  a  traditional  corporate  headquarters,  rather  we  operate  our  Service  Center  which  supports  operational  results  through  world-class  systems  and  by
providing  ancillary  expertise  in  fields  such  as  information  technology,  compliance,  human  resources,  accounting,  legal  and  education.  This  enables  individual
operations to function with the strength, synergies and economies of scale found in larger organizations, without the disadvantages of a top-down management
structure or corporate hierarchy. We believe this approach is unique within our industries and allows us to preserve the “one-operation-at-a-time” focus and culture
that has contributed to our success.

Proven  Track  Record  of  Successful  Acquisitions.  We  adhere  to  a  disciplined  acquisition  strategy  focused  on  sourcing  and  selectively  acquiring

operations within our target markets. Local leaders are heavily involved in the acquisition process and

9

Table of Contents

are recognized and rewarded as these acquired operations become the provider of choice in the communities they serve. Through our innovative operating model
and  disciplined  approach  to  strategic  growth,  we  have  completed  and  successfully  transitioned  dozens  of  value-add  operations.  Our  expertise  in  acquiring  and
transforming strategic and underperforming operations allows us to consider a broad range of potential acquisition targets and will be a key element of our future
success.

Superior Clinical Outcomes and Quality Care. We will continue to achieve success by delivering high quality home health, hospice and senior living
services. Using the CMS five-star quality rating criteria, our home health agencies achieved an average of 4.4 out of 5 stars across all agencies for the for the year
ended December 31, 2021, compared to the industry average of 3.0 stars (see Government Regulation below for further discussion on the five-star quality rating
system). Our locally-driven, patient-centered approach to clinical care allows us to meet the unique needs of our patients, resulting in improved clinical outcomes,
including reduced hospital readmission rates. These improved outcomes are driven by both our talented local clinicians and our data-driven analytical approach to
patient care and risk stratification. We believe that our achievement of high-quality clinical outcomes positions us as a solution for patients, residents and referral
sources, leading to census growth and improved profitability.

Diversified  Portfolio  by  Payor  and  Services.  As  of  December  31,  2021,  we  operated  88  home  health  and  hospice  agencies  and  54  senior  living
communities across 14 states. Because of this diversified portfolio, our blended payor mix was 49.3% Medicare, 13.3% Medicaid, 11.2% managed care and 26.2%
private pay for the year ended December 31, 2021. Our balanced payor mix can provide greater business stability through economic cycles and mitigates volatility
arising  from  government-driven  reimbursement  changes.  For  the  year  ended  December  31,  2021,  we  generated  70.4%  of  our  revenue  from  home  health  and
hospice services and 29.6% of our revenue from senior living services. Our diversified service portfolio allows us to opportunistically execute on our acquisition
strategy as valuations fluctuate over industry cycles.

Effective  Talent  Recruitment,  Development  and  Retention.  We  believe  we  have  been  successful  in  attracting,  developing  and  retaining  outstanding
business  and  clinical  leaders  to  lead  our  independent  operating  subsidiaries.  Our  unique  operating  model,  which  emphasizes  local  decision  making  and  team
building, supported by our platform of expert resources and best-in-class systems, attracts a highly talented and entrepreneurial group of leaders. Our operational
leaders  are  committed  to  ongoing  training  and  participation  in  regular  leadership  development  and  educational  programs.  We  believe  that  our  commitment  to
professional development strengthens the quality of our operational leaders and staff and will continue to differentiate us from our competitors.

Human Capital

The operation of our home health and hospice operations and senior living communities requires a large number of highly skilled healthcare professionals
and support staff. As of December 31, 2021, we had 6,441 employees who were employed by our independent operating subsidiaries or our Service Center. None
of those employees is subject to a collective bargaining agreement relating to our operations.

Our ability to attract and retain future leaders is critical to our ongoing success. Therefore, we are dedicated to continuously recruiting and developing a
diverse group of capable leaders. As described in Item 1. Grow Talent Base and Develop Future Leaders, our CEO-in-Training program provides significant in-
person instruction and extensive training with key leaders from across the organization to empower local leaders.

For the year ended December 31, 2021, 56.7% of our total expenses were payroll related for our operations. Periodically, market forces, which vary by
region,  require  that  we  increase  wages  in  excess  of  general  inflation  or  in  excess  of  increases  in  reimbursement  rates  we  receive.  We  believe  that  we  staff
appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. We seek to manage our labor costs by improving staff
retention,  improving  operating  efficiencies,  maintaining  competitive  wage  rates  and  benefits  and  reducing  reliance  on  overtime  compensation  and  temporary
nursing agency services.

The healthcare industry as a whole has been experiencing shortages of qualified professional clinical staff. We believe that our ability to attract and retain
qualified professional clinical staff stems from our ability to offer attractive wage and benefits packages, a high level of employee training, a culture that provides
incentives for individual efforts and a quality work environment.

Government Regulation

General. The laws and statutes affecting the regulatory landscape of the home health, hospice and senior living industries continue to expand. In addition

to this changing regulatory environment, federal, state and local officials are

10

Table of Contents

increasingly focusing their efforts on the enforcement of these laws. In order to operate our businesses, we must comply with federal, state and local laws relating
to, among other things, licensure, delivery and adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, fire prevention,
immigration,  employment,  rate-setting,  billing  and  reimbursement,  building  codes  and  environmental  protection.  Additionally,  we  must  also  adhere  to  anti-
kickback statutes, physician referral laws, and safety and health standards set by the Occupational Safety and Health Administration (“OSHA”). Changes in the
law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Our independent operating subsidiaries are also subject to various regulations and licensing requirements promulgated by state and local health and social
service agencies and other regulatory authorities. Requirements vary from state to state and these requirements can affect, among other things, personnel education
and  training,  patient  and  personnel  records,  services,  staffing  levels,  monitoring  of  patient  wellness,  patient  furnishings,  housekeeping  services,  dietary
requirements, emergency plans and procedures, certification and licensing of staff prior to beginning employment, and patient rights. These laws and regulations
could limit our ability to expand into new markets and to expand our services and facilities in existing markets.

Medicare. All providers are subject to compliance with various federal, state and local statues and regulations in the U.S. and receive periodic inspection

by state licensing agencies to review standards of medical care, equipment and safety.

Conditions  of  Participation.  Our  home  health  and  hospice  operations  must  comply  with  regulations  promulgated  by  the  United  States
Department of Health and Human Services (“HHS”) and CMS in order to participate in the Medicare program and receive Medicare payments. Among
other things, these conditions of participation (the “CoPs”), relate to the type of operation, its personnel and its standards of medical care, as well as its
compliance with state and local laws and regulations.

Home Health Quality Reporting Requirements. The CoPs require home health agencies to submit quality reporting data through Outcome and
Assessment  Information  Set  (“OASIS”)  assessments  within  30  days  of  completing  the  assessment  of  the  Medicare  and  Medicaid  beneficiary  as  a
condition of payment and for quality measurement purposes. If the OASIS assessment is not found in CMS's quality system upon receipt of a final claim
for a home health episode and the receipt date of the claim is more than 30 days after the assessment completion date, CMS will deny the claim. Home
health agencies that do not submit quality measure data to CMS incur a 2% reduction in their annual home health payment update. Under the rule, all
home health agencies are required to timely submit both a Start of Care or Resumption of Care OASIS assessment and a Transfer or Discharge OASIS
assessment for a minimum of 90% of all episodes.

In addition, CMS requires that all Medicare certified home health and hospice agencies participate in the Consumer Assessment of Healthcare
Providers  and  Systems  (“CAHPS”).  CAHPS  surveys  are  designed  to  produce  comparable  data  on  the  perspective  of  patients  and  their  caregivers  that
allows  meaningful  and  objective  comparisons  between  agencies.  Home  health  and  hospice  agencies  that  do  not  submit  the  required  data  incur  a  2%
reduction in their annual base rate payment update.

Home Health Star Rating. As a consumer tool for selecting a home health provider, CMS has used a five-star rating model to rate home health
agencies  since  2015.  This  Quality  of  Patient  Care  Star  Rating  is  a  summary  measure  of  a  home  health  agency’s  performance  based  upon  how  well  it
provides patient care. CMS uses seven measurements indicating quality to determine its rating, including how often the agency initiated care in a timely
manner,  how  often  patients  demonstrated  improvements  in  ambulation,  bed  transferring,  bathing,  oral  medication  administration,  decreased  pain  with
activity, less shortness of breath, and decreased need for acute care hospitalization. According to CMS, a 3-star rating means the agency provides good
quality of care. According to CMS Home Health Compare star rating criteria, our home health agencies have achieved an average of 4.4 out of 5 stars
across all agencies compared to the industry average of 3.0 stars for the year ended December 31, 2021.

Home Health Reimbursement, including HH PPS and PDGM. To qualify for home health services, Medicare CoPs require that beneficiaries
(1) be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort); (2) require intermittent skilled
nursing, physical therapy or speech therapy services; (3) have a face to face encounter that (a) has occurred no more than 90 days prior to the start of care
or  within  30  days  after  the  start  of  care,  (b)  was  related  to  the  primary  reason  the  patient  requires  home  health  services,  and  (c)  was  performed  by  a
physician or allowed non-physician provider; and (4) receive treatment under a plan of care established and periodically reviewed by a physician.

11

Table of Contents

Through  December  31,  2019,  under  the  Medicare  HH  PPS,  Medicare  pays  home  health  agencies  a  predetermined  base  payment  adjusted  for
case-mix (the health condition and care needs of the beneficiary), as well as geographic differences in wages for home health agencies across the country.
There are also outlier payments to account for beneficiaries who incur unusually large costs. For patients who do not receive at least a specified number of
visits during their episode of care, HH PPS uses a low-utilization payment adjustment (“LUPA”). Until January 1, 2020, HH PPS provided home health
agencies with payments for each 60-day episode of care for each beneficiary. There were no limits to the number of episodes an eligible beneficiary can
receive.

In October 2019, CMS issued a final rule implementing PDGM. The PDGM reimbursement structure involves case mix calculation methodology
refinements,  changes  to  LUPA  thresholds,  the  elimination  of  therapy  thresholds,  a  change  to  the  unit  of  payment  from  a  60-day  episode  to  a  30-day
payment period, and the reduction in fiscal year 2020 and full elimination in fiscal year 2021 of the RAP. Effective January 1, 2020, under PDGM the
initial certification of patient eligibility, plan of care, and comprehensive assessment remains valid for 60-day episodes of care and payments for home
health services are made based upon 30-day periods. During 2020, we received 20% of the estimated payment for a patient’s initial or subsequent period
of care up-front (after the initial assessment is completed and upon initial billing) and the remaining 80% upon submission of the final claim following the
30-day period of care. Beginning on January 1, 2022, the RAP process is replaced by a home health agency filing a NOA to cover continuous 30-day
periods  of  care  until  the  patient  is  discharged.  Within  five  calendar  days  of  beginning  care,  home  health  agencies  must  submit  a  NOA  or  else  face  a
reduction in the payment that is equal to a 1/30th reduction of the expected wage and case-mix adjusted 30-day payment period for each day from the start
of care, equal to the current late submission deduction for RAPs. PDGM’s ultimate impact will vary by provider based on factors including case-mix,
admission source, and providers’ ability to adapt to the new reimbursement model's coding and therapy thresholds.

Home Health Value Based Purchasing (HH VBP). The Center for Medicare and Medicaid Innovation (“Innovation Center”) implemented the
original Home Health Value-Based Purchasing (“HHVBP”) Model from January 1, 2016 through December 31, 2021. The model was designed to support
greater quality and efficiency of care among Medicare-certified Home Health Agencies (“HHA”) across the nation. The HHVBP Model supported efforts
to  build  a  health  care  system  that  delivers  better  care,  spends  health  care  dollars  more  wisely,  and  results  in  healthier  people  and  communities.  All
Medicare-certified  HHAs  that  provided  services  in  Massachusetts,  Maryland,  North  Carolina,  Florida,  Washington,  Arizona,  Iowa,  Nebraska,  and
Tennessee competed on value, where payment was tied to quality performance. The overall purpose of the HHVBP Model was to improve the quality and
delivery of home health care services to Medicare beneficiaries with specific goals to; provide incentives for better quality care with greater efficiency,
study  new  potential  quality  and  efficiency  measures  for  appropriateness  in  the  home  health  setting,  and,  enhance  the  public  reporting  process.  The
HHVBP Model was expanded nationwide in the Calendar Year (“CY”) 2022 HH PPS rule. In addition, the rule finalized the end of the HHVBP Model
one year early for the HHAs in the nine original Model states, such that CY 2020 performance data will not be used to calculate a payment adjustment for
HHAs in the nine states and will not have their payments impacted in CY 2022.

The expanded HHVBP Model begins on January 1, 2022 and includes Medicare-certified HHAs in all fifty (50) states. Calendar Year 2022 is the
pre-implementation  year  wherein  CMS  will  provide  HHAs  with  resources  and  training.  This  will  allow  HHAs  time  to  prepare  and  learn  about  the
expectations and requirements of the expanded HHVBP Model without risk to payments. The first full performance year for the expanded HHVBP Model
is CY 2023 (beginning January 1, 2023). Calendar Year 2025 will be the first year when payment will be adjusted determined on CY 2023 performance.

Review  Choice  Demonstration  for  Home  Health  Services.  The  Review  Choice  Demonstration  for  Home  Health  Services  (RCD)  provides
flexibility and choice for Home Health Agencies (HHAs), as well as risk-based changes to reduce burden on providers demonstrating compliance with
Medicare home health policies. The demonstration is mandatory for all Medicare certified HHAs in 5 states Illinois, Ohio, North Carolina, Floria and
Texas. Providers select from three initial choices:

Pre-claim review
Post-payment review

•
•
• Minimal post-payment review with a 25% payment reduction

After  a  6-month  period,  HHAs  demonstrating  compliance  with  Medicare  rules  through  pre-claim  review  or  postpayment  review  will  have
additional choices, including relief from most reviews except for a review of a small sample of claims. (To be eligible, HHAs must meet a 90% target full
provisional  affirmation  rate  based  on  a  minimum  10  requests/claims  submitted.)  This  program  is  designed  to  reduce  the  number  of  Medicare  appeals,
improve provider

12

Table of Contents

compliance with Medicare program requirements, should not delay care to Medicare beneficiaries, and does not alter the Medicare home health benefit.

Hospice Reimbursement and Cap Amounts. Payments are based on daily rates for each day a beneficiary is enrolled in the hospice benefit and
are subject to two annual caps. Rates are set based on specific levels of care, are adjusted by a wage index to reflect healthcare labor costs across the
country and are established annually through federal legislation. The following are the four levels of care provided under the hospice benefit:

•

Routine Home Care (“RHC”). Care that is not classified under any of the other levels of care, such as the work of nurses, social workers or
home health aides.

• General Inpatient Care. Pain control or acute or chronic symptom management that cannot be managed in a setting other than an inpatient

Medicare-certified facility, such as a hospital, skilled nursing facility or hospice inpatient facility.

•

•

Continuous Home Care. Care for patients experiencing a medical crisis that requires nursing services to achieve palliation and symptom
control, if the agency provides a minimum of eight hours of care within a 24-hour period.

Inpatient Respite Care. Short-term, inpatient care to give temporary relief to the caregiver who regularly provides care to the patient.

CMS has established a two-tiered payment system for RHC. Hospices are reimbursed at a higher rate for RHC services provided from days of
service  one  through  60  and  then  a  lower  rate  for  all  subsequent  days  of  service.  CMS  also  provided  for  a  Service  Intensity  Add-On,  which  increases
payments for certain RHC services provided by registered nurses and social workers to hospice patients during the final seven days of life.

Medicare payments are subject to two fixed annual caps, which are assessed on a provider number basis, and are broken into an inpatient cap
amount and an overall payment cap. These cap amounts are calculated and published by the Medicare fiscal intermediary on an annual basis covering the
period from October 1 through September 30. The inpatient cap limits hospice care provided on an inpatient basis. This cap limits the number of days that
are paid at the higher inpatient care rate to 20.0% of the total number of days of hospice care that are provided to all Medicare beneficiaries served by a
provider.  The  daily  rate  for  all  days  exceeding  the  cap  is  the  standard  RHC  daily  rate,  and  the  provider  must  reimburse  Medicare  for  any  payments
received in excess of that amount. The overall payment cap is calculated by the Medicare fiscal intermediary at the end of each hospice cap period to
determine  the  maximum  allowable  payments  to  a  hospice  provider  during  the  period.  We  estimate  our  potential  cap  exposure  by  using  available
information to compare our actual reimbursement for all hospice services provided during the period to the number of beneficiaries we served multiplied
by  the  statutory  per  beneficiary  cap  amount.  If  payments  received  by  any  one  of  our  hospice  provider  numbers  exceeds  either  of  these  caps,  we  are
required to reimburse Medicare for payments received in excess of the cap amounts. The hospice cap amount for the 2022 cap year is equal to the 2021
cap amount of $30,683.93 updated by 2% or $31,297.61 per beneficiary.

Improving  Medicare  Post-Acute  Care  Transformation  Act  of  2014  (“IMPACT  Act”).  The  IMPACT  Act  requires  the  submission  of
standardized  assessment  data  for  quality  improvement,  payment  and  discharge  planning  purposes  across  the  spectrum  of  post-acute  care  providers
(“PACs”),  including  home  health  agencies.  The  IMPACT  Act  requires  PACs  to  report:  (1)  standardized  patient  assessment  data  at  admission  and
discharge; (2) new quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls, and patient preference
regarding  treatment  and  discharge;  and  (3)  resource  use  measures,  including  Medicare  spending  per  beneficiary,  discharge  to  community,  and
hospitalization rates of potentially preventable readmissions for home health agencies. Failure to report such data when required would subject a PAC to a
2% reduction in market basket prices then in effect.

The  IMPACT  Act  also  included  provisions  impacting  Medicare-certified  hospices,  including  (1)  increasing  survey  frequency  for  Medicare-
certified hospices to once every 36 months, (2) imposing a medical review process for operations with a high percentage of stays in excess of 180 days,
and (3) updating the annual aggregate Medicare payment cap.

Hospice Quality Reporting Requirements (“HQRP”). HQRP, mandated by the Patient Protection and Affordable Care Act, requires hospice agencies to

submit required quality data for inclusion on the public facing Hospice Compare website

13

Table of Contents

hosted by CMS. Hospices that fail to meet quality reporting requirements receive a 2.0% reduction to the annual market basket update for the fiscal years 2021,
2022, and 2023. This reduction penalty will be increased to 4.0% beginning in fiscal year 2024.

Licensure and Certificates of Need (“CON”). Home health, hospice and most senior living communities operate under licenses granted by the health
authorities of their respective states. Some states require healthcare providers (including home health, hospice and most senior living providers) to obtain prior
state approval for the purchase, construction or expansion of healthcare operations, or changes in services. Certain states, including a number in which we operate,
carefully  restrict  new  entrants  into  the  market  based  on  demographic  and/or  demonstrative  usage  of  additional  providers.  These  states  limit  the  entry  of  new
providers or services and the expansion of existing providers or services in their markets through a CON process, which is periodically evaluated and updated as
required by applicable state law. For those states that require a CON, we must also complete a separate application process establishing a location and must receive
required approvals. Washington and Montana are the only CON state in which we operate home health or hospice agencies.

Patient  Protection  and  Affordable  Care  Act  (“ACA”).  Various  healthcare  reform  provisions  became  law  upon  enactment  of  the  ACA  in  2010.  The
reforms contained in the ACA have affected our independent operating subsidiaries in some manner and are directed in large part at increased quality and cost
reductions. These reforms include modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and
the imposition of enrollment limitations on new providers. Presidential and congressional elections may result in significant changes in legislation, regulation, and
implementation of Medicare, Medicaid, and government policy, along with potential changes to tax rates and other tax treatment of our operations. We continually
monitor these developments so we can respond to the changing regulatory environment impacting our business.

Civil  and  Criminal  Fraud  and  Abuse  Laws  and  Enforcement.  Various  complex  federal  and  state  laws  exist  which  govern  a  wide  array  of  referrals,
relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-
fraud efforts. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and the Balanced Budget Act of 1997 (“BBA”) expanded the penalties
for  healthcare  fraud.  Additionally,  in  connection  with  our  involvement  with  federal  healthcare  reimbursement  programs,  the  government  or  those  acting  on  its
behalf may bring an action under the False Claims Act (“FCA”), alleging that a healthcare provider has defrauded the government by submitting a claim for items
or services not rendered as claimed, which may include coding errors, billing for services not provided, and submitting false or erroneous cost reports. The Fraud
Enforcement  and  Recovery  Act  of  2009  (“FERA”)  expanded  the  scope  of  the  FCA  by,  among  other  things,  creating  liability  for  knowingly  and  improperly
avoiding repayment of an overpayment received from the government and broadening protections for whistleblowers. The FCA clarifies that if an item or service
is provided in violation of the Anti-Kickback Statute, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a
false claim. Civil monetary penalties (“CMPs”) under the FCA range from approximately $11,803 to $23,607 and are adjusted annually for inflation. Under the qui
tam or “whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a
percentage of the federal government’s recovery. Due to these whistleblower incentives, lawsuits have become more frequent. Many states also have a false claim
prohibition that mirrors or tracks the federal FCA. Federal law also provides that the Office of the Inspector General for HHS (“OIG”) has the authority to exclude
individuals  and  entities  from  federally  funded  health  care  programs  on  a  number  of  grounds,  including,  but  not  limited  to,  certain  types  of  criminal  offenses,
licensure revocations or suspensions, and exclusion from state or other federal healthcare programs. In addition, CMS can recover overpayments from health care
providers up to five years following the year in which payment was made.

Monitoring Compliance in our Operations. As a healthcare provider, we have a compliance program to help us comply with various requirements of
federal, state and private healthcare programs. Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws,
regulations,  government  manuals  and  industry  practices  and  customs  that  govern  the  clinical,  reimbursement  and  operational  aspects  of  our  subsidiaries;  (2)
training about our compliance process for the employees of our independent operating subsidiaries, our directors and officers; (3) training about Medicare and
Medicaid  laws,  fraud  and  abuse  prevention,  clinical  standards  and  practices,  and  claim  submission  and  reimbursement  policies  and  procedures  for  appropriate
employees; and (4) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision
of  patient  care,  services,  and  supplies  as  required  by  applicable  standards  and  laws,  accuracy  of  clinical  assessment  and  treatment  documentation,  and
implementation of judicial and regulatory requirements (e.g., background checks, licensing and training).

Additionally, governmental agencies and other authorities periodically inspect our operations to assess our compliance with various standards, rules and
regulations. The robust regulatory and enforcement environment continues to impact healthcare providers, especially in connection with responses to any alleged
noncompliance  identified  in  periodic  surveys  and  other  inspections  by  governmental  authorities.  Unannounced  surveys  or  inspections  generally  occur  at  least
annually at our independent operating subsidiaries and may also follow a government agency's receipt of a complaint about an operation. We

14

Table of Contents

are  also  subject  to  regulatory  reviews  relating  to  Medicare  services,  billings  and  potential  overpayments  resulting  from  the  Recovery  Audit  Contractors,  Zone
Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid
Integrity Contributors programs in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify
potential  improper  payments  under  the  Medicare  programs.  We  must  pass  these  inspections  to  maintain  our  licensure  under  state  law,  to  obtain  or  maintain
certification  under  the  Medicare  and  Medicaid  programs,  to  continue  participation  in  the  Veterans  Administration  (VA)  program  at  some  operations,  and/or  to
comply  with  our  provider  contracts  with  managed  care  clients  at  many  operations.  From  time  to  time,  we,  like  others  in  the  healthcare  industry,  may  receive
notices from federal and state regulatory agencies alleging that we failed to substantially comply with applicable standards, rules or regulations. These notices may
require us to take corrective action, may impose CMPs for noncompliance, and may threaten or impose other operating restrictions. If our operations fail to comply
with  these  directives  or  otherwise  fail  to  comply  substantially  with  licensure  and  certification  laws,  rules  and  regulations,  we  could  lose  our  certification  as  a
Medicare or Medicaid provider, lose our state licenses to operate and be subject to imposed fines and penalties.

Healthcare  operations  in  our  industries  with  otherwise  acceptable  regulatory  histories  are  generally  given  an  opportunity  to  correct  deficiencies  and
continue their participation in the Medicare and Medicaid programs by a certain date, usually within nine months, although where denial of payment or similar
remedies  are  asserted,  such  interim  remedies  go  into  effect  much  sooner.  Operations  with  poor  regulatory  histories  continue  to  be  classified  by  CMS  as  poor
performing  operations  notwithstanding  any  intervening  change  in  ownership,  unless  the  new  owner  obtains  a  new  Medicare  provider  agreement  instead  of
assuming the operation's existing agreement. However, new owners (including us, historically) nearly always assume the existing Medicare provider agreement
due  to  the  difficulty  and  time  delays  generally  associated  with  obtaining  new  Medicare  certifications,  especially  in  previously-certified  locations  with  sub-par
operating histories. Accordingly, operations that have poor regulatory histories before we acquire them may be more likely to have sanctions imposed upon them
by CMS or state regulators.

Regulations  Regarding  Financial  Arrangements.  We  are  also  generally  subject  to  federal  and  state  laws  that  regulate  financial  arrangements  by

healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.

The Anti-Kickback Statute, Section 1128B of the Social Security Act (the “Anti-Kickback Statute”) prohibits the knowing and willful offer, payment,
solicitation,  or  receipt  of  any  remuneration,  directly  or  indirectly,  overtly  or  covertly,  in  cash  or  in-kind,  to  induce  the  referral  of  an  individual,  in  return  for
recommending,  or  to  arrange  for,  the  referral  of  an  individual  for  any  item  or  service  payable  under  any  federal  healthcare  program,  including  Medicare  or
Medicaid.  The  OIG  has  issued  regulations  that  create  “safe  harbors”  for  certain  conduct  and  business  relationships  that  are  deemed  protected  under  the  Anti-
Kickback Statute. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does
not fall within one of these safe harbors, however, does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to
satisfy  the  applicable  safe  harbor  criteria,  if  investigated,  will  be  evaluated  based  upon  all  facts  and  circumstances  and  risk  increased  scrutiny  and  possible
sanctions by enforcement authorities.

Violations of the Anti-Kickback Statute can result in criminal penalties of up to $100,000 and ten years’ imprisonment. Violations of the Anti-Kickback
Statute  can  also  result  in  CMPs  of  over  $100,000  per  violation  (adjusted  annually  for  inflation)  and  an  assessment  of  up  to  three  times  the  total  amount  of
remuneration offered, paid, solicited, or received. Violation of the Anti-Kickback Statute may also result in an individual’s or organization’s exclusion from future
participation in Medicare, Medicaid and other state and federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many
states  in  which  we  operate  have  adopted  or  are  considering  similar  legislative  proposals,  some  of  which  extend  beyond  the  Medicaid  program,  to  prohibit  the
payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care. We believe that business practices of providers and
financial relationships between providers have become subject to increased scrutiny as healthcare reform efforts continue at the federal and state levels.

In addition to these regulations, we may face adverse consequences if we violate the federal Stark laws related to certain Medicare physician referrals.
Section  1877  of  the  Social  Security  Act,  commonly  known  as  the  “Stark  Law,”  provides  that  a  physician  may  not  refer  a  Medicare  or  Medicaid  patient  for  a
“designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement
meets an exception under the Stark Law or its regulations. Any funds collected for an item or service resulting from a referral that violates the Stark Law must be
repaid to Medicare or Medicaid, any other third-party payor, and the patient. In addition, CMPs, which are adjusted for annual inflation, and treble damages may
be imposed for presenting or causing to be presented, a claim for a service rendered in violation of the Stark Law. These CMPs include a penalty of over $25,000
per prohibited claim, and over $170,000 for knowingly entering into certain prohibited cross-referral schemes (adjusted annually for inflation), and potential

15

Table of Contents

exclusion from Medicare for any person who presents or causes to be presented a bill or claim the person knows or should know is submitted in violation of the
Stark laws. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the
designated health services under the Stark Law.

Regulations Regarding Patient Record Confidentiality. We are also subject to laws and regulations enacted to protect the confidentiality of patient health
information.  For  example,  HHS  has  issued  rules  pursuant  to  HIPAA  as  amended  by  the  Health  Information  Technology  for  Economic  and  Clinical  Health
(“HITECH”) Act, which relate to the privacy of certain patient information and provide patients with the right of access to their health information. These rules
govern our use and disclosure of protected health information. We have established policies and procedures to comply with HIPAA privacy, security and breach
notification requirements at our facilities and operations subject to HIPAA. We maintain a company-wide HIPAA compliance plan, which we believe complies
with the HIPAA regulations. The HIPAA regulations have and will continue to impose significant costs on our facilities in order to comply with these standards.
Our operations are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws
vary and could impose additional penalties for privacy and security breaches.

Antitrust Laws. We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and
antitrust  liability  may  arise  in  a  wide  variety  of  circumstances,  including  third  party  contracting,  physician  relations,  joint  venture,  merger,  affiliation  and
acquisition activities. In some respects, the application of federal and state antitrust laws to healthcare is still evolving, and enforcement activity by federal and
state agencies appears to be increasing. At various times, healthcare providers and insurance and managed care organizations may be subject to an investigation by
a  governmental  agency  charged  with  the  enforcement  of  antitrust  laws  or  may  be  subject  to  administrative  or  judicial  action  by  a  federal  or  state  agency  or  a
private party. Violators of the antitrust laws could be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.

Regulations Specific to Senior Living Communities. Senior living services revenue is primarily derived from private pay residents at rates we establish
based upon the needs of the resident, the amount of services we provide the resident, and market conditions in the area of operation. In addition, Medicaid or other
state-specific programs may supplement payments for board and care services provided in senior living communities. A majority of states provide, or are approved
to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities under waivers granted by or under
Medicaid  state  plans  approved  by  CMS.  State  Medicaid  programs  control  costs  for  assisted  living  and  other  home-  and  community-based  services  by  various
means such as restrictive financial and functional eligibility standards, enrollment limits and waiting lists. States that administer Medicaid programs for services in
senior living communities are responsible for monitoring the services at, and physical conditions of, the participating communities. As a result of the growth of
assisted living in recent years, states have adopted licensing standards applicable to assisted living communities. Most state licensing standards apply to assisted
living communities regardless of whether they accept Medicaid funding.

Our senior living segment is subject to a variety of federal, state and local environmental laws and regulations. As a senior living services provider, we
face regulatory requirements in areas of air and water quality control, medical and low-level radioactive waste management and disposal, asbestos management,
response to mold and lead-based paint in our facilities and employee safety.

As  an  operator  of  our  communities,  we  also  may  be  required  to  investigate  and  remediate  hazardous  substances  that  are  located  on  and/or  under  the
property, including any such substances that may have migrated off, or may have been discharged or transported from the property. Part of our operations involves
the  handling,  use,  storage,  transportation,  disposal  and  discharge  of  medical,  biological,  infectious,  toxic,  flammable  and  other  hazardous  materials,  wastes,
pollutants or contaminants. In addition, we are sometimes unable to determine with certainty whether prior uses of our communities and properties or surrounding
properties may have produced continuing environmental contamination or noncompliance, particularly where the timing or cost of making such determinations is
not deemed cost-effective. These activities, as well as the possible presence of such materials in, on and under our properties, may result in damage to individuals,
property or the environment; may interrupt operations or increase costs; may result in legal liability, damages, injunctions or fines; may result in investigations,
administrative proceedings, penalties or other governmental agency actions. Associated costs may not be covered by insurance.

Available Information

We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the Exchange Act). Consequently, we are required
to file reports and information with the Securities and Exchange Commission (“SEC”), including reports on the following forms: annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on

16

Table of Contents

Form  8-K,  and  amendments  to  those  reports  filed  or  furnished  pursuant  to  Section  13(a)  or  15(d)  of  the  Exchange  Act.  These  reports  and  other  information
concerning our company may be accessed through the SEC’s website at http://www.sec.gov.

You  may  also  find  on  our  website  at  www.pennantgroup.com  electronic  copies  of  our  annual  reports  on  Form  10-K,  quarterly  reports  on  Form  10-Q,
current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. Such filings are placed on
our website as soon as reasonably possible after they are filed with the SEC. All such filings are available free of charge. Information contained in our website is
not deemed to be a part of this Annual Report on Form 10-K.

Item 1A. Risk Factors -

Based on the information currently known to us, we believe that the following information identifies material risk factors affecting our company. However,
the risks and uncertainties we face are not limited to those described below. Additional risks and uncertainties may also adversely affect our business. If any of the
following risks and uncertainties develops into actual events, these events could have a material adverse effect on our business, financial condition or results of
operations. In such case, the trading price of our common stock could decline.

Risks Related to Our Business and Industry

Our  revenue  could  be  impacted  by  federal  changes  to  reimbursement  and  other  aspects  of  Medicare.  We  derived  49.3%  of  our  revenue  from  the  Medicare
program for the year ended December 31, 2021, which is typical. In addition, other payors may use published Medicare rates as a basis for reimbursements. The
Medicare program and its reimbursement rates, caps, deductibles and rules are subject to frequent change for a variety of reasons, each of which is discussed in
Item  1.,  Government  Regulation.  Budget  pressures  also  frequently  lead  the  federal  government  to  reduce  or  limit  reimbursement  rates  under  Medicare.
Additionally,  Medicare  payments  can  be  delayed  or  declined  (including  retroactively)  due  to  determinations  that  certain  costs,  services  or  providers  are  not
covered. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, or if there are changes in the way these programs pay
for services or what services or providers are covered, our business and results of operations would be adversely affected. CMS has also introduced in the past, and
will likely introduce in the future, new payment models, such as value-based arrangements, in markets in which we operate. Those models may depend on the
formation  of  preferred  provider  relationships  among  payors  and  providers.  Our  operations  may  not  successfully  implement  or  adapt  to  these  changes  and  our
operations could be materially impacted. As discussed below, Medicare reimbursement and participation may also be tied to the vaccination of employees pursuant
to a new interim final rule published by CMS on November 5, 2021. After initial litigation, the United States Supreme Court stayed injunctions that had been
entered  against  CMS’  enforcement  of  this  rule  as  of  January  13,  2022,  allowing  this  interim  final  rule  requiring  employees  of  certain  Medicare-participating
facilities and services including home health agencies and hospices to be vaccinated, which affects our businesses and employees.

Reductions in Medicaid reimbursement rates or changes in the rules governing the Medicaid program could have a material, adverse effect on our revenues,
financial condition and results of operations. We derived 13.3% of our revenue from Medicaid programs for the year ended December 31, 2021, which is typical.
Medicaid is a state-administered program financed by both state funds and matching federal funds and its reimbursement rates and rules are subject to frequent
change (including retroactively) at both the federal and state level, as discussed in Item 1., Government Regulation. Any budget reductions or funding restrictions,
discontinuance or reduction of federal matching, change in payment methodology or delays in states in which we operate could adversely affect our net patient
service revenue and profitability. We can expect continuing cost containment pressures on Medicaid outlays for our services.

Reforms to the U.S. healthcare system continue to impose new requirements upon us and may lower our reimbursements. The ACA included sweeping changes
to how healthcare is paid for and furnished in the United States. The ACA continues to face legal challenges and calls for repeal or amendment. We cannot predict
what effect these challenges, or other legislative or regulatory changes (including, for instance, proposals for Medicare for All or public option insurers operated by
one or more individual states), will have on our business, including the demand for our services or the amount of reimbursement available for those services. It is
possible new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.

We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts
previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs. As
discussed in greater detail in Item 1., Government Regulation, as a result of our participation in the Medicaid and Medicare programs, we are frequently subject to
various governmental reviews, audits and investigations to verify our compliance with these programs. Private pay sources also reserve the right to conduct audits.
Disagreements about billing and reimbursement are common in our industry due in part to the subjectivity

17

Table of Contents

inherent in patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes. An adverse review,
audit or investigation could result in (1) an obligation to refund amounts previously paid to us by payors in amounts that could vastly exceed the revenue derived
from claims actually reviewed in the audit, and could be material to our business; (2) state or federal agencies imposing fines, penalties and other sanctions on us;
(3) suspension of Medicare or Medicaid payments (4) loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;
(5) an increase in private litigation against us; and (6) damage to our reputation in various markets.

In  cases  where  claim  and  documentation  review  by  any  CMS  contractor  results  in  repeated  poor  performance,  an  operation  can  be  subjected  to  protracted
oversight, and sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare
decertification.  Additionally,  both  federal  and  state  government  agencies  have  heightened  and  coordinated  civil  and  criminal  enforcement  efforts  as  part  of
numerous  ongoing  investigations  of  healthcare  companies.  The  focus  of  these  investigations  includes,  among  other  things:  cost  reporting  and  billing  practices;
quality of care; financial relationships with referral sources; and medical necessity of services provided. If any of our affiliated operations is decertified, loses its
licenses, or is subject to criminal charges or civil claims, administrative sanctions or penalties, our revenue, financial condition or results of operations would be
adversely affected. We or some of the key personnel of our independent operating subsidiaries could also be temporarily or permanently excluded from future
participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare. In addition, the report of such issues at any of our affiliated
operations  could  harm  our  reputation  for  quality  care  and  could  cause  us  to  be  in  default  under  some  of  our  agreements,  including  agreements  governing
outstanding  indebtedness.  Responding  to  audits,  litigation  or  enforcement  efforts  diverts  material  time,  resources  and  attention,  and  could  have  a  materially
detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail.

If  we  do  not  operate  in  compliance  with  the  extensive  laws  and  regulations  to  which  we  are  subject,  or  if  these  laws  and  regulations  change,  we  could  be
required  to  make  significant  expenditures  or  change  our  operations  to  bring  our  operations  into  compliance.  We,  like  other  companies  in  the  healthcare
industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels as discussed in greater detail in
Item 1., Government Regulation. These laws and regulations are subject to frequent and unpredictable change. If we fail to comply with these applicable laws and
regulations,  we  could  suffer  civil  or  criminal  penalties  and  other  detrimental  consequences,  including  denial  of  reimbursement,  imposition  of  fines,  temporary
suspension  of  admission  of  new  patients,  suspension  or  decertification  from  the  Medicaid  and  Medicare  programs,  restrictions  on  our  ability  to  acquire  new
operations or expand or operate existing operations, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement
programs. These laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and
regulations.  Changing  interpretations  or  enforcement  of  these  laws  and  regulations  could  subject  our  current  or  past  practices  to  allegations  of  impropriety  or
illegality or could require us to change our operations, equipment, personnel, services, capital expenditure programs and operating expenses.

Public and government calls for increased survey and enforcement efforts toward our industries could result in increased scrutiny and potential sanctions or
costly remedies. Government authorities have increased the scope or number of inspections or surveys and the severity of consequent citations for alleged failure
to  comply  with  regulatory  requirements.  As  discussed  in  Item  1.,  Government  Regulation,  from  time  to  time  in  the  ordinary  course  of  business,  we  receive
deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. Although most inspection deficiencies are resolved through
an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified operation, which
could result in the imposition of fines, imposition of a provisional or conditional license, suspension or revocation of a license, suspension of new admission or bed
holds, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. Furthermore, in
some  states,  citations  in  one  operation  can  impact  other  operations  in  the  state.  Revocation  of  a  license  or  decertification  at  a  given  operation  could  therefore
impair our ability to obtain new licenses or to renew existing licenses at other operations, which may also trigger defaults or cross-defaults under our leases and
our credit arrangements, or adversely affect our ability to operate in the future. If state or federal regulators were to determine, formally or otherwise, that one
operation’s regulatory history ought to impact another of our existing or prospective communities, this could also increase costs, result in increased scrutiny by
state and federal survey agencies, and impact our expansion plans. In addition, from time to time, we may opt to voluntarily stop accepting new patients pending
completion  of  a  new  state  survey,  to  avoid  straining  staff  and  other  resources  while  retraining  staff,  upgrading  operating  systems  or  making  other  operational
improvements, all of which can impact our financial results.

Future cost containment initiatives undertaken by payors may limit our future revenue and profitability. Our Managed Care revenue and profitability may be
affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare by lowering payment rates, narrowing the scope of covered services
and network providers, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect
the number of

18

Table of Contents

patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced revenue. There can be no assurance
that third-party payors will make timely payments for our services, or that we will continue to maintain our current payor or revenue mix. We are continuing our
efforts to develop our private pay sources of revenue. Any changes in payment levels from current or future third-party payors could have a material adverse effect
on our business and combined financial condition, results of operations and cash flows.

Increased  competition  for,  or  a  shortage  of,  nurses  and  other  skilled  personnel  could  increase  our  staffing  and  labor  costs  and  negatively  impact  our
operations.  Our  success  depends  upon  our  ability  to  retain  and  attract  nurses,  certified  nurse  assistants,  social  workers  and  speech,  physical  and  occupational
therapists,  as  well  as  skilled  personnel  who  are  responsible  for  the  day-to-day  operations  of  each  of  our  affiliated  operations.  If  we  fail  to  attract  and  retain
qualified and skilled personnel, or if the associated costs increase, our independent operating subsidiaries’ ability to conduct their business operations effectively
could  be  harmed.  Staffing  challenges  have  increased  during  the  pandemic  due  to  health  care  worker  burnout,  COVID  exposures,  vaccine  mandates,  and  wage
inflation, increasing the competition for qualified staff and cost of retaining personnel.

We depend on our management team and local leaders, and the loss of their services could harm our business. We believe that our success depends in part on
the continued services of our executive management and local leadership teams. The loss of, or failure to recruit, such key personnel could have a material adverse
effect on our business and could adversely affect our strategic relationships and impede our ability to execute our business strategies. The market for qualified
individuals is highly competitive and finding and recruiting suitable replacements for our leaders may be difficult, time consuming and costly.

Our hospice independent operating subsidiaries are subject to annual Medicare caps calculated by Medicare. With respect to our hospice independent operating
subsidiaries, overall payments made by Medicare for each Medicare beneficiary are subject to caps calculated by Medicare, as discussed in greater detail in Item
1., Government Regulation. If payments received by any one of our hospice provider numbers exceeds the caps for the beneficiary, we are required to reimburse
Medicare for payments received in excess of the caps, which could have a material adverse effect on our business.

Security breaches and other cyber-security incidents could subject us to significant liability. Our business is dependent on the proper functioning and availability
of our computer systems and networks. Our safety and security measures designed to protect our information systems, data and patient health information and
disaster recovery plan may not prevent damage, interruption, or breach of our information systems and operations. In addition, hardware, software or applications
we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our
information systems. Unauthorized parties may attempt to gain access to our systems or operations, or those of third parties with whom we do business, through
fraud or other forms of deceiving our employees or contractors. In addition, costs and potential problems and interruptions associated with the implementation of
new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.
If a cyber-security attack or other unauthorized attempt to access our systems or operations were to be successful, it could result in the theft, destruction, loss,
misappropriation or release of confidential information or intellectual property, and could cause operational or business delays or disruptions that may materially
impact our ability to provide various healthcare services. Any successful cyber-security attack or other unauthorized attempt to access our systems or operations
also  could  result  in  negative  publicity  which  could  damage  our  reputation  or  brand  with  our  patients,  referral  sources,  payors  or  other  third  parties  and  could
subject us to substantial regulatory, civil or criminal penalties, fines, investigations and enforcement actions, including under HIPAA and other federal and state
privacy  laws,  including,  for  example,  the  California  Consumer  Privacy  Act,  which  includes  a  private  right  of  action  that  may  expose  us  to  private  litigation
regarding our privacy practices and significant damages awards or settlements in civil litigation.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of the number of home health, hospice or senior living
operations could impair our ability to expand or result in increased competition. As discussed in greater detail in Item 1., Government Regulation, our ability to
acquire or establish new home health, hospice or senior living operations or expand or provide new services at existing operations would be adversely affected if
we  are  unable  to  obtain  the  necessary  approvals,  if  there  are  changes  in  the  standards  applicable  to  those  approvals,  or  if  we  experience  delays  and  increased
expenses associated with obtaining those approvals. We may not be able to obtain licensure, CON approval, Medicare or Medicaid certification, Attorney General
approval or other necessary approvals for future expansion projects. Conversely, and specific to the highly competitive senior living industry, the elimination or
reduction of state regulations that limit the construction, expansion or renovation of new or existing communities could result in increased competition to us. In
general, regulatory and other barriers to entry in the senior living industry are not prohibitive. Over the last several years, there has been a significant increase in
the construction of new senior living communities, including in the markets where we provide services. This has resulted in increased competition in many of our
markets.  Such  new  competition  may  limit  our  ability  to  attract  new  residents,  raise  rents  or  otherwise  expand  our  senior  living  business,  which  could  have  a
material adverse effect on our revenues, results of operations and cash flow.

19

Table of Contents

Changes in federal and state employment-related laws and regulations could increase our cost of doing business. Our independent operating subsidiaries are
subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs
such matters as minimum wages, overtime and other working conditions, the Americans with Disabilities Act (the “ADA”) and similar state laws that provide civil
rights  protections  to  individuals  with  disabilities  in  the  context  of  employment,  public  accommodations  and  other  areas,  the  National  Labor  Relations  Act,
regulations  of  the  Equal  Employment  Opportunity  Commission,  regulations  of  the  Office  of  Civil  Rights,  regulations  of  state  Attorneys  General,  family  leave
mandates and a variety of similar laws. Because labor represents a large portion of our operating costs, changes in federal and state employment-related laws and
regulations could increase our cost of doing business. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation
of  equal  employment  law.  Employment  claims,  such  as  wage  and  hour  claims,  frequently  are  the  subject  of  class  action  lawsuits  in  many  states  in  which  our
independent affiliates operate, including, for example, California.

Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive
reimbursement  for  such  properties.  Our  independent  operating  subsidiaries  must  be  licensed  under  applicable  state  law  and,  depending  upon  the  type  of
operation,  certified  or  approved  as  providers  under  the  Medicare  and/or  Medicaid  programs.  In  the  process  of  acquiring  or  transferring  operating  assets,  our
operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid, and third party payors. If there are any delays in
receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays could result
in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to
us. We must incur the expense of complying with the federal Fair Housing Act and similar state laws, and applicable fire and safety regulations, building codes
and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time and
the expense may be substantial. Changes to these laws may require us to close operations, limit occupancy, or make other costly changes.

Our  revenue,  financial  condition  and  results  of  operations  could  be  negatively  impacted  by  any  changes  in  the  acuity  mix  of  patients  in  our  affiliated
operations as well as payor mix and payment methodologies. Our revenue is determined in part by the acuity of home health and hospice patients and senior
living residents. Changes in the acuity level of patients we attract, as well as our payor mix among Medicare, Medicaid, managed care organizations and private
payors, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us
at different rates. For the year ended December 31, 2021, 62.6% of our revenue was provided by government payors that reimburse us at predetermined rates,
which  is  typical.  If  we  fail  to  maintain  our  proportion  of  high  acuity  patients  or  if  there  is  any  significant  increase  in  the  percentage  of  the  patients  of  our
independent operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected. Among other initiatives,
these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will
continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce
the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Our business involves a significant risk
of liability given the age and health of the patients and residents of our independent operating subsidiaries and the services we provide. The frequency and severity
of  litigation  in  the  healthcare  industry  has  increased,  due  in  part  to  large  verdicts  and  punitive  damage  awards.  Claims  are  filed  based  upon  a  wide  variety  of
assertions and theories, including deficiencies in conditions of participation under certain state and federal healthcare programs and wage and hour class actions.
Plaintiffs’ attorneys have become increasingly aggressive in their pursuit of claims against healthcare providers, including home health, hospice and senior living
providers, employing a wide variety of advertising and solicitation activities to generate more claims. The defense of lawsuits may result in significant legal costs,
regardless  of  the  outcome.  Additionally,  such  litigation  may  result  in  increased  liability  insurance  premiums  and/or  a  decline  in  available  insurance  coverage
levels, which could materially and adversely affect our business, financial condition and results of operations.

Instances of noncompliance can decrease our revenue.  As  discussed  under  Item  1.,  Monitoring  Compliance  in  our  Operations,  we  have  internal  compliance
policies  and  procedures,  including  ongoing  monitoring  and  controls,  pursuant  to  which  we  have  identified,  and  may  in  the  future  identify,  deficiencies  in  the
assessment of and recordkeeping for patients and residents. We must accrue liabilities for claim costs and interest and repay any amounts due in normal course.
Failure to refund overpayments within required time frames (as described in greater detail under Item 1., Government Regulation) could result in FCA liability.
Additionally, federal and state mandates for vaccination of employees—or in some cases, state actions

20

Table of Contents

prohibiting vaccination—differ and may be difficult to comply with, and non-compliance may result in sanctions or other penalties assessed upon the Company. If
future  investigations  ultimately  result  in  findings  of  significant  billing  and  reimbursement  noncompliance,  which  require  us  to  record  significant  additional
provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected.

We may be unable to complete future acquisitions at attractive prices or at all, which may adversely affect our revenue growth. To date, our revenue growth has
been significantly accelerated by our acquisition of new operations. Subject to general market conditions and the availability of essential resources and leadership
within our company, we continue to seek home health, hospice and senior living acquisition opportunities that are consistent with our geographic, financial and
operating objectives. We face competition for the acquisition of operations and businesses and expect this competition to increase. Based upon factors such as our
ability to identify suitable acquisition candidates, the purchase price of the operations, prevailing market conditions, the availability of leadership to manage new
operations and our own willingness to take on new operations, the rate at which we have historically acquired home health, hospice and senior living operations
has fluctuated and we anticipate similar fluctuation in the future. Further, acquisitions may require financing, which may not be available to us or may be available
to us only on terms that are not favorable. If funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders
would  be  diluted,  and  any  newly  issued  equity  securities  may  have  rights,  preferences  or  privileges  senior  to  those  of  our  common  stock.  We  may  acquire
operations that prove to be non-strategic or less desirable, and we may consider disposing of such operations or exchanging them for operations which are more
desirable.

We may not be able to successfully integrate acquired operations, and we may not achieve the benefits we expect from our acquisitions. We may not be able to
successfully  or  efficiently  integrate  new  acquisitions  with  our  existing  independent  operating  subsidiaries,  culture  and  systems.  We  also  may  determine  that
renovations of acquired operations and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our
existing operations. We may not be able to recover the costs incurred to reposition or renovate newly independent operating subsidiaries. The financial benefits we
expect  to  realize  from  many  of  our  acquisitions  are  largely  dependent  upon  our  ability  to  improve  clinical  performance,  overcome  regulatory  deficiencies,
rehabilitate or improve the reputation of the operations in the community, increase and maintain census, control costs, and in some cases change the patient acuity
mix. Growth also places significant demands on our leaders and operational, financial and management information systems. If we are unable to accomplish any of
these objectives at the independent operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated
profits, or even losses.

In undertaking acquisitions, we may be impacted by costs, liabilities and regulatory issues that may adversely affect our operations. In undertaking acquisitions,
we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated the acquired operations, against whom we may have
little or no recourse. Many operations we have historically acquired were underperforming prior to the acquisition. Even where operations have been improved, we
still  may  face  post-acquisition  regulatory  issues  related  to  pre-acquisition  events.  These  may  include,  without  limitation,  payment  recoupment  related  to  our
predecessors’ prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition
compliance  risk  due  to  the  difficulty  or  impossibility  of  immediately  or  quickly  bringing  non-compliant  operations  into  full  compliance.  Diligence  materials
pertaining to acquisition targets, especially the underperforming operations that often represent the greatest opportunity for return, are often inadequate, inaccurate
or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Operations that we have acquired or may acquire in the
future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other
resources,  or  may  otherwise  not  meet  a  risk  profile  that  our  investors  find  acceptable.  We  also  incur  regulatory  risk  in  acquiring  certain  operations  due  to  the
licensing, certification and other regulatory requirements affecting our right to operate the acquired operations, which are frequently obtained post-closing. If we
were denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and
other challenges which could cause our business to suffer.

If our referral sources fail to view us as an attractive provider, or if our referral sources otherwise refer fewer patients or residents, our patient or resident base
may  decrease.  We  rely  on  appropriate  referrals  from  physicians,  hospitals  and  other  healthcare  providers  in  the  communities  we  serve  to  attract  appropriate
residents and patients to our affiliated operations. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers.
If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as
not providing high quality patient care, our census could decline and our patient mix could change. In addition, if any of our referral sources have a reduction in
patients whom they can refer due to a decrease in their business, our census could decline and patient mix could change.

21

Table of Contents

If  we  do  not  achieve  and  maintain  competitive  quality  of  care  ratings  from  CMS  and  private  organizations  engaged  in  similar  monitoring  activities,  our
business may be negatively affected. Providing quality patient care is the cornerstone of our business. We believe that referral sources, residents and patients select
us in large part because of our reputation for delivering quality care. If we should fail to attain our goals regarding acute care hospitalization readmission rates and
other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and
combined financial condition, results of operations and cash flows.

If  we  are  unable  to  obtain  insurance,  or  if  insurance  becomes  more  costly  for  us  to  obtain,  our  business  may  be  adversely  affected.  It  may  become  more
difficult and costly for us to obtain coverage for patient care liabilities and other risks, including property and casualty insurance. Our claims history, asset mix, or
other factors may adversely affect our ability to obtain insurance at favorable rates. Our insurance carriers may require us to pay substantially higher premiums for
the  same  or  reduced  coverage  for  insurance,  including  workers  compensation,  property  and  casualty,  automobile,  employment  practices  liability,  directors  and
officers liability, employee healthcare and general and professional liability coverages. Further, many claims and other risks we face are not insurable. Attributable
to the COVID-19 pandemic, insurers may increase their exclusions of infectious diseases or raise costs of coverage significantly affecting our ability to obtain
insurance coverage.

We retain certain risks related to our insurance coverage. Under its insurance policies, the Company bears the risk of loss up to specified deductible limits, which
may be substantial if there is a surge in the volume of claims subject to the deductible. The Company recognizes obligations associated with these costs in the
period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs generally are estimated based
on our historical claims experience. Projections of self-insured retention losses are estimates that are subject to significant variability, and as a result, actual losses
and expenses may be more or less than recorded liabilities.

The  unionization  of  our  workers  may  adversely  affect  our  revenue  and  profitability.  To  date,  our  employees  have  chosen  not  to  unionize.  If  they  decide  to
unionize, our cost of doing business could increase, our operations could experience disruption, and affected operations may no longer be economical to continue
operating.

Because we lease all of our affiliated senior living communities, we could experience risks associated with leased property, including risks relating to lease
termination, lease extensions and special charges, which could adversely affect our business, financial position or results of operations. As of December 31,
2021, we leased all of our senior living communities and administrative offices. Most of our leases are triple-net leases, which means that, in addition to rent, we
are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). Under certain master leases, a
breach at a single community could subject one or more of the other communities covered by the same master lease to the same default risk. Failure to comply
with provider requirements is a default under several of the leases and master lease agreements. In addition, lease defaults could trigger cross-default provisions in
our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the
lease without the consent of the landlord.

A housing downturn could decrease demand for assisted living services. Seniors often use the proceeds of home sales to fund their admission to assisted living
communities. A downturn in the housing markets could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing
markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt and operating leases could result in
defaults  under  such  agreements  and  cross-defaults  under  other  debt  or  operating  lease  arrangements,  which  could  harm  our  independent  operating
subsidiaries and cause us to lose operations or experience foreclosures. We have significant future operating lease obligations. We intend to continue financing
operations through long-term operating leases, mortgage financing and other types of financing, including borrowings under our future credit facilities we may
obtain. We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. If we are unable to generate sufficient
cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek
additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital
expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our
operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in
an adverse effect on our future ability to generate revenue and sustain profitability and subject us to foreclosure. In addition, any such financing, refinancing or sale
of assets might not be available on terms that are economically favorable to us, or at all. Our financing arrangements contain restrictions, covenants and events of
default  that,  among  other  things,  could  limit  our  ability  to  respond  to  market  conditions,  provide  for  capital  investment  needs  or  take  advantage  of  business
opportunities by restricting our ability to incur or guarantee additional

22

Table of Contents

indebtedness or requiring us to offer to repurchase such indebtedness in the event of a change of control or a change of control triggering event; pay dividends or
make distributions; make investments or acquisitions; sell, transfer or otherwise dispose of certain assets; create liens; consolidate or merge; enter into transactions
with affiliates; and prepay and repurchase or redeem certain indebtedness.

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity
financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our future portfolio of
cash, cash equivalents and investments. Credit markets are cyclical. Volatility in financial and credit markets may reduce the availability of certain types of debt
financing and restrict the availability of credit. Further, we anticipate that our future cash, cash equivalents and investments may be held in a variety of interest-
bearing instruments. As a result of the uncertain domestic and global political, credit and financial market conditions, investments in these types of instruments
pose risks arising from liquidity and credit concerns.

Inflation may negatively impact profitability. The annual inflation rate of 7% in 2021 has impacted our operations, placing upward pricing pressure on all things
from wages to supplies to energy costs. Inflation is expected to continue in 2022 and may affect the Company’s profit in providing services. We have historically
derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs.
Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually. These adjustments may not continue in the
future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services. Labor and supply expenses make
up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the
marketplace.

Delays  in  reimbursement  may  cause  liquidity  problems.  If  we  experience  problems  with  our  billing  information  systems  or  if  issues  arise  with  Medicare,
Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors
instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews. Some states in which we operate are operating with
budget deficits or could have a budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from
time  to  time,  procedural  issues  require  us  to  resubmit  claims  before  payment  is  remitted,  which  contributes  to  our  aged  receivables.  Unanticipated  delays  in
receiving  reimbursement  from  state  programs  due  to  changes  in  their  policies  or  billing  or  audit  procedures  may  adversely  impact  our  liquidity  and  working
capital. As discussed in Item 1., Government Regulation, with the elimination in fiscal year 2021 of RAPs and introduction of the NOA submission procedure, we
may experience higher receivables and reduced cash flows as collections are delayed upon implementation. Beginning in fiscal year 2022, CMS is replacing the
RAP process with the filing of a single NOA by home health agencies, which will cover continuous 30-day periods of care until the patient is discharged. This
transition may cause delays in payment from CMS or even denial of payment, as the NOA process will be new for both CMS and the Company.

Compliance with the regulations of the Department of Housing and Urban Development (“HUD”) may require us to make unanticipated expenditures which
could  increase  our  costs.  Seventeen  of  our  affiliated  senior  living  communities  are  currently  subject  to  regulatory  agreements  with  HUD  that  give  the
Commissioner of HUD broad authority to require us to be replaced as the operator of those communities in the event that the Commissioner determines there are
operational deficiencies at such communities under HUD regulations. Compliance with HUD’s requirements can often be difficult because these requirements are
not always consistent with the requirements of other federal and state agencies and, in some instances, may require us to make additional capital expenditures to
meet  HUD’s  heightened  requirements.  Appealing  a  failed  inspection  can  be  costly  and  time-consuming  and,  if  we  do  not  successfully  remediate  the  failed
inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured
communities.

Failure to comply with existing environmental laws could result in increased expenditures, litigation and potential loss to our business and in our asset value.
Our independent operating subsidiaries are subject to regulations under various federal, state and local environmental laws, primarily those relating to the handling,
storage, transportation, treatment and disposal of medical waste; the identification and warning of the presence of asbestos-containing materials in buildings, as
well as the encapsulation or removal of such materials; and the presence of other substances in the environment. The presence of such materials may be unknown
and could result in remediation costs, fines, damages and other material harm to our business.

We  are  a  holding  company  with  no  operations  and  rely  upon  our  independent  operating  subsidiaries  to  provide  us  with  the  funds  necessary  to  meet  our
financial obligations. We are a holding company with no direct operating assets, employees or revenues. Each of our affiliated operations is operated through a
separate, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold
in  our  independent  operating  subsidiaries.  As  a  result,  we  are  dependent  upon  distributions  from  our  subsidiaries  to  generate  the  funds  necessary  to  meet  our
financial obligations. Our subsidiaries are legally distinct from us and have no obligation to make funds

23

Table of Contents

available  to  us.  The  ability  of  our  subsidiaries  to  make  distributions  to  us  will  depend  substantially  on  their  respective  operating  results  and  will  be  subject  to
restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or
stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.

Two of our directors continues to serve as a director on the Ensign board of directors, and ownership of shares of Ensign common stock or equity awards of
Ensign by our directors and executive officers may create conflicts of interest or the appearance of conflicts of interest. Two of our directors continues to serve
on the Ensign board of directors and substantially all of our executive officers and some of our non-employee directors own shares of Ensign common stock. This
could create, or appear to create, potential conflicts of interest when our or Ensign’s management or directors face decisions that could have different implications
for  us  and  Ensign,  including  the  resolution  of  any  dispute  regarding  the  terms  of  the  agreements  governing  the  Spin-Off  and  the  relationship  between  us  and
Ensign after the Spin-Off, any commercial agreements entered into in the future between us and Ensign and the allocation of such directors’ time between us and
Ensign.

Risks Related to Ownership of Our Common Stock

Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay acquisition attempts for us that you might consider
favorable. Our  amended  and  restated  certificate  of  incorporation  and  amended  and  restated  bylaws  may  make  the  merger  or  acquisition  of  our  company  more
difficult without the approval of our board of directors. Among other things, these provisions: allow us to authorize the issuance of undesignated preferred stock,
the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include super voting, special approval,
dividend, or other rights or preferences superior to the rights of the holders of common stock; establish advance notice requirements for nominations for elections
to our board or for proposing matters that can be acted upon by stockholders at stockholder meetings; create a classified board of directors whose members serve
staggered three-year terms; and limit the ability of our stockholders to call and bring business before special meetings. Further, as a Delaware corporation, we are
also subject to provisions of Delaware law, which may impair a takeover attempt that our stockholders may find beneficial. These provisions could discourage,
delay or prevent a transaction involving a change in control of our company, including actions that our stockholders may deem advantageous, or negatively affect
the trading price of our common stock. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of
their choosing and to cause us to take other corporate actions desired.

Risks Related to COVID-19

COVID-19  has  created  new  regulatory  risks  that  impact  our  operations.  COVID-19  has  generated,  and  will  likely  continue  to  generate,  dramatic  and  rapid
changes  in  the  laws  affecting  our  operations.  U.S.  Federal,  state,  and  local  regulators  have  implemented  new  laws,  rules,  regulations,  and  orders,  or  waived  or
modified existing laws, rules and regulations for the duration of the COVID-19 public health emergency. Most of these changes have been made without following
typical  regulatory  or  legislative  processes  and  procedures  and  have  been  announced  via  website  postings  or  fact  sheets  with  limited  notice  and  without  full
regulations  or  guidance  in  place.  While  many  of  the  changes  are  beneficial  in  that  they  reduce  or  eliminate  statutory  or  regulatory  requirements  for  healthcare
providers  during  the  COVID-19  public  health  emergency,  we  remain  subject  to  the  risk  of  inadvertent  non-compliance  due  to  the  quantity,  ambiguity  and
frequency of changes. The regulatory changes may also adversely effect our operations through increased legal and operational costs related to compliance with
changes and monitoring for future changes. Further, the resumption of pre-COVID-19 regulatory requirements at the conclusion of the public health emergency
may require significant operational changes on short notice.

COVID-19 and related risks have affected and could materially affect our results of operations, financial position and/or liquidity. The global spread of
COVID-19 and the various attempts to contain it have created significant volatility, uncertainty and economic disruption. See “Part I—Item 2—Management’s
Discussion and Analysis of Financial Condition and Results of Operations—COVID-19” herein. Now two years into the COVID-19 pandemic, many of the direct
and indirect consequences of COVID-19 on our business are known, although new developments such as waves of COVID-19 variants and second-order effects
such as supply chain issues are ongoing and the full range of their direct and indirect consequences on our business are not yet known. Risks presented by the
ongoing effects of COVID-19 include the following:

•

In addition to the hazards posed by COVID-19 itself, the disruption caused by repeated waves of COVID-19 variants, including breakthrough infections
of fully vaccinated individuals, poses a risk to the Company for the foreseeable future due to the potential consequences of such variants on Company
personnel, labor pool participants, availability of necessary supplies, continued adverse impact on move-in rates within senior living, and consequences
for the broader economy.

• Decreased home health and hospice volumes and senior living occupancy, which has led to decreased revenue.

24

Table of Contents

•

•

•

Increased  costs  and  staffing  requirements  related  to  implementation  of  COVID-19  infection  prevention  protocols,  including  increased  utilization  of
personal protective equipment (“PPE”), COVID-19 diagnostic testing and vaccination for staff and residents, and additional labor and cleaning supplies to
frequently sterilize equipment and surfaces.

Increased labor costs due to increased overtime or premium pay, paid leave, reduced labor force participation, wage pressure from competitors, workers
becoming ineligible for employment due to COVID-19 vaccination requirements, mandatory testing costs, and the increased need for temporary labor to
supplement our existing staffing as our front-line employees may become unable to work while awaiting the results of COVID-19 tests or as they recover
from a COVID-19 infection.

Increased scrutiny by regulators of infection control and prevention measures, including imposition of new COVID-19 disease and mortality reporting
requirements, and increased enforcement of resident rights’ violations related to visitation.

• Disruptions to supply chains which could negatively impact consistent and reliable delivery of PPE, sanitizing supplies, food, pharmaceuticals, and other

goods.

•

•

•

•

•

COVID-19  related  illnesses  in  staff  may  impact  the  quality  of  care,  which  could  lead  to  temporary  staffing  shortages  or  reliance  on  less  experienced
personnel.

Employee concerns related to workplace safety, including potential for increase in workers’ compensation claims.

Potential increase in insurance premiums and COVID-19 related claims.

Inconsistent application or interpretation of modifications to regulatory requirements by surveyors.

Potential for continued inflation resulting from changes in economic conditions and steps taken by the federal government and the Federal Reserve in
response to COVID-19, which could lead to higher inflation rates or longer-lasting inflation than anticipated, which could in turn lead to an increase in
expenses, including rent expense under our triple net leases. All of the triple net leases in our senior living business contain annual rent escalators tied to
year-over-year increases in various consumer price indices. While these leases contain provisions capping the increased rent expense each year, increased
inflation could cause our rent expense in our senior living business to increase at a greater rate than in prior years.

COVID-19 could lead to future litigation. COVID-19 has affected virtually all businesses in the country, and healthcare providers have been acutely impacted due
to  direct  involvement  with  the  virus.  The  challenges  of  dealing  with  a  global  pandemic  have  been  amplified  by  supply  shortages,  lack  of  available  tests,  and
constantly  evolving  information.  It  is  likely  that  healthcare  companies,  including  those  in  the  post-acute  care  and  senior  living  industries  in  which  we  operate,
could become targets of plaintiffs’ litigation, alleging negligence, wrongful death, and similar claims resulting from where cases of COVID-19 occurred in senior
living communities and through the direct contact with COVID-19 positive patients of our home health and hospice providers . If we or our operations are subject
to litigation of this nature, such litigation may result in legal fees, damages, fines or settlements in amounts that could be material.

Rules mandating COVID-19 vaccination may subject us to penalties and other challenges. Various federal, state and local governments have issued, or indicated
an intention to issue, COVID-19 vaccination requirements for health care workers and other workers. Most notably, on November 4, 2021, CMS issued an interim
final  rule  requiring  full  vaccination  of  personnel  working  for  operations  reimbursed  by  Medicare  or  Medicaid.  The  United  States  Supreme  Court  upheld  this
mandate on January 13, 2022, and the compliance deadline for full vaccination ranges from February 28 (in states that did not challenge the mandate) to March 15,
2022 (in most other states) to March 21, 2022 (in Texas).

States  where  we  operate  have  imposed  their  own  vaccine  mandates  as  well.  During  2021,  California,  Colorado,  Oregon  and  Washington  each  issued  orders
requiring that all or some employees and contractors of our independent operating subsidiaries be fully vaccinated. In addition, on December 22, 2021 California
ordered that health care workers who are booster-eligible must receive a vaccine booster by February 1, 2022.

The Company may be subject to fines, penalties or judgments, or may otherwise be negatively impacted, if it is found not to have complied with any such current
or future vaccination requirements. Current or prospective employees may oppose vaccination, making it more difficult to recruit or retain staff.

Additionally, as of January 2022, the FDA and CDC approved the use of COVID-19 vaccine booster shots for most individuals. The Company may be subject to
fines, penalties, judgments, or otherwise be negatively impacted based on loss of skilled

25

Table of Contents

workers  or  increased  competition  and  cost  to  acquire  skilled  workers  in  the  event  of  worker  hesitancy  or  aversion  to  vaccine  booster  shots,  or  a  change  in  the
definition  or  understanding  of  “fully  vaccinated”  under  CMS,  OSHA  or  other  state  regulations  that  currently,  or  may  in  the  future,  require  employees  to  have
received booster shots to maintain their fully vaccinated status.

Expiration  of  Certain  Waivers  and  Changes  in  CMS  Reporting  Practices. In  response  to  the  COVID-19  pandemic,  CMS  issued  numerous  blanket  waivers
effective March 20, 2020, to ease reporting requirements and other administrative burdens on health care providers during the COVID-19 public health emergency.
Certain of these waivers have begun to expire, and more waivers may expire in 2022. The expiration of these waivers may affect our operating costs due to the
reinstitution of reporting regarding staffing data and other information that was not required to be reported during the COVID-19 public health emergency until the
expiration  of  those  waivers;  the  expiration  of  these  waivers  may  additionally  affect  our  ability  to  use  certain  billing  codes  when  seeking  reimbursement  from
Medicare or Medicaid, which may affect our financial performance.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Service Center

We  lease  two  office  locations  to  accommodate  our  Service  Center.  We  lease  approximately  14,287  square  feet  of  office  space  located  at  1675  East
Riverside Drive, Suite 150, Eagle, ID 83616, pursuant to a lease that expires March 31, 2025. Our principal executive offices are located at the Service Center in
Eagle, Idaho. We have two options to extend our lease term at this location for an additional five-year term for each option. In addition, we currently lease 6,209
rentable square feet of office space located at 1600 West Broadway Road, Suite 100, Tempe, Arizona 85282, pursuant to a lease that expires September 30, 2024.
We have one option to extend our lease term at this location for one additional five-year term.

Home Health and Hospice Agencies and Senior Living Communities

As of December 31, 2021, we operated 88 home health, hospice and home care agencies in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada,

Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Office space is leased within geographies served by our agencies.

As of December 31, 2021, we operated 54 affiliated senior living communities in Arizona, California, Nevada, Texas, Washington and Wisconsin, with

4127 Senior Living units. We lease all of our communities through long-term, triple-net lease arrangements.

26

Table of Contents

The following table provides summary information regarding the locations of our home health and hospice agencies and our senior living communities

and operational units as of December 31, 2021:

State
Arizona
California
Colorado
Idaho
Iowa
Montana
Nevada
Oklahoma
Oregon
Texas
Utah
Washington
Wisconsin
Wyoming

Total

Home Health
Agencies

  Hospice Agencies

Senior Living
Communities

4 
6 
6 
4 
1 
— 
1 
2 
2 
5 
9 
6 
1 
1 
48 

8 
5 
1 
3 
1 
1 
2 
1 
1 
8 
4 
3 
1 
1 
40 

Senior Living Units
1,249 
761 
— 
164 
— 
— 
385 
— 
— 
712 
— 
98 
758 
— 
4,127 

7 
9 
— 
2 
— 
— 
4 
— 
— 
12 
— 
1 
19 
— 
54 

Item 3.    Legal Proceedings

We are involved in various claims and lawsuits arising in the ordinary course of business, none of which, in the opinion of management, is expected to
have a material adverse effect on our results of operations or financial condition. However, the results of such matters cannot be predicted with certainty and we
cannot assure you that the ultimate resolution of any legal or administrative proceeding or dispute will not have a material adverse effect on our business, financial
condition, results of operations and cash flows. See Note 15, Commitments and Contingencies, to the Audited Consolidated and Combined Financial Statements
for a description of claims and legal actions arising in the ordinary course of our business.

Item 4.    Mine Safety Disclosures

None.

Item 5.     Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Part II.

Our Common stock has traded under the symbol “PNTG” on the NASDAQ Global Select Market since our Spin-Off on October 1, 2019. Prior to that
date  we  were  a  subsidiary  of  Ensign,  which  trades  under  the  ticker  “ENSG”  on  the  NASDAQ  Global  Select  Market.  As  of  February  28,  2022,  there  were
approximately 60 holders of record of our stock.

Dividend Policy

We do not intend to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our future earnings will be retained to

support our operations and to finance the growth and development of our business.

27

Table of Contents

Stock Performance Graph

The  following  Stock  Performance  Graph  and  related  information  shall  not  be  deemed  “soliciting  material”  or  “filed”  with  the  SEC,  nor  should  such
information be incorporated by reference into any future filings under the Securities Act or the Exchange Act except to the extent that we specifically incorporate it
by reference in such filing.

The graph below compares the cumulative total stockholder return on our common stock, $0.001 par value per share, during the period from the date of
the Spin-Off on October 1, 2019, through December 31, 2021, with the cumulative total return on the NASDAQ composite index and an industry peer group over
the same period (assuming the investment of $100 in our common stock, the NASDAQ composite index and the industry peer group on October 1, 2019 and the
reinvestment  of  dividends).  The  peer  group  we  selected  is  comprised  of:  Amedysis,  Inc.  (“AMED”),  Addus  Homecare  Corporation  (“ADUS”),  Chemed
Corporation (“CHE”), Encompass Health Corporation (“EHC”), LHC Group, Inc. (“LHCG”), Sonida Senior Living Inc., formerly known as Capital Senior Living
Corporation  (“SNDA”),  and  Brookdale  Senior  Living,  Inc.  (“BKD”).  The  cumulative  total  stockholder  return  on  the  following  graph  is  historical  and  is  not
necessarily indicative of future stock price performance. No cash dividends have been paid on our common stock.

10/1/2019

12/31/2019

3/31/2020

6/30/2020

9/30/2020

12/31/2020

3/31/2021

6/30/2021

9/30/2021

12/31/2021

PNTG
NASDAQ
Peer Group

100 
100 
100 

219 
113 
113 

94 
97 
105 

150 
127 
116 

256 
141 
129 

385 
163 
147 

304 
167 
134 

271 
183 
134 

186 
183 
113 

152 
199 
120 

Item 6.     [Reserved]

Item 7.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the consolidated and combined financial statements and accompanying notes, which appear
elsewhere  in  this  Annual  Report.  This  discussion  contains  forward-looking  statements  that  involve  risks  and  uncertainties.  Our  actual  results  could  differ
materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual
Report. See Item 1A., Risk Factors and Cautionary Note Regarding Forward-Looking Statements.

Overview

We are a leading provider of high-quality healthcare services to patients and residents of all ages, including the growing senior population, in the United
States. We strive to be the provider of choice in the communities we serve through our innovative operating model. We operate in multiple lines of businesses
including home health, hospice and senior living services across Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah,
Washington, Wisconsin and Wyoming. As of December 31, 2021, our home health and hospice business provided home health, hospice and home care services
from 88 agencies operating across 14 states, and our senior living business operated 54 senior living communities throughout seven states.

28

Table of Contents

The following table summarizes our affiliated home health and hospice agencies and senior living communities as of:

Home health and hospice agencies
Senior living communities
Senior living units
Total number of home health, hospice, and senior
living operations

COVID-19

2013

2014

2015

2016

16 
12 
1,256 

25 
15 
1,587 

32 
36 
3,184 

39 
36 
3,184 

December 31,
2017

2018

2019

2020

2021

46 
43 
3,434 

54 
50 
3,820 

63 
52 
3,963 

76 
54 
4,127 

88 
54 
4,127 

28 

40 

68 

75 

89 

104 

115 

130 

142 

We have been, and we expect to continue to be, impacted by several factors related to the viral disease known as COVID-19 that may cause actual results
to differ from our historical results or current expectations. Due to the COVID-19 pandemic, the results presented in this report are not necessarily indicative of
future operating results. The situation surrounding COVID-19 remains fluid. We are actively managing our response in collaboration with government officials,
team members and business partners, and we are assessing potential impacts to our financial position and operating results, as well as adverse developments in our
business.

Home Health and Hospice

During the year ended December 31, 2021, the labor challenges experienced throughout the COVID-19 pandemic were exacerbated as cases rose sharply,
leading to further wage pressure, increased overtime and greater use of agency and registry staffing resulting in challenges to properly staff referrals. Home health
admissions  during  the  second  half  of  the  year  were  impacted  as  more  staff  entered  the  quarantine  protocol  and  by  a  significant  decline  in  elective  procedures,
particularly in a few key markets and states that re-imposed temporary halts on such procedures.

Senior Living

COVID-19 continues to impact all aspects of our senior living business and geographies, including impacts on our residents, team members, vendors and
business partners. We experienced a decline in occupancy during the first quarter of the year followed by several months of increased occupancy that began in the
second quarter and continued into the third quarter. Our occupancy began to decline in the latter part of September and our overall senior living occupancy has
decreased since the onset of the COVID-19 pandemic due to a greater number of move outs net of move ins. We cannot be sure if or when the occupancy levels in
our senior living communities will improve over multiple measurement periods or return to pre-pandemic levels.

Labor

We have experienced and expect to continue to see increased labor costs due to greater competition for skilled workers, worker burnout, increased wage
rates, increased overtime and premium pay, and the increased need for temporary labor to supplement our existing staffing. We are monitoring the ongoing impact
of our COVID-19 response actions on our revenue and expenses, including labor acquisition and turnover costs that may be imposed by existing and anticipated
state and federal vaccination mandates imposed for workers in home health agencies, senior living communities and other health care service providers. However,
the extent to which COVID-19 will continue to impact our operations will depend on future developments, which remain uncertain and cannot be predicted with
confidence, including the pace of spread and impact of other potential variant strains, and the actions taken to contain COVID-19 or treat its impact, among others.

Recent Activities

Acquisitions.  During  2021,  we  expanded  our  operations  with  the  addition  of  five  home  health  agencies,  four  hospice  agencies  and  two  home  care
agencies. We entered into a separate operations transfer agreement with the prior operator as part of each transaction. The aggregate value for these acquisitions
was $14.1 million. For further discussion of our acquisitions, see Note 7, Acquisitions, in the Notes to the consolidated and combined financial statements.

Amended Credit Facility. On February 23, 2021, we amended our existing revolving credit facility to increase our aggregate principal amount available

from $75.0 million to $150.0 million.

29

Table of Contents

Subsequent  Transaction.  On  January  27,  2022,  certain  of  our  affiliates  entered  into  operations  transfer  agreements  (collectively,  the  “Transfer
Agreements”)  with  affiliates  of  Ensign,  providing  for  the  transfer  of  the  operations  of  certain  senior  living  communities  (the  “Transaction”).  The  Transfer
Agreements  require  one  of  the  transferors  to  place  in  escrow  $6.5  million  to  cover  post-closing  capital  expenditures  and  operating  losses  related  to  one  of  the
communities. The closing of the Transaction is anticipated to occur in the first half of 2022, subject to receipt of applicable regulatory approvals and satisfaction of
other customary closing conditions set forth in the Transfer Agreements. For further details about the impact of the transaction see Note 16, Subsequent Event.

Trends

Since the pandemic began and until the first quarter of 2021, we experienced a steady decline in senior living occupancy as move-ins declined relative to
move-outs due to the pandemic. Beginning in the second quarter of 2021, and continuing into the third quarter, we experienced a slight increase in our senior living
occupancy; however with the emergence of the “Omicron” variant strain of COVID-19 in the fourth quarter we experienced a slight decrease in occupancy during
the  year  ended  December  31,  2021.  We  cannot  be  sure  when  the  occupancy  levels  in  our  senior  living  communities  will  return  to  pre-pandemic  levels.  As
uncertainty  regarding  the  COVID-19  pandemic  persists  and  with  the  resurgence  in  cases  due  to  variant  strains  aggressively  emerging,  we  could  see  a  more
prolonged recovery.

When we acquire turnaround or start-up operations, we expect that our combined metrics may be impacted. We expect these metrics to vary from period
to period based upon the maturity of the operations within our portfolio. We have generally experienced lower occupancy rates at our senior living communities
and lower census at our home health and hospice agencies for recently acquired operations; as a result, we generally anticipate lower consolidated and segment
margins during years of high acquisition growth. We established three start-up hospice agencies in Arizona, Texas and Washington, and one home care agency in
Arizona during the year ended December 31, 2021.

Regulation

The  Coronavirus  Aid,  Relief,  and  Economic  Security  Act  (the  “CARES  Act”)  was  enacted  on  March  27,  2020  in  the  United  States  and  subsequent
regulatory actions. The CARES Act contained provisions for accelerated or advance Medicare payments (“AAP”) to provide supporting cash flow to providers and
suppliers combating the effects of the COVID-19 pandemic. We applied for and received $28.0 million in 2020. These funds are subject to automatic recoupment
through offsets to new claims beginning one year after payment were issued. In April, 2021, CMS began to automatically recoup 25% of Medicare payments from
individual agencies, which will continue for 11 months. At the end of the 11 months assuming full repayment has not occurred, recoupment will increase to 50%
for  another  six  months.  Any  balance  outstanding  after  these  two  recoupment  periods  will  be  subject  to  repayment  at  a  4%  interest  rate.  As  of  the  year  ended
December 31, 2021, the Company had repaid $21.8 million of the AAP funds, with the remaining balance of $6.2 million recorded in other accrued liabilities on
the consolidated balance sheets. We anticipate completing repayment of the AAP within the allotted recoupment periods.

The CARES Act temporarily suspended the 2% sequestration payment adjustment on Medicare fee-for-service payment beginning May 1, 2020 and was
extended  through  December  31,  2021.  We  recognized  $3.6  million  and  $2.8  million  in  revenue  related  to  the  suspension  of  sequestration  for  the  years  ended
December 31, 2021 and 2020, respectively, exclusive of our start-up operations. Further, the CARES Act payroll tax deferral program allowed employers to defer
the deposit and payment of the employer’s portion of social security taxes that otherwise would be due between March 27, 2020, and December 31, 2020. The
CARES Act permits employers to deposit half of these deferred payments by the end of 2021 and the other half by the end of 2022. We deferred approximately
$7.8 million of employer-paid portion of social security tax. In the fourth quarter of the current year, we repaid $3.7 million and approximately $4.1 million of the
balance remains deferred and is recorded in accrued wages and related liabilities on the consolidated balance sheets.

The American Rescue Plan Act of 2021 (the “ARP Act”) was enacted on March 11, 2021 in the United States. The ARP Act was designed to assist the
country with the effects of the COVID-19 pandemic and included a number of tax components. The ARP Act’s primary tax impact on us is a new revenue raising
provision that requires us to include the next five highest paid employees to the list of covered officers already subject to the IRC Section 162(m) wage limitation
beginning in the 2027 tax year.

Segments

We  have  two  reportable  segments:  (1)  home  health  and  hospice  services,  which  includes  our  home  health,  home  care  and  hospice  businesses;  and  (2)

senior living services, which includes the operation of assisted living, independent living and

30

Table of Contents

memory care communities. Our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), reviews financial information at the operating
segment level using segment adjusted EBITDAR from operations. We also report an “all other” category that includes general and administrative expense from our
Service Center.

Key Performance Indicators

We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. These indicators and their

definitions include the following:

Home Health and Hospice Services

•

•

•

•

•

Total home health admissions. The total admissions of home health patients, including new acquisitions, new admissions and readmissions.

Total Medicare home health admissions. Total admissions of home health patients, who are receiving care under Medicare reimbursement programs,
including new acquisitions, new admissions and readmissions.

Average  Medicare  revenue  per  completed  60-day  home  health  episode.  The  average  amount  of  revenue  for  each  completed  60-day  home  health
episode generated from patients who are receiving care under Medicare reimbursement programs.

Total hospice admissions. Total admissions of hospice patients, including new acquisitions, new admissions and recertifications.

Average hospice daily census. The average number of patients who are receiving hospice care during any measurement period divided by the number
of days during such measurement period.

• Hospice Medicare revenue per day. The average daily Medicare revenue recorded during any measurement period for services provided to hospice

patients.

The following table summarizes our overall home health and hospice statistics for the periods indicated:

Home health services:

Total home health admissions
Total Medicare home health admissions
Average Medicare revenue per 60-day completed episode

(a)

Hospice services:

Total hospice admissions
Average hospice daily census
Hospice Medicare revenue per day

Year Ended December 31,
2020
2021

37,366 
17,356 

3,405  $

8,613 
2,291 

174  $

26,670 
12,974 
3,290 

8,186 
2,083 
166 

$

$

(a)

The year to date average for Medicare revenue per 60-day completed episode includes post period claim adjustments for prior periods.

Senior Living Services

• Occupancy. The ratio of actual number of days our units are occupied during any measurement period to the number of units available for occupancy

during such measurement period.

•

Average  monthly  revenue  per  occupied  unit.  The  revenue  for  senior  living  services  during  any  measurement  period  divided  by  actual  occupied
senior living units for such measurement period divided by the number of months for such measurement period.

The following table summarizes our senior living statistics for the periods indicated:

31

Table of Contents

Occupancy
Average monthly revenue per occupied unit

Revenue Sources

Home Health and Hospice Services

Year Ended December 31,

2021

2020

$

72.7 %
3,207 

$

77.7 %
3,188 

Home Health. We derive the majority of our home health revenue from Medicare and managed care. The Medicare payment is adjusted for differences
between  estimated  and  actual  payment  amounts,  an  inability  to  obtain  appropriate  billing  documentation  or  authorizations  acceptable  to  the  payor  and  other
reasons unrelated to credit risk. For Medicare episodes that began prior to January 1, 2020, home health agencies were reimbursed under the Medicare HH PPS,
while Medicare periods of care that began on or after that date are reimbursed under the PDGM methodology. Under PDGM, Medicare provides agencies with
payments for each 30-day period of care provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second
30-day payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive.
While  payment  for  each  30-day  period  of  care  is  adjusted  to  reflect  the  beneficiary’s  health  condition  and  needs,  a  special  outlier  provision  exists  to  ensure
appropriate  payment  for  those  beneficiaries  that  have  the  most  expensive  care  needs.  The  payment  under  the  Medicare  program  is  also  adjusted  for  certain
variables including, but not limited to: (a) a low utilization payment adjustment if the number of visits is below an established threshold that varies based on the
diagnosis  of  a  beneficiary;  (b)  a  partial  payment  if  the  patient  transferred  to  another  provider  or  the  Company  received  a  patient  from  another  provider  before
completing the period of care; (c) adjustment to the admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting
within 14 days prior to the start of a 30-day payment period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date,
regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-
day  period  of  care;  (f)  changes  in  the  base  payments  established  by  the  Medicare  program;  (g)  adjustments  to  the  base  payments  for  case  mix  and  geographic
wages; and (h) recoveries of overpayments.

Hospice. We derive the majority of our hospice business revenue from Medicare reimbursement. The estimated payment rates are calculated as daily rates
for each of the levels of care we deliver. Rates are set based on specific levels of care, are adjusted by a wage index to reflect healthcare labor costs across the
country and are established annually through federal legislation. The following are the four levels of care provided under the hospice benefit:

•

Routine Home Care (“RHC”). Care that is not classified under any of the other levels of care, such as the work of nurses, social workers or home health
aides.

• General Inpatient Care. Pain control or acute or chronic symptom management that cannot be managed in a setting other than an inpatient Medicare-

certified facility, such as a hospital, skilled nursing facility or hospice inpatient facility.

•

•

Continuous Home Care. Care for patients experiencing a medical crisis that requires nursing services to achieve palliation and symptom control, if the
agency provides a minimum of eight hours of care within a 24-hour period.

Inpatient Respite Care. Short-term, inpatient care to give temporary relief to the caregiver who regularly provides care to the patient.

CMS has established a two-tiered payment system for RHC. Hospices are reimbursed at a higher rate for RHC services provided from days of service 1
through 60 and a lower rate for all subsequent days of service. CMS also provided for a Service Intensity Add-On, which increases payments for certain RHC
services provided by registered nurses and social workers to hospice patients during the final seven days of life.

Medicare  reimbursement  is  adjusted  for  an  inability  to  obtain  appropriate  billing  documentation  or  authorizations  acceptable  to  the  payor  and  other
reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider
numbers and based upon empirical experience estimate amounts due back to Medicare to the extent that the cap has been exceeded.

32

Table of Contents

Senior  Living  Services.  Within  our  senior  living  operations,  we  generate  revenue  primarily  from  private  pay  sources,  with  a  portion  earned  from

Medicaid or other state-specific programs.

Primary Components of Expense

Cost of Services (excluding rent, general and administrative expense and depreciation and amortization). Our cost of services represents the costs of
operating  our  independent  operating  subsidiaries,  which  primarily  consists  of  employee  wages  and  related  benefits,  supplies,  purchased  services,  and  ancillary
expenses such as the cost of pharmacy and therapy services provided to patients or residents. Cost of services also includes the cost of general and professional
liability insurance and other general cost of services specifically attributable to our operations.

Rent—Cost  of  Services.  Rent—cost  of  services  consists  solely  of  base  minimum  rent  amounts  payable  under  lease  agreements  to  our  landlords.  Our
subsidiaries lease and operate but do not own the underlying real estate at our operations, and these amounts do not include taxes, insurance, impounds, capital
reserves or other charges payable under the applicable lease agreements.

General and Administrative Expense. General and administrative expense consists primarily of payroll and related benefits and travel expenses for our
Service  Center  personnel  in  providing  training  and  other  operational  support.  General  and  administrative  expense  also  includes  professional  fees  (such  as
accounting and legal fees), costs relating to our information systems, share-based compensation and rent for our Service Center offices.

Depreciation and Amortization. Property and equipment are recorded at their original historical cost. Depreciation is computed using the straight-line
method over the estimated useful lives of the depreciable assets (ranging from three to 15 years). Leasehold improvements are amortized on a straight-line basis
over the shorter of their estimated useful lives or the remaining lease term.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated and combined financial statements, which
have  been  prepared  in  accordance  with  U.S.  generally  accepted  accounting  principles  (“GAAP”).  The  preparation  of  these  financial  statements  and  related
disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis we review
our judgments and estimates, including but not limited to those related to revenue, cost allocations, leases, intangible assets, goodwill, and income taxes. We base
our estimates and judgments upon our historical experience, knowledge of current conditions and our belief of what could occur in the future considering available
information,  including  assumptions  that  we  believe  to  be  reasonable  under  the  circumstances.  By  their  nature,  these  estimates  and  judgments  are  subject  to  an
inherent  degree  of  uncertainty,  and  actual  results  could  differ  materially  from  the  amounts  reported.  While  we  believe  that  our  estimates,  assumptions,  and
judgments are reasonable, they are based on information available when the estimate was made. Refer to Note 2, Basis of Presentation and Summary of Significant
Accounting Policies, within the Consolidated and Combined Financial Statements for further information on our critical accounting estimates and policies, which
are as follows:

•

•

•

•

•

Self-insurance reserves - The valuation methods and assumptions used in estimating costs up to retention amounts to settle open claims of insureds and
an estimate of the cost of insured claims up to retention amounts that have been incurred but not reported;

Revenue recognition - The amounts owed by private pay individuals for services and estimate of variable considerations to arrive at the transaction price,
including methods and assumptions, used to determine settlements with Medicare and Medicaid adjustments due to audits and reviews;

Cost allocation - The Consolidated and Combined Financial Statements include allocations of costs for certain shared services provided to the Company
by Ensign subsidiaries prior to the spin-off on October 1, 2019. These costs were allocated to the Company on a basis of revenue, location, employee
count, or other measures;

Leases - We use our estimated incremental borrowing rate based on the information available at lease commencement date in determining the present
value of future lease payments;

Acquisition accounting  -  The  assumptions  used  to  allocate  the  purchase  price  paid  for  assets  acquired  and  liabilities  assumed  in  connection  with  our
acquisitions; and

33

 
 
 
Table of Contents

•

Income taxes - The estimation of valuation allowance or the need for and magnitude of liabilities for uncertain tax position.

Recent Accounting Pronouncements

    Information concerning recently issued accounting pronouncements which are not yet effective is included in Note 2, Basis of Presentation and Summary of
Significant  Accounting  Policies  in  the  Consolidated  and  Combined  Financial  Statements.  As  of  December  31,  2021,  there  were  no  recently  issued  accounting
pronouncements that were expected to have an impact on the Company.

Results of Operations

The following table sets forth details of our expenses and earnings as a percentage of total revenue for the periods indicated:

Total revenue
Expense:

Cost of services
Rent—cost of services
General and administrative expense
Depreciation and amortization

Total expenses

Income from operations
Other income (expense):

Other income
Interest expense, net

Other income (expense), net

Income before provision for income taxes
Provision for income taxes

Net income
Less: net income/ (loss) attributable to noncontrolling interest

(a)

Net income attributable to Pennant

Year Ended December 31,
2020

2021

2019

100.0 %

100.0 %

100.0 %

80.3 
9.3 
8.2 
1.1 
98.9 
1.1 

— 
(0.5)
(0.5)
0.6 
0.1 
0.5 
(0.1)
0.6 %

75.9 
10.1 
8.0 
1.2 
95.2 
4.8 

0.1 
(0.3)
(0.2)
4.6 
0.6 
4.0 
— 
4.0 %

76.5 
10.3 
10.4 
1.1 
98.3 
1.7 

— 
(0.1)
(0.1)
1.6 
0.6 
1.0 
0.2 
0.8 %

(a)

Net loss attributable to noncontrolling interest for the year ended December 31, 2020 was less than 0.1% and thus not meaningful as a percentage of total revenue.

Consolidated and Combined GAAP Financial Measures:
Total revenue
Total expenses
Income from operations

34

2021

Year Ended December 31,
2020
(In thousands)

2019

$
$
$

439,694  $
434,999  $
4,695  $

390,953  $
372,036  $
18,917  $

338,531 
332,861 
5,670 

Table of Contents

The following table presents certain financial information regarding our reportable segments. General and administrative expenses are not allocated to the

reportable segments and are included in “All Other”:

Segment GAAP Financial Measures:
Year Ended December 31, 2021
Revenue
Segment Adjusted EBITDAR from Operations
Year Ended December 31, 2020
Revenue
Segment Adjusted EBITDAR from Operations
Year Ended December 31, 2019
Revenue
Segment Adjusted EBITDAR from Operations

Home Health and
Hospice Services

Senior Living
Services

All Other

Total

(In thousands)

$
$

$
$

$
$

309,570  $
55,565  $

253,659  $
49,501  $

206,624  $
33,354  $

130,124  $
37,517  $

137,294  $
48,309  $

131,907  $
47,344  $

—  $
(26,208) $

—  $
(22,762) $

—  $
(18,591) $

439,694 
66,874 

390,953 
75,048 

338,531 
62,107 

The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:

Segment Adjusted EBITDAR from Operations
Less: Depreciation and amortization
Rent—cost of services
Other (expense)/ income

(a)

Adjustments to Segment EBITDAR from Operations:
Less: Costs at start-up operations

(b)

(c)

(d)

Share-based compensation expense
Acquisition related costs
Spin-Off related transaction costs
Transition services costs
COVID-19 related costs and supplies
Impairment of long-lived assets

(h)

(e)

(f)

(g)

Add: Net income/ (loss) attributable to noncontrolling interest

Income from operations

35

2021

Year Ended December 31,
2020
(In thousands)

2019

$

$

66,874  $
4,784 
40,863 
(24)

1,045 
10,040 
80 
— 
2,008 
— 
2,835 
(548)
4,695  $

75,048  $
4,675 
39,191 
225 

1,787 
8,335 
99 
— 
1,181 
447 
— 
(191)
18,917  $

62,107 
3,810 
34,975 
— 

483 
3,382 
665 
13,219 
532 
— 
— 
629 
5,670 

Table of Contents

)

)
)
d)
)
)

g)

h)

Segment Adjusted EBITDAR from Operations is net income/ (loss) attributable to the Company's reportable segments excluding interest expense, provision for income taxes, depreciation and
amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2)
share-based compensation, (3) acquisition related costs, (4) Spin-Off transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) net income/
(loss) attributable to noncontrolling interest, (7) net COVID-19 related costs and (8) impairment of long-lived assets. General and administrative expenses are not allocated to the reportable
segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company's segment
measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited.

Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
Acquisition related costs that are not capitalizable.
Costs incurred related to the Spin-Off are included in general and administrative expense.
A portion of the costs incurred under the Transition Services Agreement identified as redundant or nonrecurring that are included in general and administrative expense. Fees incurred under the

Transition Services Agreement, net of the Company’s payroll reimbursement, were $3,124, $5,536, and $2,982, for the years ended December 31, 2021, 2020 and 2019, respectively.

Beginning in the first quarter of fiscal year 2021, we updated our definition of Segment Adjusted EBITDAR to no longer include an adjustment for COVID-19 expenses offset by the amount of
sequestration relief. COVID-19 expenses continue to be part of daily operations for which less specific identification is visible. Furthermore, the sequestration relief was extended through
December 31, 2021. Sequestration relief was $3,555 for the year ended December 31, 2021.

The  2020  amount  represents  incremental  costs  incurred  as  part  of  the  Company's  response  to  COVID-19  including  direct  medical  supplies,  labor,  and  other  expenses,  net  of  $2,765  in
increased revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.

On January 27, 2022, affiliates of the Company, entered into certain operations transfer agreements (collectively, the “Transfer Agreements”) with affiliates of Ensign, providing for the transfer of
the operations of certain senior living communities (the “Transaction”). The closing of the Transaction is anticipated to occur in the first half of 2022. The Company impaired certain leasehold
improvements included in property and equipment primarily related to the operations included in the transaction with Ensign.

Performance and Valuation Measures:

Consolidated and Combined Non-GAAP Financial Measures:
Performance Metrics

Consolidated and Combined EBITDA
Consolidated and Combined Adjusted EBITDA

Valuation Metric

Consolidated and Combined Adjusted EBITDAR

Segment Non-GAAP Measures:
Segment Adjusted EBITDA from Operations

(a)

Home health and hospice services
Senior living services

(a)

General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss.

36

2021

Year Ended December 31,
2020
(In thousands)

2019

$
$

$

$
$

10,003  $
26,407  $

24,008  $
36,080  $

8,851 
27,157 

66,874 

2021

Year Ended December 31,
2020
(In thousands)

2019

51,045  $
1,570  $

46,015  $
12,827  $

30,415 
15,333 

Table of Contents

The  table  below  reconciles  Consolidated  and  Combined  Net  Income  to  Consolidated  and  Combined  EBITDA,  Consolidated  and  Combined  Adjusted

EBITDA and Consolidated and Combined Adjusted EBITDAR for the periods presented:

Consolidated and Combined Net income
Less: Net (loss) income attributable to noncontrolling interest
Add: Provision for income taxes (benefit)

Net interest expense
Depreciation and amortization
Consolidated and Combined EBITDA

Adjustments to Consolidated and Combined EBITDA
Add: Costs at start-up operations

(a)

(b)

(c)

Share-based compensation expense
Acquisition related costs
Spin-Off related transaction costs
Transition services costs
Net COVID-19 related costs
Impairment of long-lived assets
Rent related to items (a) above

(d)

(g)

(e)

(f)

Consolidated and Combined Adjusted EBITDA

Rent—cost of services
Rent related to items (a) above
Adjusted rent—cost of services

Consolidated and Combined Adjusted EBITDAR

2021

Year Ended December 31,
2020
(In thousands)

2019

$

$

2,148  $
(548)
582 
1,941 
4,784 
10,003 

15,553  $
(191)
2,350 
1,239 
4,675 
24,008 

1,045 
10,040 
80 
— 
2,008 
— 
2,835 
396 
26,407 
40,863 
(396)
40,467 
66,874 

1,787 
8,335 
99 
— 
1,181 
447 
— 
223 
36,080 
39,191 
(223)
38,968 

3,175 
629 
2,085 
410 
3,810 
8,851 

483 
3,382 
665 
13,219 
532 
— 
— 
25 
27,157 
34,975 
(25)
34,950 

(a)
(b)
(c)
(d)
(e)

(f)

(g)

Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
Acquisition related costs that are not capitalizable.
Costs incurred related to the Spin-Off are included in general and administrative expense.
A portion of the costs incurred under the Transition Services Agreement identified as redundant or nonrecurring that are included in general and administrative expense. Fees incurred under the
Transition Services Agreement, net of the Company’s payroll reimbursement, were $3,124, $5,536, and $2,982, for the years ended December 31, 2021, 2020 and 2019, respectively.
Beginning in the first quarter of fiscal year 2021, we updated our definition of Segment Adjusted EBITDAR to no longer include an adjustment for COVID-19 expenses offset by the amount of
sequestration  relief.  COVID-19  expenses  continue  to  be  part  of  daily  operations  for  which  less  specific  identification  is  visible.  Furthermore,  the  sequestration  relief  was  extended  through
December 31, 2021. Sequestration relief was $3,555 for the year ended December 31, 2021.

The 2020 amount represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased
revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.
On January 27, 2022, affiliates of the Company, entered into certain operations transfer agreements (collectively, the “Transfer Agreements”) with affiliates of Ensign, providing for the transfer of
the operations of certain senior living communities (the “Transaction”). The closing of the Transaction is anticipated to occur in the first half of 2022. The Company impaired certain leasehold
improvements included in property and equipment primarily related to the operations included in the transaction with Ensign.

37

Table of Contents

The table below reconciles Segment Adjusted EBITDAR from Operations to Segment Adjusted EBITDA from Operations for the periods presented:

Year Ended December 31,

Home Health and Hospice
2020

2019

2021

Senior Living
2020

2021

2019

Segment Adjusted EBITDAR from Operations
Less: Rent—cost of services

Rent related to start-up operations

Segment Adjusted EBITDA from Operations

$

$

55,565  $
4,906 
(386)
51,045  $

49,501  $
3,629 
(143)
46,015  $

(In thousands)
33,354  $
2,964 
(25)
30,415  $

37,517  $
35,957 
(10)
1,570  $

48,309  $
35,562 
(80)
12,827  $

47,344 
32,011 
— 
15,333 

The  following  discussion  includes  references  to  certain  performance  and  valuation  measures,  which  are  non-GAAP  financial  measures,  including
Consolidated and Combined EBITDA, Consolidated and Combined Adjusted EBITDA, Segment Adjusted EBITDA from Operations, and Consolidated Adjusted
EBITDAR (collectively, “Non-GAAP Financial Measures”). Non-GAAP Financial Measures are used in addition to, and in conjunction with, results presented in
accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Non-GAAP Financial Measures reflect an additional way of
viewing aspects of our operations and company that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial
measures, we believe can provide a more comprehensive understanding of factors and trends affecting our business.

We  believe  these  Non-GAAP  Financial  Measures  are  useful  to  investors  and  other  external  users  of  our  financial  statements  regarding  our  results  of

operations because:

•

•

•

•

•

•

•

•

•

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry
without regard to items such as interest expense, rent expense and depreciation and amortization, which can vary substantially from company to company
depending on the book value of assets, the length of the lease to which the asset applies, the method by which assets were acquired, and differences in
capital structures;

they help investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base and capital structure
from our operating results; and

Consolidated and Combined Adjusted EBITDAR is used by investors and analysts in our industry to value the companies in our industry without regard
to capital structures.

We use Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis from period to period;

to allocate resources to enhance the financial performance of our business;

to assess the value of a potential acquisition;

to assess the value of a transformed operation’s performance;

to evaluate the effectiveness of our operational strategies; and

to compare our operating performance to that of our competitors.

We typically use Non-GAAP Financial Measures to compare the operating performance of each operation from period to period. We find that Non-GAAP
Financial Measures are useful for this purpose because they do not include such costs as interest expense, income taxes, depreciation and amortization expense,
which may vary from period-to-period depending upon various factors, including the method used to finance operations, the date of acquisition of a community or
business, and the tax law of the state in which a business unit operates.

38

Table of Contents

Non-GAAP  Financial  Measures  have  no  standardized  meaning  defined  by  GAAP.  Therefore,  our  Non-GAAP  Financial  Measures  have  limitations  as
analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these
limitations are:

•

•

•

•

•

•

•

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;

they do not reflect changes in, or cash requirements for, our working capital needs;

they do not reflect the net interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;

in the case of Consolidated and Combined Adjusted EBITDAR, it does not reflect rent expenses, which are normal and recurring operating expenses that
are necessary to operate our leased operations;

they do not reflect any income tax payments we may be required to make;

although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and
these non-cash charges do not reflect any cash requirements for such replacements; and

other  companies  in  our  industry  may  calculate  the  same  Non-GAAP  Financial  Measures  differently  than  we  do,  which  may  limit  their  usefulness  as
comparative measures.

We  compensate  for  these  limitations  by  using  Non-GAAP  Financial  Measures  only  to  supplement  net  income  on  a  basis  prepared  in  accordance  with

GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

We strongly encourage investors to review our Consolidated and Combined Financial Statements, included in this report in their entirety and to not rely
on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures
with  other  companies’  Non-GAAP  financial  measures  having  the  same  or  similar  names.  These  Non-GAAP  Financial  Measures  should  not  be  considered  a
substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation
of income from operations to the Non-GAAP Financial Measures in the table presented above, along with our Financial Statements and related notes included
elsewhere in this report.

We believe the following Non-GAAP Financial Measures are useful to investors as key operating performance measures and valuation measures:

Performance Measures:

Consolidated and Combined EBITDA

We believe Consolidated and Combined EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and
compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating
results.

We  calculate  Consolidated  and  Combined  EBITDA  as  net  income,  adjusted  for  net  income/  (loss)  attributable  to  noncontrolling  interest,  before

(a) interest expense (b) provision for income taxes and (c) depreciation and amortization.

Consolidated and Combined Adjusted EBITDA

We  adjust  Consolidated  and  Combined  EBITDA  when  evaluating  our  performance  because  we  believe  that  the  exclusion  of  certain  additional  items
described  below  provides  useful  supplemental  information  to  investors  regarding  our  ongoing  operating  performance.  We  believe  that  the  presentation  of
Consolidated and Combined Adjusted EBITDA, when considered with Consolidated and Combined EBITDA and GAAP net income is beneficial to an investor’s
complete understanding of our operating performance. 

We  calculate  Consolidated  and  Combined  Adjusted  EBITDA  by  adjusting  Consolidated  and  Combined  EBITDA  to  exclude  the  effects  of  non-core

business items, which for the reported periods includes, to the extent applicable:

•

•

•

costs at start-up operations;

share-based compensation expense;

acquisition related costs;

39

Table of Contents

•

•

•

•

Spin-Off related transaction costs;

redundant or nonrecurring costs incurred as part of the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent
Investment);

COVID-19 related costs and supplies; and

impairment of long-lived assets.

Segment Adjusted EBITDA from Operations

We calculate Segment Adjusted EBITDA from Operations by adjusting Segment Adjusted EBITDAR from Operations to include rent-cost of services.
We believe that the inclusion of rent-cost of services provides useful supplemental information to investors regarding our ongoing operating performance for each
segment.

Valuation Measure:

Consolidated and Combined Adjusted EBITDAR

We  use  Consolidated  and  Combined  Adjusted  EBITDAR  as  one  measure  in  determining  the  value  of  prospective  acquisitions.  It  is  also  a  measure
commonly  used  by  us,  research  analysts  and  investors  to  compare  the  enterprise  value  of  different  companies  in  the  healthcare  industry,  without  regard  to
differences in capital structures. Additionally, we believe the use of Consolidated and Combined Adjusted EBITDAR allows us, research analysts and investors to
compare  operational  results  of  companies  without  regard  to  operating  or  financed  leases.  A  significant  portion  of  financed  lease  expenditures  are  recorded  in
interest, whereas operating lease expenditures are recorded in rent expense.

This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense and, as such, does
not reflect our cash requirements for leasing commitments. Our presentation of Consolidated and Combined Adjusted EBITDAR should not be construed as a
financial performance measure.

The adjustments made and previously described in the computation of Consolidated and Combined Adjusted EBITDA are also made when computing
Consolidated  and  Combined  Adjusted  EBITDAR.  We  calculate  Consolidated  and  Combined  Adjusted  EBITDAR  by  excluding  rent-cost  of  services  and  rent
related to start up operations from Consolidated and Combined Adjusted EBITDA.

Year Ended December 31, 2021 Compared to the Year Ended December 31, 2020

Revenue 

Home health and hospice services

Home health
Hospice
Home care and other
Total home health and hospice services

(a)

Senior living services

Total revenue

Year Ended December 31,

2021

2020

Revenue Dollars

Revenue Percentage

Revenue Dollars

Revenue Percentage

$

$

136,505 
151,612 
21,453 
309,570 
130,124 
439,694 

(In thousands)

31.0 % $
34.5 
4.9 
70.4 
29.6 
100.0 % $

98,267 
134,075 
21,317 
253,659 
137,294 
390,953 

25.1 %
34.3 
5.5 
64.9 
35.1 
100.0 %

(a)

Home care and other revenue is included with home health revenue in other disclosures in this report.

Our consolidated and combined revenue increased $48.7 million, or 12.5% driven by the net organic growth of existing operations across all segments of

$36.8 million or 9.4% as well as increased revenue from acquired operations of $11.9 million or 3.1% during the year ended December 31, 2021.

40

Table of Contents

Home Health and Hospice Services

Home health and hospice revenue

Home health services
Hospice services
Home care and other

Total home health and hospice revenue

Home health services:

Total home health admissions
Total Medicare home health admissions
Average Medicare revenue per 60-day completed episode

(a)

Hospice services:

Total hospice admissions
Average daily census
Hospice Medicare revenue per day

Number of home health and hospice agencies at period end

Year Ended December 31,
2020
2021

(In thousands)

Change

% Change

136,505  $
151,612 
21,453 
309,570  $

98,267  $
134,075 
21,317 
253,659  $

38,238 
17,537 
136 
55,911 

38.9 %
13.1 
0.6 

22.0 %

Year Ended December 31,
2020
2021

Change

% Change

37,366 
17,356 

26,670 
12,974 

3,405  $

3,290  $

8,613 
2,291 

174  $
88 

8,186 
2,083 

166  $
76 

10,696 
4,382 
115 

427 
208 
8 
12 

40.1 %
33.8 
3.5 

5.2 
10.0 
4.8 
15.8 %

$

$

$

$

(a)

The year to date average for Medicare revenue per 60-day completed episode includes post period claim adjustments for prior periods.

Home health and hospice revenue increased $55.9 million, or 22.0%. Revenue grew due to an increase in all key performance indicators including an
increase in total home health admissions of 40.1%, an increase in Medicare home health admissions of 33.8%, an increase in average Medicare revenue per 60-day
completed episode of 3.5%, an increase of 5.2% in total hospice admissions, and an increase of 10.0% in hospice average daily census. The improvement in these
metrics resulted in organic revenue growth of $44.0 million for the year ended December 31, 2021. Growth was also driven by the acquisition of 11 home health,
hospice and home care operations,  between  December  31,  2020  and  December  31,  2021,  resulting  in  an  increase  in  revenue  of  $11.9  million  or  4.7%  overall.
Revenue attributable to sequestration suspension accounted for $3.6 million in the current year.

Senior Living Services

Year Ended December 31,
2020
2021

Change

% Change

Revenue (in thousands)
Number of communities at period end
Occupancy
Average monthly revenue per occupied unit

$

$

130,124 
54 
72.7 %
3,207 

$

$

137,294 
54 
77.7 %
3,188 

$

$

(7,170)
— 
(5.0)%
19 

(5.2)%
— %

0.6 %

Senior  living  revenue  decreased  $7.2  million,  or  5.2%,  for  the  year  ended  December  31,  2021  when  compared  to  the  same  period  in  the  prior  year

primarily due to a 5.0% decrease in occupancy related to the COVID-19 pandemic between December 31, 2020 and December 31, 2021.

41

Table of Contents

Cost of Services

The following table sets forth total cost of services by each of our reportable segments for the periods indicated: 

Year Ended December 31,

2021

2020

Change

% Change

Home Health and Hospice
Senior Living

Total cost of services

$

$

257,251 
95,842 
353,093 

206,094 
90,780 
296,874 

$

$

51,157 
5,062 
56,219 

24.8 
5.6 

18.9 

%

%

$

(In thousands)
$

Consolidated and combined cost of services increased $56.2 million or 18.9% for the year ended December 31, 2021 when compared to the year ended
December  31,  2020.  Cost  of  services  as  a  percentage  of  revenue  increased  by  4.4%  from  75.9%  to  80.3%  over  the  same  time  period.  The  increase  in  cost  of
services was driven by the increase in revenue, new acquisitions in the current year, an increase in wages and benefits, and additional costs related to the impact of
the COVID-19 pandemic.

Home Health and Hospice Services

Year Ended December 31,
2020
2021

(In thousands)

Change

% Change

Cost of service
Cost of services as a percentage of revenue

$

257,251 

$

206,094 

$

83.1 %

81.2 %

51,157 

1.9 %

24.8 %

Cost of services related to our home health and hospice services segment increased $51.2 million, or 24.8%, primarily due to increased volume of services
provided. Cost of services as a percentage of revenue for the year ended December 31, 2021 increased 1.9% compared to the year ended December 31, 2020,
primarily due to wage costs increased over the prior year in per hour wages, increase in overtime, and reduced staff availability due to the impact of COVID-19 on
the staffing environment, resulting in higher overtime and per hour wages.

Senior Living Services

Cost of service
Cost of services as a percentage of revenue

Year Ended December 31,
2020
2021

Change

% Change

$

(In thousands)

95,842 

$

73.7 %

90,780 

$

66.1 %

5,062 

7.6 %

5.6 %

Cost of services related to our senior living services segment increased $5.1 million, or 5.6% for the year ended December 31, 2021 when compared to the year
ended December 31, 2020. As a percentage of revenue, costs of service increased by 7.6% as a result of a decrease in occupancy while wage costs increased.

Rent—Cost of Services. Rent increased 4.3% from $39.2 million to $40.9 million for the year ended December 31, 2021 compared to the year ended December 31,
2020, primarily as a result of acquisitions and CPI adjustments. Rent as a percentage of total revenue decreased from 10.1% to 9.3% in the year ended December
31, 2021, as the growth in revenue outpaced the increase in rent expense.

General and Administrative Expense. Our general and administrative expense increased $5.0 million or 15.9% from $31.3 million to $36.3 million and as a percent
of revenue from 8.0% to 8.2% for the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase in general and administrative
costs was primarily driven by an increase of $4.8 million in wages and benefits, of which stock-based compensation accounted for $0.7 million, during the year
ended December 31, 2021.

Depreciation and Amortization. Depreciation and amortization expense decreased slightly as a percentage of total revenue.

42

Table of Contents

Provision for Income Taxes. Our effective tax rate for the year ended December 31, 2021 was 21.3% of earnings before income taxes compared with an effective
tax rate of 13.1% for the year ended December 31, 2020. The increase in the effective tax rate was due to an increase in non-deductible expenses. See Note 14,
Income Taxes, to the Consolidated and Combined Financial Statements included elsewhere in this report filed on Form 10-K for further discussion.

Comparison of Prior Year Information

For a comparison of our results of operations of the fiscal year ended December 31, 2020 as compared to the year ended December 31, 2019 refer to Item

7. Management's Discussion and Analysis of Financial Condition and Results of Operation on Form 10-K filed with the SEC on February 24, 2021.

Liquidity and Capital Resources

Our primary sources of liquidity are cash generated through operating activities and borrowings under our revolving credit facility.

Revolving Credit Facility    

On February 23, 2021, Pennant entered into an amendment to its existing credit agreement (as amended, the “Credit Agreement”), which provides for an
increased revolving credit facility with a syndicate of banks with a borrowing capacity of $150.0 million (the “Revolving Credit Facility”). The Revolving Credit
Facility is not subject to interim amortization and the Company will not be required to repay any loans under the Revolving Credit Facility prior to maturity in
2026. The Company is permitted to prepay all or any portion of the loans under the Revolving Credit Facility prior to maturity without premium or penalty, subject
to reimbursement of any LIBOR breakage costs of the lenders.

The Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its
independent  operating  subsidiaries  to  grant  liens  on  their  assets,  incur  indebtedness,  sell  assets,  make  investments,  engage  in  acquisitions,  mergers  or
consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Financial covenants require compliance with certain
levels of leverage ratios that impact the amount of interest. As of December 31, 2021, we were in compliance with all covenants.

As of December 31, 2021 we had $5.2 million of cash and $92.3 million of available borrowing capacity on our Revolving Credit Facility.

We  believe  that  our  existing  cash,  cash  generated  through  operations  and  our  access  to  financing  facilities,  together  with  funding  through  third-party

sources such as commercial banks, will be sufficient to fund our operating activities and growth needs, and provide adequate liquidity for the next twelve months.

The following table presents selected data from our combined statement of cash flows for the periods presented:

Net cash (used in) provided by operating activities
Net cash used in investing activities
Net cash provided by (used in) financing activities

Net change in cash
Cash at beginning of year

Cash at end of year

Year Ended December 31,

2021

2020

(In thousands)

(18,223) $
(20,120)
43,490 
5,147 
43 
5,190  $

50,204 
(41,616)
(8,947)
(359)
402 
43 

$

$

Year Ended December 31, 2021 Compared to the Year Ended December 31, 2020

Our net cash from operating activities for the year ended December 31, 2021 decreased by $68.4 million when compared to the year ended December 31,
2020 . The decrease was primarily related to the repayment of $21.8 in the current year related to AAP from the CARES Act resulting in a change of $49.8 million
in operating cash flow. Exclusive of the repayment of AAP, our net cash flow from operations would have been $3.6 million positive for the year ended December
31,

43

    
Table of Contents

2021. Other factors that contributed to the net cash used in operating activities was a decrease in net income of $13.4 million when compared to the year ended
December 31, 2021.

Our net cash used in investing activities for the year ended December 31, 2021 decreased by $21.5 million compared to the year ended December 31,

2020. The decrease in funds used for investing activities was primarily due to a decrease of $19.6 million in cash paid for acquisitions during the year ended
December 31, 2021.

    Our net cash provided by financing activities increased by approximately $52.4 million for the year ended December 31, 2021 when compared to the year ended
December 31, 2020 primarily due to an increase in borrowing on our revolving credit facility, partially offset by payments on our deferred financing costs related
to the refinance of our credit facility in the first quarter 2021.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. We are exposed to risks associated with market changes in interest rates. Our Revolving Credit Facility exposes us to variability in
interest payments due to changes in LIBOR. A 1.0% interest rate change would cause interest expense to change by approximately $0.5 million annually based
upon our outstanding long-term debt as of December 31, 2021. We manage our exposure to this market risk by monitoring available financing alternatives.

LIBOR Phase-Out.  LIBOR  is  in  the  process  of  being  wound  down.  As  of  December  31,  2021  all  CHF  and  EUR  LIBOR  settings,  the  1  Week  and  2
Months  USD  LIBOR  settings,  and  the  Overnight/Spot  Next,  1  Week,  2  Months  and  12  Months  GBP  and  JPY  LIBOR  settings  have  ceased  to  be  published.
However, the Overnight and the 1-, 3-, 6- and 12-Months USD LIBOR settings will continue until June 2023. We are required to pay interest on borrowings under
our Credit Facility at floating rates based on the 1-month LIBOR and thus, we do not expect to transition away from the LIBOR benchmark until June 2023.

Future  debt  that  we  may  incur  may  also  require  that  we  pay  interest  based  upon  LIBOR,  or  a  “synthetic”  benchmark  equivalent  such  as  the  Standard
Overnight Financing Rate or (“SOFR”). We currently expect that the determination of interest under our credit agreement would be revised as provided under the
agreement or amended as necessary to provide for an interest rate that approximates the existing interest rate as calculated in accordance with LIBOR for similar
types of loans. Despite our current expectations, we cannot be sure that, if LIBOR is phased out or transitioned, the changes to the determination of interest under
our agreement would approximate the current calculation in accordance with LIBOR. We do not know what standard, if any, will replace LIBOR if it is phased out
or transitioned.

Item 8.    Financial Statements and Supplementary Data

The consolidated and combined financial statements and accompanying notes listed in Part IV, Item 15(a)(1) of this Annual Report on Form 10-K are

included elsewhere in this report.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under  the  supervision  and  with  the  participation  of  our  management,  including  the  Chief  Executive  Officer  and  Chief  Financial  Officer,  we  have
evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this Annual Report. Based on that evaluation, the Chief Executive Officer and
Chief  Financial  Officer  have  concluded  that  these  disclosure  controls  and  procedures  were  effective  to  provide  reasonable  assurance  that  information  we  are
required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in
SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial
Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

44

Table of Contents

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the
Exchange Act). Management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2021 based on the
criteria set forth in “Internal Control-Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Based  on  this  assessment,  management  has  concluded  that  our  internal  control  over  financial  reporting  was  effective  as  of  December  31,  2021  based  on  those
criteria.

Our  independent  registered  public  accounting  firm,  Deloitte  &  Touche  LLP,  has  audited  the  consolidated  financial  statements  included  in  this  Annual
Report on Form 10-K and, as part of their audit, has issued an audit report, included herein, on the effectiveness of our internal control over financial reporting.
Their report is set forth below.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended December 31, 2021, there were no material changes in our internal control over financial reporting that occurred during

our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

45

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of The Pennant Group, Inc.

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of The Pennant Group, Inc. and subsidiaries (the “Company”) as of December 31, 2021, based on
criteria  established  in  Internal  Control  —  Integrated  Framework  (2013)  issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission
(COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on
criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial
statements as of and for the year ended December 31, 2021 of the Company and our report dated February 28, 2022 expressed an unqualified opinion on those
financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal
control  over  financial  reporting,  included  in  the  accompanying  Management’s  Report  on  Internal  Control  Over  Financial  Reporting.  Our  responsibility  is  to
express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.

We  conducted  our  audit  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable
assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding
of  internal  control  over  financial  reporting,  assessing  the  risk  that  a  material  weakness  exists,  testing  and  evaluating  the  design  and  operating  effectiveness  of
internal  control  based  on  the  assessed  risk,  and  performing  such  other  procedures  as  we  considered  necessary  in  the  circumstances.  We  believe  that  our  audit
provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial
reporting  includes  those  policies  and  procedures  that  (1)  pertain  to  the  maintenance  of  records  that,  in  reasonable  detail,  accurately  and  fairly  reflect  the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial  statements  in  accordance  with  generally  accepted  accounting  principles,  and  that  receipts  and  expenditures  of  the  company  are  being  made  only  in
accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because  of  its  inherent  limitations,  internal  control  over  financial  reporting  may  not  prevent  or  detect  misstatements.  Also,  projections  of  any  evaluation  of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.

/s/ DELOITTE & TOUCHE LLP

Boise, Idaho
February 28, 2022

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

46

Table of Contents

None

Item 10.     Directors, Executive Officers and Corporate Governance

Part III.

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2022 Annual Meeting of

Stockholders.

Item 11. Executive Compensation

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2022 Annual Meeting of

Stockholders.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2022 Annual Meeting of

Stockholders.

Item 13.     Certain Relationships and Related Transactions and Director Independence

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2022 Annual Meeting of

Stockholders.

Item 14.     Principal Accountant Fees and Services

The information required by this Item is hereby incorporated by reference to our definitive proxy statement on Form 14A for the 2022 Annual Meeting of

Stockholders.

47

Table of Contents

Item 15. Exhibits, Financial Statements and Schedules

The following documents are filed as a part of this report:

(a)(1) Financial Statements:

Part IV.

The following Consolidated and Combined Financial Statements of the Company are included in Part II, Item 8 of this Annual Report on Form 10-K.

•

•

•

•

•

Report of Independent Registered Public Accounting Firm

Consolidated Balance Sheets as of December 31, 2021 and 2020

Consolidated and Combined Statements of Income for the Years Ended December 31, 2021, 2020 and 2019

Consolidated and Combined Statements of Changes in Shareholders' Equity and Net Parent Investment for the Years Ended December 31, 2021,
2020 and 2019

Consolidated and Combined Statements of Cash Flows for the Years Ended December 31, 2021, 2020 and 2019

• Notes to the Consolidated and Combined Financial Statements

(a)(2) Financial Statement Schedules:

There are no financial schedules included in this Report as they are either not applicable or included in the financial statements.

(a) (3) Exhibits:  The following exhibits are filed with this Report or incorporated by reference:

Exhibits

Exhibit No.

2.1#

3.1

3.2

4.1

10.1

10.2

10.3

10.4

Exhibit Description
Master Separation Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated
by reference to Exhibit 2.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3,
2019).
Second Amended and Restated Certificate of Incorporation of The Pennant Group, Inc., effective as of February 21, 2022 (incorporated by
reference to Exhibit 3.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC February 22, 2022).
Amended and Restated By-laws of The Pennant Group, Inc. (incorporated by reference to Exhibit 3.2 to The Pennant Group, Inc.’s Current
Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Description of Securities of The Pennant Group, Inc. (incorporated by reference to Exhibit 4.1 to The Pennant Group, Inc.’s Annual Report on
Form 10-K (File No. 001-389000) filed with the SEC on March 4, 2020).
Transition Services Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated
by reference to Exhibit 10.1 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3,
2019).
Tax Matters Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated by
reference to Exhibit 10.2 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3,
2019).
Employee Matters Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc. (incorporated
by reference to Exhibit 10.3 to The Pennant Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3,
2019).
Form of Lease Agreement by and among subsidiaries of The Ensign Group, Inc. and subsidiaries of The Pennant Group, Inc. (incorporated by
reference to Exhibit 10.4 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed
with the SEC on August 19, 2019).

48

 
 
Table of Contents

10.5+

10.6+

10.7+

10.8+

10.9+

10.10+

10.11

10.12

10.13+

10.14+

21.1*
23.1*
31.1*
31.2*
32.1**

32.2**
101.INS*

101.SCH*
101.CAL*
101.DEF*
101.LAB*
101.PRE*

The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.12 to The Pennant Group, Inc.’s Current Report
on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Form of Options Granted Under The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to The
Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19,
2019).
Form of RSUs Granted Under The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.7 to The Pennant
Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
Form of RS Granted Under The Pennant Group, Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to The Pennant
Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19, 2019).
The Pennant Group, Inc. 2019 Long Term Incentive Plan (incorporated by reference to Exhibit 10.11 to The Pennant Group, Inc.’s Current
Report on Form 8-K (File No. 001-38900) filed with the SEC on October 3, 2019).
Form of LTIP RS Granted Under The Pennant Group, Inc. 2019 Long Term Incentive Plan (incorporated by reference to Exhibit 10.10 to The
Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on August 19,
2019).
Form of Indemnification Agreement to be entered into between The Pennant Group, Inc. and each of its directors and executive officers
(incorporated by reference to Exhibit 10.11 to The Pennant Group, Inc.’s Amendment No. 2 to the Registration Statement on Form 10 (File No.
001-38900) filed with the SEC on August 19, 2019).
Credit Agreement, dated February 23, 2021, by and among the Company and certain of its subsidiaries, the lenders named therein, and Truist
Bank (successor by merger to SunTrust Bank), as administrative agent for the lenders (incorporated by reference to Exhibit 10.1 to The Pennant
Group, Inc.’s Current Report on Form 8-K (File No. 001-38900) filed with the SEC on February 24, 2021).
Cornerstone Healthcare, Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.13 to The Pennant Group, Inc.’s Amendment
No. 3 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on September 3, 2019).
The Ensign Group, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.14 to The Pennant Group, Inc.’s Amendment No.
3 to the Registration Statement on Form 10 (File No. 001-38900) filed with the SEC on September 3, 2019).
Subsidiaries of The Pennant Group, Inc.
Consent of Deloitte & Touche LLP.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
Certification of Chief Financial Officer pursuant 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document.
Inline XBRL Taxonomy Extension Schema Document.
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
Inline XBRL Taxonomy Extension Definition Linkbase Document.
Inline XBRL Taxonomy Extension Label Linkbase Document.
Inline XBRL Taxonomy Extension Presentation Linkbase Document.

49

Table of Contents

104*

Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.
* Filed with this report.
** Furnished with this report.
+ Exhibit constitutes a management contract or compensatory plan or agreement.
# Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Pennant Group Inc. agrees to furnish a supplemental copy of any omitted
schedule to the SEC upon request.

Item 16.     Form 10-K Summary

Not applicable.

50

Table of Contents

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act  of  1934,  the  registrant  has  duly  caused  this  report  to  be  signed  on  its  behalf  by  the

SIGNATURES

undersigned thereunto duly authorized.

Dated: February 28, 2022

The Pennant Group, Inc.

BY: 

/s/ JENNIFER L. FREEMAN  
Jennifer L. Freeman
Chief Financial Officer (Principal Financial Officer, Principal
Accounting Officer and Duly Authorized Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the

registrant in the capacities and on the dates indicated.

Signature

Title

Date

/s/ DANIEL H WALKER
Daniel H Walker

/s/ JENNIFER L. FREEMAN
Jennifer L. Freeman

/s/ CHRISTOPER R. CHRISTENSEN
Christopher R. Christensen

/s/ JOHN G. NACKEL, Ph.D.
John G. Nackel, Ph.D.

 /s/ STEPHEN M. R. COVEY
Stephen M. R. Covey

/s/ JOANNE STRINGFIELD
JoAnne Stringfield

/s/ SCOTT E. LAMB
Scott E. Lamb

/s/ GREGORY K. MORRIS
Gregory K. Morris

/s/ BARRY M. SMITH
Barry M. Smith

Chairman and Chief Executive Officer (Principal
Executive Officer)

February 28, 2022

Chief Financial Officer (Principal Financial Officer,
Principal Accounting Officer and Duly Authorized
Officer)

Director

Director

Director

Director

Director

Director

Director

51

February 28, 2022

February 28, 2022

February 28, 2022

February 28, 2022

February 28, 2022

February 28, 2022

February 28, 2022

February 28, 2022

 
 
 
 
 
Table of Contents

THE PENNANT GROUP, INC.
INDEX TO THE CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS
AND FINANCIAL STATEMENT SCHEDULE

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)
Consolidated and Combined Financial Statements:

Consolidated Balance Sheets as of December 31, 2021 and 2020
Consolidated and Combined Statements of Income for the Years Ended December 31, 2021, 2020 and 2019
Consolidated and Combined Statements of Stockholders' Equity for the Years Ended December 31, 2021, 2020 and 2019
Consolidated and Combined Statements of Cash Flows for the Years Ended December 31, 2021, 2020 and 2019
Notes to the Consolidated and Combined Financial Statements

53

55
56
57
58
60

52

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of The Pennant Group, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of The Pennant Group, Inc. and subsidiaries (the "Company") as of December 31, 2021 and 2020,
the  related  consolidated  and  combined  statements  of  income,  stockholders'  equity  and  net  parent  investment,  and  cash  flows  for  each  of  the  three  years  in  the
period  ended  December  31,  2021,  and  the  related  notes  (collectively  referred  to  as  the  "financial  statements").  In  our  opinion,  the  financial  statements  present
fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each
of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America .

We have also audited in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal
controls  over  financial  reporting  as  of  December  31,  2021,  based  on  the  criteria  established  in  Internal  Control  -  Integrated  Framework  (2013)  issued  by  the
Committee  of  Sponsoring  Organizations  of  the  Treadway  Commissions  and  our  report  dated  February  28,  2022  expressed  an  unqualified  opinion  on  the
Company's internal control over financial reporting.
Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements
based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We  conducted  our  audits  in  accordance  with  the  standards  of  the  PCAOB.  Those  standards  require  that  we  plan  and  perform  the  audit  to  obtain  reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be
communicated  to  the  audit  committee  and  that  (1)  relates  to  accounts  or  disclosures  that  are  material  to  the  financial  statements  and  (2)  involved  especially
challenging,  subjective,  or  complex  judgments.  The  communication  of  critical  audit  matters  does  not  alter  in  any  way  our  opinion  on  the  financial  statements,
taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.

Self-Insurance Reserves— Refer to Notes 2 to the financial statements

Critical Audit Matter Description

The  Company  is  self-insured  for  general  and  professional  liability  and  workers’  compensation.  The  self-insurance  liability  is  undiscounted  and  determined
actuarially based on historical data of the Company’s claims experience. The Company has established retention amounts that limit the Company’s exposure. Self-
insurance liabilities recorded as of December 31, 2021 were $6,906 thousand.

We identified the evaluation of the Company’s self-insurance liabilities as a critical audit matter because the projected settlement value of reported and unreported
claims involves significant estimation by management. This required a high degree of auditor judgment and an increased extent of effort, including the need to
involve our actuarial specialists when performing audit procedures to evaluate whether the self-insurance liabilities were appropriately recorded as of December
31, 2021.

53

Table of Contents

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the self-insurance liabilities included the following among others:

• We  tested  the  effectiveness  of  controls  over  the  reserve  for  general  and  professional  liability  and  workers’  compensation,  including  those  over  the

determination of the case reserves for known claims.
Reading the Company’s insurance policies and comparing the coverage and terms by plan year to the assumptions used by management.
Testing the completeness and accuracy of the underlying data, including historical claims, used to determine the assumptions for loss development.
Involving actuarial specialists with specialized skill, industry knowledge, and relevant experience who assisted in:

•
•
•

– Comparing  prior-year  expected  development  and  ultimate  loss  to  actuals  incurred  during  the  current  year  to  identify  potential  bias  in  the

determination of the self-insurance reserves.

– Developing  an  independent  range  of  estimates  of  the  insurance  reserves,  utilizing  paid  and  reported  loss  development  factors  from  the

–

Company’s historical data and industry loss development factors.
Evaluating  qualifications  of  the  Company’s  actuaries  by  assessing  the  certifications  and  determining  whether  they  meet  the  Qualification
Standards of the American Academy of Actuaries to render the statements of actuarial opinion in their analyses.

/s/ DELOITTE & TOUCHE LLP

Boise, Idaho
February 28, 2022

We have served as the Company's auditor since 2019.

54

Table of Contents

Assets
Current assets:

THE PENNANT GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)

December 31, 2021

December 31, 2020

Cash
Accounts receivable—less allowance for doubtful accounts of $902 and $643, respectively
Prepaid expenses and other current assets

Total current assets

Property and equipment, net
Operating lease right-of-use assets
Escrow deposits
Deferred tax assets
Restricted and other assets
Goodwill
Other indefinite-lived intangibles

Total assets

Liabilities and equity
Current liabilities:

Accounts payable
Accrued wages and related liabilities
Operating lease liabilities—current
Other accrued liabilities

Total current liabilities

Operating lease liabilities—long-term
Other long-term liabilities
Long-term debt, net
Total liabilities

Commitments and contingencies
Equity:

Common stock, $0.001 par value; 100,000 shares authorized; 28,826 and 28,499 shares issued and
outstanding at December 31, 2021, respectively, and 28,696 and 28,243 shares issued and outstanding
at December 31, 2020, respectively
Additional paid-in capital
Retained earnings
Treasury stock, at cost, 3 shares at December 31, 2021 and 2020

Total Pennant Group, Inc. stockholders' equity

Noncontrolling interest
Total equity

Total liabilities and equity

$

$

$

$

5,190  $

53,940 
16,711 
75,841 
16,788 
300,997 
— 
3,848 
4,828 
74,265 
53,730 
530,297  $

10,553  $
23,480 
16,118 
21,484 
71,635 
287,753 
5,293 
51,372 
416,053 

28 
95,595 
14,641 
(65)
110,199 
4,045 
114,244 
530,297  $

43 
47,221 
12,335 
59,599 
17,884 
308,650 
525 
2,097 
4,289 
66,444 
47,488 
506,976 

9,761 
26,873 
14,106 
38,275 
89,015 
296,615 
11,897 
8,277 
405,804 

28 
84,671 
11,945 
(65)
96,579 
4,593 
101,172 
506,976 

See accompanying notes to consolidated and combined financial statements.

55

THE PENNANT GROUP, INC.

CONSOLIDATED AND COMBINED STATEMENTS OF INCOME
(In thousands, except for per-share amounts)

Table of Contents

Revenue

Expense:

Cost of services
Rent—cost of services
General and administrative expense
Depreciation and amortization
Total expenses

Income from operations
Other income (expense):
Other (expense) income
Interest expense, net

Other income (expense), net

Income before provision for income taxes
Provision for income taxes

Net income
Less: net (loss)/ income attributable to noncontrolling interest

Net income and other comprehensive income attributable to The Pennant Group, Inc.
Earnings per common share (Note 4):
Basic
Diluted

Weighted average common shares outstanding:

Basic
Diluted

See accompanying notes to consolidated and combined financial statements.

56

Year Ended December 31,
2020

2019

2021

$

439,694  $

390,953  $

338,531 

353,093 
40,863 
36,259 
4,784 
434,999 
4,695 

(24)
(1,941)
(1,965)
2,730 
582 
2,148 
(548)
2,696  $

296,874 
39,191 
31,296 
4,675 
372,036 
18,917 

225 
(1,239)
(1,014)
17,903 
2,350 
15,553 
(191)
15,744  $

0.09  $
0.09  $

0.56  $
0.52  $

258,941 
34,975 
35,135 
3,810 
332,861 
5,670 

— 
(410)
(410)
5,260 
2,085 
3,175 
629 
2,546 

0.11 
0.11 

28,406 
30,642 

28,029 
30,228 

27,838 
29,586 

$

$
$

Table of Contents

THE PENNANT GROUP, INC.

CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY
AND NET PARENT INVESTMENT
(In thousands)
Retained
Earnings/
(Accumulated
Deficit)

Additional
Paid-In
Capital

Common Stock

Treasury Stock

Amount

Amount

Shares

Shares

Net Parent
Investment

Non-
Controlling
Interest

Total

Balance at December 31, 2018
Noncontrolling interest attributable to
subsidiary equity plan
Share repurchase related to subsidiary
equity plan
Net income attributable to
noncontrolling interest
Net transfer from parent
Net income attributable to The Pennant
Group, Inc.
Cash Dividend to Parent
Reclassification of Invested Equity
Issuance of Common Stock after spin-
off
Share-based Compensation after spin-off
Exercise of Stock Options, issuance of
other awards after spin-off

Balance at December 31, 2019
Noncontrolling interests assumed related
to acquisitions
Sale of noncontrolling interests, net of
tax
Net loss attributable to Non-Controlling
interests
Net income attributable to The Pennant
Group, Inc.
Share-based compensation
Issuance of common stock from the
exercise of stock options
Issuance/ (cancellation) of restricted
stock
Shares of common stock withheld to
satisfy tax withholding obligations

Balance at December 31, 2020
Net income/ (loss) attributable to The
Pennant Group, Inc.
Net loss attributable to Non-Controlling
interests
Share-based compensation
Issuance of common stock from the
exercise of stock options
Net issuance of restricted stock

Balance at December 31, 2021

—  $

—  $

—  $

— 

— 

— 
— 

— 
— 
— 

27,834 
— 

601 
28,435 

— 

— 

— 

— 
— 

238 

26 

(3)
28,696 

— 

— 
— 

— 

— 

— 
— 

— 
— 
— 

28 
— 

— 
28 

— 

— 

— 

— 
— 

— 

— 

— 
28 

— 

— 
— 

— 

— 

— 
— 

— 
— 
72,893 

(28)
1,987 

30 
74,882 

— 

313 

— 

— 
8,335 

1,141 

— 

— 
84,671 

— 

— 
10,040 

115 
15 
28,826  $

— 
— 
28  $

884 
— 
95,595  $

— 

— 

— 

— 
— 

(3,799)
— 
— 

— 
— 

— 
(3,799)

— 

— 

— 

15,744 
— 

— 

— 

— 
11,945 

2,696 

— 
— 

— 
— 
14,641 

—  $

—  $

55,856  $

9,432  $

65,288 

— 

— 

— 
— 

— 
— 

— 
— 

— 
— 

— 

— 

— 

— 
— 

— 

— 

3 
3 

— 

— 
— 

— 

— 

— 
— 

— 
— 
— 

— 
— 

— 
— 

— 

— 

— 

— 
— 

— 

— 

(65)
(65)

— 

— 
— 

(2,991)

— 

— 
11,894 

6,345 
(11,600)
(59,504)

— 
— 

— 
— 

— 

— 

— 

— 
— 

— 

— 

— 
— 

— 

— 
— 

— 
— 
3  $

— 
— 
(65) $

— 
— 
—  $

3,585 

(394)

629 
— 

— 

(13,252)

— 
— 

— 
— 

594 

(394)

629 
11,894 

2,546 
(11,600)
137 

— 
1,987 

30 
71,111 

4,646 

4,646 

138 

(191)

— 
— 

— 

— 

451 

(191)

15,744 
8,335 

1,141 

— 

— 
4,593 

(65)
101,172 

— 

2,696 

(548)
— 

(548)
10,040 

— 
— 

884 
— 
4,045  $ 114,244 

See accompanying notes to consolidated and combined financial statements.

57

Table of Contents

THE PENNANT GROUP, INC.
CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS
(In thousands)

Cash flows from operating activities:

Net income
Adjustments to reconcile net income to net cash (used in) provided by operating activities:

2021

Year Ended December 31,
2020

2019

$

2,148  $

15,553  $

Depreciation and amortization
Amortization of deferred financing fees
Provision for doubtful accounts
Share-based compensation
Deferred income taxes
Impairment of long-lived assets
Change in operating assets and liabilities:

Accounts receivable
Prepaid expenses and other assets
Operating lease obligations
Accounts payable
Accrued wages and related liabilities
Other accrued liabilities
Advance payments
Other long-term liabilities

Net cash (used in) provided by operating activities

Cash flows from investing activities:

Purchase of property and equipment
Cash payments for business acquisitions
Escrow deposits
Restricted and other assets

Net cash used in investing activities

Cash flows from financing activities:

Proceeds from sale of subsidiary shares
Repurchase of subsidiary shares
Net investment from parent
Cash distribution to parent in connection with Spin-Off
Sale of noncontrolling interest
Proceeds from revolver agreement
Payments on revolver agreement
Repurchase of shares of common stock to satisfy tax withholding obligations
Payments for deferred financing costs
Issuance of common stock upon the exercise of options

Net cash provided by (used in) financing activities

Net increase (decrease) in cash
Cash beginning of period

Cash end of period

4,784 
488 
616 
10,040 
(1,752)
2,835 

(7,335)
(4,624)
803 
562 
(3,864)
2,570 
(21,786)
(3,708)
(18,223)

(6,303)
(13,550)
— 
(267)
(20,120)

— 
— 
— 
— 
— 
125,500 
(81,500)
— 
(1,394)
884 
43,490 
5,147 
43 
5,190  $

4,675 
330 
560 
8,335 
(2,201)
— 

(15,712)
(7,435)
2,068 
993 
10,538 
2,427 
27,997 
2,076 
50,204 

(7,253)
(33,193)
(525)
(645)
(41,616)

— 
— 
— 
— 
555 
52,700 
(63,200)
(65)
(78)
1,141 
(8,947)
(359)
402 
43  $

$

3,175 

3,810 
78 
858 
3,382 
79 
— 

(8,571)
(2,746)
(1,861)
4,069 
3,376 
1,720 
— 
2,185 
9,554 

(6,714)
(18,760)
(1,400)
409 
(26,465)

2,293 
(2,687)
10,788 
(11,600)
— 
42,500 
(22,500)
— 
(1,552)
30 
17,272 
361 
41 
402 

See accompanying notes to consolidated and combined financial statements.

58

Table of Contents

THE PENNANT GROUP, INC.
CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS - (Continued)
(In Thousands)

Supplemental disclosures of cash flow information:

Cash paid during the period for:

Interest

Income taxes

Operating lease liabilities

Right-of-use assets obtained in exchange for new operating lease obligations

Net non-cash adjustment to right-of-use assets and lease liabilities from lease modifications
Non-cash investing activity:

Capital expenditures in accounts payable

2021

Year Ended December 31,
2020

2019

$

$

$

$

$

$

1,448  $

2,616  $

39,151  $

3,230  $

4,674  $

1,116  $

7,865  $

35,853  $

5,451  $

1,939  $

730  $

560  $

156 

120 

37,088 

9,059 

77,462 

946 

See accompanying notes to consolidated and combined financial statements.

59

Table of Contents

THE PENNANT GROUP INC.
NOTES TO THE CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS
(Dollars in thousands, except per share data and operational senior living units)

1. DESCRIPTION OF BUSINESS

The Pennant Group, Inc. (herein referred to as “Pennant,” the “Company,” “it,” or “its”), is a holding company with no direct operating assets, employees
or revenue. The Company, through its independent operating subsidiaries, provides healthcare services across the post-acute care continuum. As of December 31,
2021,  the  Company’s  subsidiaries  operated  88  home  health,  hospice  and  home  care  agencies  and  54  senior  living  communities  located  in  Arizona,  California,
Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming.

On October 1, 2019, The Ensign Group, Inc. (NASDAQ: ENSG) (“Ensign” or the “Parent”) completed the separation of Pennant from Ensign through a
tax-free distribution of substantially all of Pennant’s issued and outstanding common stock to the stockholders of Ensign (the “Spin-Off”). To accomplish the Spin-
Off, Ensign contributed the Company’s assets and liabilities into Pennant and each Ensign stockholder received a distribution of one share of Pennant common
stock for every two shares of Ensign’s common stock, plus cash in lieu of fractional shares. Additionally, the noncontrolling interest was converted into shares of
Pennant at the established conversion ratio. As a result of the Spin-Off on October 1, 2019, Pennant began trading as an independent company on the NASDAQ
under the symbol “PNTG.”

Certain  of  the  Company’s  subsidiaries,  collectively  referred  to  as  the  Service  Center,  provide  accounting,  payroll,  human  resources,  information

technology, legal, risk management, and other services to the operations through contractual relationships.

Each of the Company’s affiliated operations are operated by separate, independent subsidiaries that have their own management, employees and assets.
References herein to the consolidated “Company” and “its” assets and activities is not meant to imply, nor should it be construed as meaning, that Pennant has
direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by Pennant.

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis  of  Presentation  -  The  accompanying  consolidated  and  combined  financial  statements  of  the  Company  (the  “Financial  Statements”)  reflect  the
Company’s  financial  position  for  the  years  ended  December  31,  2021  and  2020,  and  the  Company’s  results  of  operations  and  cash  flows  for  the  years  ended
December  31,  2021,  2020  and  2019  and  have  been  prepared  in  accordance  with  accounting  principles  generally  accepted  in  the  United  States  (“GAAP”)  and
pursuant  to  the  regulations  of  the  Securities  and  Exchange  Commission  (“SEC”).  Prior  to  the  Spin-Off,  the  combined  financial  statements  were  prepared  on  a
stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements
reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of
operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period.

All  intercompany  transactions  and  balances  between  the  various  legal  entities  comprising  the  Company  have  been  eliminated  in  consolidation.  The

consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest.

The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living
operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue
was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect
direct costs and allocated costs prior to the Spin-Off.

Estimates and Assumptions - The preparation of the Financial Statements in conformity with GAAP requires management to make certain estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and
the  reported  amounts  of  revenue  and  expenses  during  the  reporting  periods.  The  most  significant  estimates  in  the  Financial  Statements  relate  to  self-insurance
reserves,  revenue,  cost  allocations  from  prior  to  the  Spin-Off,  intangible  assets  and  goodwill,  right-of-use  assets  and  lease  liabilities  for  leases  greater  than  12
months, and income taxes. Actual results could differ from those estimates.

60

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Revenue Recognition - Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the
Company  expects  to  be  entitled  from  patients  and  third-party  payors,  including  Medicaid,  Medicare  and  insurers  (private  and  Medicare  replacement  plans),  in
exchange for providing patient care. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction
price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The
Company  uses  the  expected  value  method  in  determining  the  variable  component  that  should  be  used  to  arrive  at  the  transaction  price,  using  contractual
agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may
be  constrained,  and  is  included  in  the  net  revenue  only  to  the  extent  that  it  is  probable  that  a  significant  reversal  in  the  amount  of  the  cumulative  revenue
recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts
these estimates, which would effect net service revenue in the period such variances become known.

As the Company’s contracts have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does
not  consider  the  time  value  of  money.  Further,  because  of  the  short  duration  of  these  contracts,  the  Company  has  not  disclosed  the  transaction  price  for  the
remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has
applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs (“ASC 340”), and all incremental customer contract acquisition costs are
expensed as they are incurred because the amortization period would have been one year or less. See Note 5, Revenue and Accounts Receivable.

CARES Act: The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 in the United States. During
the second quarter of 2020 the Company applied for and received $27,997 in funds under the Accelerated and Advance Payment (“AAP”) Program. For the year
ended  December  31,  2021,  the  Company  repaid  $21,786  of  the  AAP  funds,  with  the  remaining  balance  of  $6,211  recorded  in  other  accrued  liabilities  on  the
consolidated balance sheets. The CARES Act allowed for deferred payment of the employer-paid portion of social security taxes through the end of 2020, with
approximately 50% due on December 31, 2021 and the remainder due on December 31, 2022. The Company deferred approximately $7,836 of employer-paid
portion of social security tax. In the fourth quarter of the current year, we repaid $3,707 and approximately $4,129 of the balance remains deferred and is recorded
in accrued wages and related liabilities. The CARES Act temporarily suspended the 2% sequestration payment adjustment on Medicare fee-for-service payment
beginning  May  1,  2020  and  was  extended  through  December  31,  2021.  The  Company  recognized  $3,555  and  $2,765  in  revenue  related  to  the  suspension  of
sequestration for the years ended December 31, 2021 and 2020, respectively, exclusive of our start-up operations. The Company will continue to assess the effect
of the CARES Act and ongoing other government legislation related to the COVID-19 pandemic that may be issued.

Cash -  Cash  consists  of  petty  cash  and  bank  deposits  and  therefore  approximates  fair  value.  The  Company  places  its  cash  with  high  credit  quality

financial institutions.

Accounts  Receivable  and  Allowance  for  Doubtful  Accounts  -  Accounts  receivable  consist  primarily  of  amounts  due  from  Medicare  and  Medicaid
programs,  other  government  programs,  managed  care  health  plans  and  private  payor  sources,  net  of  estimates  for  variable  consideration.  The  allowance  for
doubtful accounts is the Company’s best estimate of current expected credit losses in the accounts receivable balance.

Property  and  Equipment  -  Property  and  equipment  are  initially  recorded  at  their  historical  cost.  Repairs  and  maintenance  are  expensed  as  incurred.
Depreciation  is  computed  using  the  straight-line  method  over  the  estimated  useful  lives  of  the  depreciable  assets  (ranging  from  three  to  15  years).  Leasehold
improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

Impairment  of  Long-Lived  Assets  -  The  Company  reviews  the  carrying  value  of  long-lived  assets  that  are  held  and  used  in  the  independent  operating
subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of
these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s
best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the
asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company
estimates the fair value of assets based on the estimated future discounted cash flows of the asset. For the year ended December 31, 2021, management evaluated
its long-lived assets and the Company identified $2,835 in long-lived asset impairment related to six senior living communities. Management did not identify any

61

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

asset impairment during the years ended December 31, 2020 and 2019. See further discussion at Note 8, Property and Equipment, Net.

Intangible  Assets  and  Goodwill  -  The  Company’s  indefinite-lived  intangible  assets  consist  of  trade  names  and  Medicare  and  Medicaid  licenses.  The
Company  tests  indefinite-lived  intangible  assets  for  impairment  on  an  annual  basis  or  more  frequently  if  events  or  changes  in  circumstances  indicate  that  the
carrying amount of the intangible asset may not be recoverable. The Company did not identify any indefinite-lived intangible asset impairment during the years
ended December 31, 2021, 2020 and 2019.

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to
annual  test  for  impairment  as  of  the  beginning  of  the  fourth  quarter  or  more  frequently  if  events  or  changes  indicate  that  the  Company's  goodwill  might  be
impaired. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. If the Company determines it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then it is required to perform a
quantitative impairment test by comparing the fair value with the carrying amount of the reporting unit. If the carrying amount of a reporting unit exceeds its fair
value, then the Company records an impairment of goodwill equal to the amount that the carrying amount of a reporting unit exceeds its fair value.

As  of  December  31,  2021,  we  evaluated  potential  triggering  events  that  might  be  indicators  that  our  goodwill  and  indefinite  lived  intangibles  were
impaired. As a result of our evaluation, no goodwill or indefinite intangible asset impairments were recorded during the years ended December 31, 2021, 2020 and
2019. See further discussion at Note 9, Goodwill and Intangible Assets, Net.

Self-Insurance  Reserve  -  The  Company  retains  risk  for  a  substantial  portion  of  potential  claims  for  general  and  professional  liability  and  workers’
compensation. Beginning on January 1, 2022 the Company transitioned its employee health plans to a self insurance model. Prior to that date the Company did not
retain risk related to its employee health plans.

The Company recognizes obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including
with respect to both reported claims and claims incurred but not reported. The Company evaluates the adequacy of the self insurance reserves in conjunction with
an independent actuarial assessment.As of December 31, 2021 the general and professional liability insurance has a retention limit of $150 per claim with a $500
corridor  as  an  additional  out-of-pocket  retention  we  must  satisfy  for  claims  within  the  policy  year  before  the  carrier  will  reimburse  losses.  The  workers’
compensation insurance has a retention limit of $250 per claim, except for policies held in Texas and Washington which are subject to state insurance and possess
their own limits.

These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and
updated by us on a quarterly basis. Additionally, the Company has partially indemnified Ensign for general and professional liabilities incurred prior to the Spin-
off but not reported until after that date and included that amount in its accrual below.

The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities
and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are
less  than  our  noted  insurance  coverage  amounts,  which  includes  outstanding  claims  and  claims  incurred  but  not  reported.  The  amounts  are  reported  gross  of
reinsurance receivable of $927 and $704 included in restricted and other assets for the years ended December 31, 2021 and 2020, respectively.

62

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Type of Insurance
General and professional liability
Workers’ compensation

Total estimated liability

Less: long-term portion, included in other long-term liabilities

Current portion of estimated liability, included in other accrued liabilities

December 31, 2021

2021

2020

$

$

2,007  $
4,899 
6,906 
(5,293)
1,613  $

1,063 
2,783 
3,846 
(2,492)
1,354 

Fair Value of Financial Instruments - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable, accrued
liabilities, and debt. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short
durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers
include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within
Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data
exists, therefore requiring an entity to develop its own assumptions.

Income Taxes - Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the
Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its
deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely
than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain
estimates  and  assumptions.  These  estimates  and  assumptions  are  based  on,  among  other  things,  knowledge  of  operations,  markets,  historical  trends  and  likely
future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s
estimates and assumptions, actual results could differ.

Noncontrolling Interest - The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented
within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income/
(loss) attributable to The Pennant Group, Inc. in its consolidated and combined statements of income. Net income per share is calculated based on net income/
(loss) attributable to The Pennant Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary
earnings based on ownership interest.

Share-Based  Compensation  -The  Company  measures  and  recognizes  compensation  expense  for  all  share-based  payment  awards,  including  employee
stock options and restricted stock, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award.
The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted
stock awards issued, the amount of which is contingent upon the number of future grants and other variables. The total amount of share-based compensation was
$10,040, $8,335, and $3,382 for the years ended December 31, 2021, 2020 and 2019, respectively, of which $7,964, $7,222 and $2,769, respectively, was recorded
in general and administrative expense, with the difference being recorded in cost of services. For further discussion see Note 12, Options and Awards.

Earnings Per Share - In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are
reflected  in  basic  and  diluted  net  income  per  share  for  the  years  ended  December  31,  2021,  2020  and  2019,  respectively.  For  further  discussion  see  Note  4,
Computation of Net Income Per Common Share

Prior to Spin-Off

Cost Allocation - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior
to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology,
compliance, legal, payroll, insurance, tax,

63

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

treasury,  and  other  general  and  administrative  items.  These  costs  were  allocated  to  the  Company  on  a  basis  of  revenue,  location,  employee  count,  or  other
measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income for the year ended
December 31, 2019, including for share-based compensation expenses disclosed in Note 12, Options and Awards. The amount of general and administrative costs
allocated from January 1, 2019 to October 1, 2019, the date of the Spin-Off, inclusive of share-based compensation expense, was $23,710. Management believes
the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods.

Insurance  -  Prior  to  the  Spin-Off  Ensign  was  partially  self-insured  for  healthcare,  general  and  professional  liability,  and  workers’  compensation,  and
historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined
adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as
these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage
provided by Ensign’s self-insured policies.

Debt  -  Ensign’s  external  debt  and  related  interest  expense  were  not  allocated  to  the  Company  for  any  of  the  periods  presented  as  no  portion  of  the

borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off.

Income Taxes - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and
all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information
contained  in  these  Financial  Statements  were  presented  using  a  separate  tax  return  approach.  Under  this  approach,  the  provision  for  income  taxes  represents
income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing
hypothetical  income  tax  returns.  Management  believes  that  the  assumptions  and  estimates  used  to  determine  these  tax  amounts  are  reasonable.  However,  the
Company’s Financial Statements may not necessarily reflect its income tax expense or tax payments in the future, or what tax amounts would have been if the
Company had been a stand-alone company for the entire period presented.

Invested Capital - The net parent investment on the consolidated and combined statement of stockholders equity and statement of cash flows represents
Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested
capital was reclassified into additional paid-in-capital at the date of the Spin-Off.

Noncontrolling  Interest  -  Prior  to  the  Spin-Off,  the  Company  presented  the  noncontrolling  interest  and  the  amount  of  consolidated  net  income/  (loss)
attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings
based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares
of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, does not receive an allocated portion of earnings.

Share-based compensation - Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the
“Ensign  Plans”)  and  the  Cornerstone  Subsidiary  Equity  plan  (the  “Subsidiary  Equity  Plan”).  Share-based  compensation  includes  the  expense  attributable  to
employees  of  the  Company’s  subsidiaries  who  participated  in  the  Ensign  Plans,  as  well  as  the  allocated  cost  related  to  Ensign  subsidiaries’  employees  that
participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the
basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation
was necessary.

Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant
date and was expensed as non-cash compensation over the vesting term. Historically, these awards were granted once per year. The fair value has been determined
by  an  independent  valuation  of  the  subsidiary  shares.  The  valuation  incorporated  a  discounted  cash  flow  analysis  combined  with  a  market-based  approach  to
determine the fair value of the subsidiary equity.

Recent Accounting Standards Adopted by the Company

64

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Except  for  rules  and  interpretive  releases  of  the  SEC  under  authority  of  federal  securities  laws  and  a  limited  number  of  grandfathered  standards,  the
Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by
the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally
accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or
operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are
under consideration.

FASB Accounting Standards Update, or ASU, ASU 2021-01 “Reference Rate Reform (Topic 848): Scope” or ASU 2020-4 - On January 7, 2021, the FASB
issued  ASU  2021-01  to  amend  the  scope  of  the  guidance  in  ASU  2020-04  “Reference  Rate  Reform  (Topic  848):  Facilitation  of  the  Effects  of  Reference  Rate
Reform on Financial Reporting” or ASU 2020-4. Specifically, the amendments in ASU 2021-01 clarify that “certain optional expedients and exceptions in Topic
848  for  contract  modifications  and  hedge  accounting  apply  to  derivatives  that  are  affected  by  the  discounting  transition.”  The  amendment  in  ASU  2021-1  is
available to all entities: (i) on a full retrospective basis as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020
through the date that the final update to the standard was issued or (ii) on a prospective basis for new contract modifications through December 31, 2022. The
Company has adopted ASU 2021-01 on a prospective basis effective as of January 7, 2021. There was no material impact to the Company’s Consolidated and
Combined Financial Statements or related disclosures as a result of the adoption of ASU 2021-01.

3. RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT

Prior to the Spin-Off, our businesses were included as subsidiaries of Ensign. As a result, our transactions were considered related party transactions. On
October 1, 2019, in connection with the Spin-Off, Pennant entered into several agreements with Ensign that set forth the principal actions taken or to be taken in
connection with the Spin-Off and govern the relationship of the parties following the Spin-Off. On October 1, 2021 the company concluded its Transition Services
Agreement with Ensign.

The Company has incurred $3,124, $5,536, and $2,982 in costs related to the Transitions Services Agreement for the years ended December 31, 2021,
2020 and 2019, respectively. Additionally, the Company has recognized $208, $578, and $291 in tax benefits related to the Tax Matters Agreement for the years
ended  December  31,  2021,  2020  and  2019,  respectively,  and  has  recorded  a  payable  to  Ensign  in  connection  with  any  unpaid  portion  of  these  amounts.  See
“Certain Relationships and Related Party Transactions—Agreements with Ensign Related to the Spin-Off,” contained within the Information Statement as well as
the Form 8-K filed with the SEC on October 3, 2019 for further discussion of the agreements entered into in connection with the Spin-Off.

The Company leases 32 of its senior living communities from subsidiaries of Ensign, each of the leases have a term of between 14 and 20 years from the
lease commencement date. The total amount of rent expense included in Rent - cost of services paid to subsidiaries of Ensign was $12,773, $12,536, and $11,292
for the years ended December 31, 2021, 2020 and 2019, respectively.

Certain related party activity occurred as the Company’s subsidiaries received services from Ensign’s subsidiaries. Services included in cost of services

were $3,084, $4,205, and $3,166 for the years ended December 31, 2021, 2020 and 2019, respectively.

4. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic  net  income  per  share  is  computed  by  dividing  net  income  attributable  to  stockholders  of  the  Company  by  the  weighted  average  number  of
outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had
been issued.

Prior to Spin-Off

Net income attributable to the noncontrolling interest has been included in the numerator for the year ended December 31, 2019, as the non-controlling
subsidiary interest that existed prior to the Spin-Off was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the
date of the Spin-Off.

65

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The following table sets forth the computation of basic and diluted net income per share for the periods presented:

Numerator:
Net income
Add: net (loss)/ income attributable to noncontrolling interests

Net income attributable to The Pennant Group, Inc.

Denominator:

Weighted average shares outstanding for basic net income per share
Plus: incremental shares from assumed conversion

(a)

Adjusted weighted average common shares outstanding for diluted income per share

Earnings Per Share:

Basic net income per common share
Diluted net income per common share

(b)

(b)

Year Ended December 31,
2020

2019

2021

2,148  $
(548)
2,696  $

15,553  $
(191)
15,744  $

3,175 
629 
2,546 

28,406 
2,236 
30,642 

28,029 
2,199 
30,228 

27,838 
1,748 
29,586 

0.09  $
0.09  $

0.56  $
0.52  $

0.11 
0.11 

$

$

$
$

(a)

(b)

The calculation of dilutive shares outstanding excludes out-of-the-money stock options (i.e., such options’ exercise prices were greater than the average market price of our common shares for the
period) because their inclusion would have been antidilutive. Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were
478, 93, and 15 for the years ended December 31, 2021, 2020 and 2019, respectively.
For the year ended December 31, 2019 basic and diluted earnings per share were calculated based on net income as the numerator, which included the conversion of the noncontrolling interest in
connection with the Spin-Off. For the years ended December 31, 2021 and 2020, basic and diluted earnings per share were calculated based on net income attributable to The Pennant Group, Inc.
as the numerator.

5. REVENUE AND ACCOUNTS RECEIVABLE

Revenue  is  recognized  when  services  are  provided  to  the  patients  at  the  amount  that  reflects  the  consideration  to  which  the  Company  expects  to  be
entitled  from  patients  and  third-party  payors,  including  Medicaid,  Medicare  and  managed  care  programs  (Commercial,  Medicare  Advantage  and  Managed
Medicaid plans), in exchange for providing patient care. The healthcare services in home health and hospice patient contracts include routine services in exchange
for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such,
patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary
services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when
those services are rendered.

Revenue  recognized  from  healthcare  services  are  adjusted  for  estimates  of  variable  consideration  to  arrive  at  the  transaction  price.  The  Company
determines  the  transaction  price  based  on  contractually  agreed-upon  amounts  or  rate,  adjusted  for  estimates  of  variable  consideration.  The  Company  uses  the
expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical
reimbursement  experience  within  each  payor  type.  The  amount  of  variable  consideration  which  is  included  in  the  transaction  price  may  be  constrained,  and  is
included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a
future  period.  If  actual  amounts  of  consideration  ultimately  received  differ  from  the  Company’s  estimates,  the  Company  adjusts  these  estimates,  which  would
affect net service revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 62.6%, 60.1%, and 55.6% of the Company’s revenue for the years ended December
31, 2021, 2020 and 2019, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their
expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive
adjustment  by  governmental  and  third-party  agencies.  Consistent  with  healthcare  industry  accounting  practices,  any  changes  to  these  governmental  revenue
estimates are recorded in the period the change or adjustment becomes known based on final settlement.

66

 
Table of Contents

Disaggregation of Revenue

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The  Company  disaggregates  revenue  from  contracts  with  its  patients  or  residents  by  reportable  operating  segments  and  payors.  The  Company  has
determined  that  disaggregating  revenue  into  these  categories  achieves  the  disclosure  objectives  to  depict  how  the  nature,  amount,  timing  and  uncertainty  of
revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in
below.

The Company’s service specific revenue recognition policies are as follows:

Home Health Revenue

Medicare Revenue

For  Medicare  episodes  that  began  after  January  1,  2020,  net  service  revenue  is  recognized  in  accordance  with  the  Patient  Driven  Groupings  Model
(“PDGM”). This new reimbursement structure involves case mix calculation methodology refinements, changes to low-utilization payment adjustment (“LUPA”)
thresholds, the elimination of therapy thresholds, a change to the unit of payment from a 60-day episode to a 30-day payment period, and reduction of requests for
anticipated  payments  (“RAPs”)  to  20%  of  the  estimated  payment  for  a  patient’s  initial  or  subsequent  period  of  care  up-front  (after  the  initial  assessment  is
completed and upon initial billing). The RAPs were completely phased out effective January 1, 2021. Under PDGM, Medicare provides agencies with payments
for each 30-day payment period provided to beneficiaries. If a beneficiary is still eligible for care after the end of the first 30-day payment period, a second 30-day
payment period can begin. There are no limits to the number of periods of care a beneficiary who remains eligible for the home health benefit can receive. While
payment for each 30-day payment period is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate
payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including,
but not limited to: (a) a LUPA if the number of visits is below an established threshold that varies based on the diagnosis of a beneficiary; (b) a partial payment if
the patient transferred to another provider or the Company received a patient from another provider before completing the period of care; (c) adjustment to the
admission source of claim if it is determined that the patient had a qualifying stay in a post-acute care setting within 14 days prior to the start of a 30-day payment
period; (d) the timing of the 30-day payment period provided to a patient in relation to the admission date, regardless of whether the same home health provider
provided care for the entire series of episodes; (e) changes to the acuity of the patient during the previous 30-day payment period; (f) changes in the base payments
established by the Medicare program; (g) adjustments to the base payments for case mix and geographic wages; and (h) recoveries of overpayments.

For all episodes that began prior to January 1, 2020, net service revenue was recorded under the Medicare prospective payment system based on a 60-day
episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually
costly;  (b)  a  LUPA  if  the  number  of  visits  was  fewer  than  five;  (c)  a  partial  payment  if  the  patient  transferred  to  another  provider  or  transferred  from  another
provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to
a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established
by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

The  Company  adjusts  Medicare  revenue  on  completed  episodes  to  reflect  differences  between  estimated  and  actual  payment  amounts,  an  inability  to
obtain  appropriate  billing  documentation  and  other  reasons  unrelated  to  credit  risk.  Therefore,  the  Company  believes  that  its  reported  net  service  revenue  and
patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes and periods, the Company also recognizes a portion of revenue associated with episodes and
periods in progress. Episodes in progress are 30-day payment periods, if the episode started after January 1, 2020, or 60-day episodes of care, if the episode started
prior to January 1, 2020, that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and
recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected
Medicare revenue per period of care or episode of care and the Company’s estimate of the average percentage complete based on the scheduled end of period and
end of episode dates.

67

Table of Contents

Non-Medicare Revenue

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid

by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue - Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated

per visit rates, as applicable.

Hospice Revenue

Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates
are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or
authorizations acceptable to Medicare and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an
overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company regularly
evaluates and records these adjustments as a reduction to revenue and an increase to other accrued liabilities.

Senior Living Revenue

The Company has elected the lessor practical expedient within ASC Topic 842, Leases (“ASC 842”) and therefore recognizes, measures, presents, and
discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or
non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have
the same timing and pattern of transfer. The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers for its senior residency
agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract.

The  Company’s  senior  living  revenue  consists  of  fees  for  basic  housing  and  assisted  living  care.  Accordingly,  we  record  revenue  when  services  are
rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees
billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or
rates on a per resident, daily basis or as services are rendered.

Revenue by payor for the years ended December 31, 2021, 2020 and 2019, is summarized in the following tables:

Home Health and Hospice Services

Year Ended December 31, 2021

Medicare
Medicaid

Subtotal
Managed care
Private and other

(a)

Total revenue

Home Health Services
$

80,849  $
8,935 
89,784 
46,167 
22,007 
157,958  $

Hospice Services

Senior Living Services

Total Revenue

Revenue %

135,939  $
12,103 
148,042 
3,196 
374 
151,612  $

—  $

37,317 
37,317 
— 
92,807 
130,124  $

216,788 
58,355 
275,143 
49,363 
115,188 
439,694 

49.3 %
13.3 
62.6 
11.2 
26.2 
100.0 %

$

Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

68

Table of Contents

Medicare
Medicaid

Subtotal
Managed care
Private and other

(a)

Total revenue

Medicare
Medicaid

Subtotal
Managed care
Private and other

(a)

Total revenue

$

$

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Home Health and Hospice Services

Year Ended December 31, 2020

Home Health Services
$

58,399  $
7,645 
66,044 
31,572 
21,968 
119,584  $

Hospice Services

Senior Living Services

Total Revenue

Revenue %

119,873  $
12,462 
132,335 
1,546 
194 
134,075  $

—  $

36,780 
36,780 
— 
100,514 
137,294  $

178,272 
56,887 
235,159 
33,118 
122,676 
390,953 

45.6 %
14.5 
60.1 
8.5 
31.4 
100.0 %

Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Home Health and Hospice Services

Year Ended December 31, 2019

Home Health Services
$

47,819  $
6,575 
54,394 
27,711 
18,837 
100,942  $

Hospice Services

Senior Living Services

Total Revenue

Revenue %

93,933  $
10,061 
103,994 
1,536 
152 
105,682  $

—  $

29,819 
29,819 
— 
102,088 
131,907  $

141,752 
46,455 
188,207 
29,247 
121,077 
338,531 

41.9 %
13.7 
55.6 
8.6 
35.8 
100.0 %

Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations.

Balance Sheet Impact

Included in the Company’s consolidated balance sheets are contract assets, comprised of billed accounts receivable and unbilled receivables, which are
the  result  of  the  timing  of  revenue  recognition,  billings  and  cash  collections,  as  well  as,  contract  liabilities,  which  primarily  represent  payments  the  Company
receives in advance of services provided. As of December 31, 2021, the Company had contract liabilities in the amount of $6,211 related to Advance Payments
received in connection with the CARES Act. As further discussed in Note 10, Other Accrued Liabilities,  the  repayment  terms  for  Medicare  advance  payments
were modified through the passage of the Continuing Appropriations Act, 2021 and Other Extensions Act on October 1, 2020.

Accounts receivable as of December 31, 2021 and December 31, 2020 is summarized in the following table:

Medicare
Medicaid
Managed care
Private and other

Accounts receivable, gross

Less: allowance for doubtful accounts

Accounts receivable, net

December 31, 2021

December 31, 2020

31,327  $
11,793 
7,901 
3,821 
54,842 
(902)
53,940  $

28,569 
7,669 
7,590 
4,036 
47,864 
(643)
47,221 

$

$

69

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The following table summarizes the activity for our allowance for doubtful accounts for the years ended December 31, 2021, 2020 and 2019:

Balance at beginning of period
Additions to bad debt expense
Write-offs of uncollectible accounts

Balance at end of period

6. BUSINESS SEGMENTS

Year Ended December 31,
2020

2021

2019

$

$

643  $
616 
(357)
902  $

677  $
560 
(594)
643  $

616 
858 
(797)
677 

The  Company  classifies  its  operations  into  the  following  reportable  operating  segments:  (1)  home  health  and  hospice  services,  which  includes  the
Company’s home health, hospice and home care businesses; and (2) senior living services, which includes the operation of assisted living, independent living and
memory care communities. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into
those operations. Our Chief Executive Officer and President, who is our Chief Operating Decision Maker “CODM”, reviews financial information at the operating
segment level. We also report an “all other” category that includes general and administrative expense from our Service Center.

As of December 31, 2021, the Company provided services through 88 affiliated home health, hospice and home care agencies, and 54 affiliated senior
living operations. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize
the  quality  of  care  provided  and  profitability.  The  Company’s  Service  Center  provides  various  services  to  all  lines  of  business.  The  Company  does  not  review
assets by segment and therefore assets by segment are not disclosed below.

The CODM uses Segment Adjusted EBITDAR from Operations as the primary measure of profit and loss for the Company's reportable segments and to
compare the performance of its operations with those of its competitors. Segment Adjusted EBITDAR from Operations is net income/ (loss) attributable to the
Company's  reportable  segments  excluding  interest  expense,  provision  for  income  taxes,  depreciation  and  amortization  expense,  rent,  and,  in  order  to  view  the
operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation,
(3) acquisition related costs, (4) Spin-Off transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) net income/
(loss) attributable to noncontrolling interest, (7) net COVID-19 related costs and (8) impairment of long-lived assets. General and administrative expenses are not
allocated to the reportable segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general
and  administrative  expenses.  The  Company's  segment  measures  may  be  different  from  the  calculation  methods  used  by  other  companies  and,  therefore,
comparability may be limited.

The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the

reportable segments and are included in “All Other”.

Year Ended December 31, 2021
Revenue
Segment Adjusted EBITDAR from Operations
Year Ended December 31, 2020
Revenue
Segment Adjusted EBITDAR from Operations
Year Ended December 31, 2019
Revenue
Segment Adjusted EBITDAR from Operations

Home Health and
Hospice Services

Senior Living
Services

All Other

Total

$
$

$
$

$
$

309,570  $
55,565  $

253,659  $
49,501  $

206,624  $
33,354  $

130,124  $
37,517  $

137,294  $
48,309  $

131,907  $
47,344  $

—  $
(26,208) $

—  $
(22,762) $

—  $
(18,591) $

439,694 
66,874 

390,953 
75,048 

338,531 
62,107 

70

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:

Segment Adjusted EBITDAR from Operations
Less: Depreciation and amortization
Rent—cost of services
Other income

Adjustments to Segment EBITDAR from Operations:
Less: Costs at start-up operations

(a)

(b)

(c)

Share-based compensation expense
Acquisition related costs
Spin-off related transaction costs
Transition services costs
COVID-19 Related costs and supplies
Impairment of long-lived assets

(g)

(d)

(e)

(f)

Add: Net income/ (loss) attributable to noncontrolling interest

Consolidated and Combined Income from operations

Year Ended December 31,
2020

2021

2019

66,874  $
4,784 
40,863 
(24)

1,045 
10,040 
80 
— 
2,008 
— 
2,835 
(548)
4,695  $

75,048  $
4,675 
39,191 
225 

1,787 
8,335 
99 
— 
1,181 
447 
— 
(191)
18,917  $

62,107 
3,810 
34,975 
— 

483 
3,382 
665 
13,219 
532 
— 
— 
629 
5,670 

$

$

Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.
Share-based compensation expense incurred which is included in cost of services and general and administrative expense.
Acquisition related costs that are not capitalizable.
Costs incurred related to the Spin-Off are included in general and administrative expense.
A portion of the costs incurred under the Transition Services Agreement identified as redundant or nonrecurring that are included in general and administrative expense. Fees incurred under the

Transition Services Agreement, net of the Company’s payroll reimbursement, were $3,124, $5,536, and $2,982, for the years ended December 31, 2021, 2020 and 2019, respectively.

Beginning in the first quarter of fiscal year 2021, we updated our definition of Segment Adjusted EBITDAR to no longer include an adjustment for COVID-19 expenses offset by the amount of
sequestration relief. COVID-19 expenses continue to be part of daily operations for which less specific identification is visible. Furthermore, the sequestration relief was extended through
December 31, 2021. Sequestration relief was $3,555 for the year ended December 31, 2021.

The 2020 amount represents incremental costs incurred as part of the Company's response to COVID-19 including direct medical supplies, labor, and other expenses, net of $2,765 in increased

revenue related to the 2% payment increase in Medicare reimbursements for sequestration relief for the year ended December 31, 2020.

On January 27, 2022, affiliates of the Company, entered into certain operations transfer agreements (collectively, the “Transfer Agreements”) with affiliates of Ensign, providing for the transfer of
the  operations  of  certain  senior  living  communities  (the  “Transaction”).  The  closing  of  the  Transaction  is  anticipated  to  occur  in  the  first  half  of  2022.  The  Company  impaired  certain
leasehold improvements included in property and equipment primarily related to the operations included in the transaction with Ensign.

7. ACQUISITIONS

The  Company’s  acquisition  focus  is  to  purchase  or  lease  operations  that  are  complementary  to  the  Company’s  current  businesses,  accretive  to  the
Company’s  business  or  otherwise  advance  the  Company’s  strategy.  The  results  of  all  the  Company’s  independent  operating  subsidiaries  are  included  in  the
Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting.

2021 Acquisitions

During the year ended December 31, 2021, the Company expanded its operations with the addition of five home health agencies, four hospice agencies,
and two home care agencies. The aggregate purchase price for these acquisitions was $14,135. A subsidiary of the Company entered into a separate operations
transfer agreement with the prior operator of each acquired operation as part of each transaction. The goodwill was primarily attributable to intangible assets that
do not qualify for separate recognition and to synergies the Company expects to achieve related to the acquisition and was allocated to the Company's operating
segments which are its reporting units. The Company anticipates that the total goodwill recognized

71

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

will be fully deductible for tax purposes. Acquisition costs related to the business combinations of home health, hospice, and home care acquisitions of $80 were
expensed related to the business combinations during the year ended December 31, 2021.

Two  of  the  hospice  agencies  were  acquired  Medicare  licenses  and  are  considered  asset  acquisitions.  The  fair  value  of  assets  for  the  hospice  licenses

acquired totaled $585 and was allocated to indefinite-lived intangible assets.

2020 Acquisitions

During the year ended December 31, 2020, the Company expanded its operations with the addition of six home health agency, six hospice agencies, and
two senior living communities. The aggregate purchase price for these acquisitions was $39,239. In connection with the addition of the senior living communities,
the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The addition of these operations added a total of 164 operational senior
living  units  to  be  operated  by  the  Company’s  independent  operating  subsidiaries.  A  subsidiary  of  the  Company  entered  into  a  separate  operations  transfer
agreement  with  the  prior  operator  of  each  acquired  operation  as  part  of  each  transaction.  The  goodwill  was  primarily  attributable  intangible  assets  that  do  not
qualify for separate recognition and to synergies the Company expects to achieve related to the acquisition and was allocated to the Company's operating segments
which are its reporting units. The Company anticipates that the total goodwill recognized will be fully deductible for tax purposes. Acquisition costs related to the
business  combinations  of  home  health,  hospice,  and  home  care  acquisitions  of  $99  were  expensed  related  to  the  business  combinations  during  the  year  ended
December 31, 2020.

In October 2020, the Company announced it closed on a home health joint venture and hospice joint venture with Scripps Health (“Scripps”), a leading
nonprofit integrated health system based in San Diego, California. The closing was effective October 1, 2020. The resulting joint ventures, which combined certain
assets  and  the  operations  of  Scripps’  home  health  business  and  the  assets  and  operations  of  the  local  Pennant-affiliated  home  health  and  hospice  agencies,  are
majority-owned and managed by an independent operating subsidiary of the Company and provide home health and hospice services to patients throughout San
Diego County. The fair value of assets contributed by Scripps to the home health joint venture were included in the total value of assets acquired as described
above and in the summary table below. The Company paid Scripps $6,200 in cash and contributed assets from the local Pennant-affiliated home health agency
with a net book value of $614. The Company acquired 60.0% ownership interest in the joint venture. The contributions of assets by Scripps to the joint venture,
resulted  in  the  Company  recording  a  noncontrolling  interest  with  a  fair  value  of  $4,646.  The  fair  value  of  the  noncontrolling  interest  was  determined  using
discounted cash flow models. As part of the transaction with Scripps, the Company contributed the assets of the local Pennant-affiliated hospice agency to another
joint venture. The Company sold Scripps a noncontrolling interest in the hospice joint venture for $555 in cash. The company retained an 80.0% ownership interest
in the hospice joint venture. The transaction resulted in the Company recognizing a noncontrolling interest of $138 and a contribution to additional paid in capital
of $313, net of $104 of the income tax effect.

2019 Acquisitions

During the year ended December 31, 2019, the Company expanded its operations with the addition of two home health agencies, five hospice agencies,
two home care agencies and two senior living operations. In connection with the acquisition of one of the senior living communities, the Company entered into a
new  long-term  “triple-net”  lease  with  a  subsidiary  of  Ensign.  The  Company  did  not  acquire  any  material  assets  or  assume  any  liabilities.  A  subsidiary  of  the
Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The addition of these
operations added a total of 143 operational senior living units to be operated by the Company’s independent operating subsidiaries. The aggregate purchase price
for these acquisitions was $18,760. Acquisition costs related to the business combinations of home health, hospice, and home care was $611 during the year ended
December 31, 2019.

The fair value of assets for home health and hospice acquisitions was mostly concentrated in goodwill and as such, these transactions were classified as

business combinations in accordance with ASC Topic 805, Business Combinations (“ASC

72

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

805”). The table below presents the allocation of the purchase price for the operations acquired in acquisitions during the years ended December 31, 2021, 2020
and 2019 as noted above:

Equipment, furniture, and fixtures
Goodwill
Other indefinite-lived intangible assets
Other assets
Liabilities assumed
    Total acquisitions
Less: noncontrolling interest and additional paid in capital
Less: cash paid in prior year (held in escrow)

(b)

(a)

Total cash paid for acquisitions

2021

December 31, 2021
2020

2019

$

$

$

62  $

7,821 
6,242 
10 
— 
14,135  $
— 
(585)
13,550  $

174  $

25,211 
14,026 
— 
(172)
39,239  $
(4,646)
(1,400)
33,193  $

(a)
(b)

Consists of the of noncontrolling interest related to Scripps contribution of assets to the joint venture.
Total cash paid for acquisitions for the year ended December 31, 2021 includes $585 as an escrow deposit that was paid in the prior year.

8. PROPERTY AND EQUIPMENT—NET

Property and equipment, net consist of the following:

Leasehold improvements
Equipment
Furniture and fixtures

Less: accumulated depreciation

Property and equipment, net

December 31, 2021

2021

2020

$

$

11,660  $
22,415 
1,199 
35,274 
(18,486)
16,788  $

91 
10,341 
8,326 
2 
— 
18,760 
— 
— 
18,760 

9,984 
22,420 
1,186 
33,590 
(15,706)
17,884 

Depreciation expense was $4,751, $4,661 and $3,757 for the years ended December 31, 2021, 2020 and 2019, respectively.

Asset Impairment

The Company reviews the carrying value of long-lived assets impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. On January 27, 2022, affiliates of the Company, entered into certain operations transfer agreements with affiliates of Ensign,
providing for the transfer of the operations of certain senior living communities (the “Transaction”). The closing of the Transaction is anticipated to occur in the
first half of 2022. As of the year ended December 31, 2021, management determined that the long-lived assets for the impacted communities were not recoverable
and  the  Company  recognized  a  non-cash  long-lived  asset  impairment  charge  of  $2,835  in  cost  of  services  in  the  Consolidated  and  Combined  Statements  of
Income.

9. GOODWILL AND INTANGIBLE ASSETS—NET

The Company tests goodwill during the fourth quarter of each year and also if events or changes in circumstances indicate the occurrence of a triggering
event which might indicate there may be impairment. The Company performs its goodwill impairment analysis for each reporting unit that constitutes a component
for which (1) discrete financial information is available and (2) segment management regularly reviews the operating results of that component, in accordance with
the provisions of ASC Topic 350, Intangibles-Goodwill and Other (“ASC 350”).

73

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair
value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If
it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify
goodwill impairment. If it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, it is unnecessary
to  perform  a  quantitative  analysis.  The  Company  may  elect  to  bypass  the  qualitative  assessment  and  proceed  directly  to  performing  a  quantitative  analysis.
Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. An impairment loss is recognized for the amount that
the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. The
Company did not identify any impairment charge during the years ended December 31, 2021, 2020 and 2019.

The following table represents activity in goodwill by segment as of and for the year ended December 31, 2021:

December 31, 2019
Additions
December 31, 2020
Additions

December 31, 2021

Other indefinite-lived intangible assets consist of the following:

Home Health and
Hospice Services

Senior Living Services

Total

$

$

37,591  $
25,211 
62,802 
7,821 
70,623  $

3,642  $
— 
3,642 
— 
3,642  $

41,233 
25,211 
66,444 
7,821 
74,265 

1,355 
46,133 
47,488 

December 31, 2021

2021

2020

1,355  $

52,375 
53,730  $

Trade name
Medicare and Medicaid licenses

Total

10. OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:

Refunds payable
Deferred revenue
Resident deposits
Contract liabilities (CARES Act advance payments)
Property taxes
Accrued insurance retention - current portion
Other

Other accrued liabilities

$

$

$

$

December 31, 2021

December 31, 2020

3,095  $
1,456 
5,111 
6,211 
1,102 
1,613 
2,896 
21,484  $

2,664 
1,271 
5,647 
22,771 
982 
1,354 
3,586 
38,275 

Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs
when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to residents and a small portion consists of
non-refundable deposits recognized into revenue over a period of time. The CARES Act also expanded the Centers for Medicare & Medicaid Services’ (“CMS”)
ability  to  provide  accelerated/advance  payments  intended  to  increase  the  cash  flow  of  healthcare  providers  and  suppliers  impacted  by  COVID-19.  During  the
second quarter of 2020, the Company applied for and received $27,997 in funds under the AAP Program. On October 1, 2020, the Continuing Appropriations Act,
2021 and Other Extensions Act (the “CA Act”) was signed into law. Among other things, the CA Act significantly changed the repayment terms for AAP. These
funds are subject to

74

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

automatic  recoupment  through  offsets  to  new  claims  beginning  one  year  after  funds  were  issued  beginning  in  April  2021,  at  which  time,  Medicare  began  to
automatically  recoup  25%  of  Medicare  payments  for  11  months.  At  the  end  of  the  11  months  and  assuming  full  repayment  has  not  occurred,  recoupment  will
increase to 50% for another six months. Any balance outstanding after these two recoupment periods will be subject to repayment at a 4% interest rate. For the
year ended December 31, 2021, the Company repaid $21,786 of the AAP funds. The Company reclassified $5,226 of AAP to other long-term liabilities for the
year ended December 31, 2020. The Company anticipates completing repayment of the AAP within the allotted recoupment periods.

11. DEBT

Long-term debt, net consists of the following:

Revolving credit facility

Less: unamortized debt issuance costs

(a)

Long-term debt, net

(a)

December 31, 2021

2021

2020

$

$

53,500  $
(2,128)
51,372  $

9,500 
(1,223)
8,277 

Amortization expense for debt issuance costs was $488, $330, and $78 for the years ended December 31, 2021, 2020 and 2019, respectively, and is recorded in interest 

net on the Consolidated and Combined Statements of Income.

On February 23, 2021, Pennant entered into an amendment to its existing credit agreement (as amended, the “Credit Agreement”), which provides for an
increased revolving credit facility with a syndicate of banks with a borrowing capacity of $150,000 (the “Revolving Credit Facility”). The interest rates applicable
to loans under the Revolving Credit Facility are, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Credit Agreement) plus a margin ranging
from 2.3% to 3.3% per annum or (ii) Base Rate plus a margin ranging from 1.3% to 2.3% per annum, in each case based on the ratio of Consolidated Total Net
Debt  to  Consolidated  EBITDA  (each,  as  defined  in  the  Credit  Agreement).  In  addition,  Pennant  pays  a  commitment  fee  on  the  undrawn  portion  of  the
commitments under the Revolving Credit Facility which ranges from 0.35% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated
EBITDA ratio of the Company and its subsidiaries. The Company is not required to repay any loans under the Credit Agreement prior to maturity in 2026, other
than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Agreement. As of December 31, 2021, the Company’s weighted
average  interest  rate  on  its  outstanding  debt  was  2.64%.  As  of  December  31,  2021,  the  Company  had  available  borrowing  on  the  Revolving  Credit  Facility  of
$92,314, which is net of outstanding letters of credit of $4,186.

The fair value of the Revolving Credit Facility approximates carrying value, due to the short-term nature and variable interest rates. The fair value of this

debt is categorized within Level 2 of the fair value hierarchy based on the observable market borrowing rates.

The Credit Agreement is guaranteed, jointly and severally, by certain of the Company’s independent operating subsidiaries, and is secured by a pledge of
stock  of  the  Company's  material  independent  operating  subsidiaries  as  well  as  a  first  lien  on  substantially  all  of  each  material  operating  subsidiary's  personal
property. The Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its
independent  operating  subsidiaries  to  grant  liens  on  their  assets,  incur  indebtedness,  sell  assets,  make  investments,  engage  in  acquisitions,  mergers  or
consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Financial covenants require compliance with certain
levels of leverage ratios that impact the amount of interest. As of December 31, 2021, the Company was compliant with all such financial covenants.

12. OPTIONS AND AWARDS

Share-based  compensation  expense  consists  of  share-based  payment  awards  made  to  employees  and  directors,  including  employee  stock  options,
restricted stock awards (“RSA”), and restricted stock units (“RSU” and together with RSA, “Restricted Stock”), based on estimated fair values, ratably over the
requisite service period of the award. The Company accounts for forfeitures as they occur.

75

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

In connection with the Spin-Off, the Company issued new options and restricted stock awards to Pennant and Ensign employees under the 2019 Omnibus

Incentive Plan (the “OIP”) and Long-Term Incentive Plan (the “LTIP”, together referred to as the “Pennant Plans”).

Prior to Spin-Off

For  all  periods  prior  to  the  Spin-Off,  employees  of  the  Company  participated  in  Ensign's  share-based  compensation  plans.  The  compensation  expense
recorded  by  the  Company  included  the  expense  associated  with  these  employees,  as  well  as  an  allocation  of  share-based  compensation  of  certain  Ensign
employees who provided general and administrative services on our behalf.

Outstanding  options  held  by  employees  of  the  Company  under  the  Ensign  stock  plans  (collectively  the  “Ensign  Plans”)  and  outstanding  options  and
restricted stock awards under the Company Subsidiary Equity Plan (together with the Ensign Plans the “Pre-Spin Plans”) were modified and replaced with Pennant
awards under the Pennant Plans at the Spin-Off date.

Share-Based Compensation

The following disclosures represent share-based compensation expense relating to the Ensign and Pennant Plans, including awards to employees of the
Company’s subsidiaries and an allocation of costs from employees in the Service Center prior to the Spin-Off, and total share-based compensation after the Spin-
Off.

Total share-based compensation expense for all of the Plans for the years ended December 31, 2021, 2020 and 2019:

Prior to the Spin-Off:
Total share-based compensation

Following the Spin-Off:
Share-based compensation expense related to stock options
Share-based compensation expense related to Restricted Stock
Share-based compensation expense related to Restricted Stock to non-employee directors

Total share-based compensation

2021

Year Ended December 31,
2020

2019

—  $

—  $

1,395 

3,093 
6,141 
806 
10,040  $

1,660 
6,200 
475 
8,335  $

315 
1,589 
83 
3,382 

$

$

In  future  periods,  the  Company  estimates  it  will  recognize  the  following  share-based  compensation  expense  for  unvested  stock  options  and  unvested

Restricted Stock, which were unvested as of December 31, 2021:

Unvested stock options
Unvested Restricted Stock

Total unrecognized share-based compensation expense

Stock Options

Unrecognized Compensation
Expense

$

$

12,620 
4,780 
17,400 

Weighted Average
Recognition Period (in years)
3.8
0.9

Under the Pennant Plans, options granted to employees of the subsidiaries of Pennant generally vest over five years at 20% per year on the anniversary of

the grant date. Options expire ten years after the date of grant.

The Company uses the Black-Scholes option-pricing model to recognize the value of share-based compensation expense for share-based payment awards
under  the  Plans.  Determining  the  appropriate  fair-value  model  and  calculating  the  fair  value  of  share-based  awards  at  the  grant  date  requires  considerable
judgment, including estimating stock price volatility and

76

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

expected option life. The Company develops estimates based on historical data and market information, which can change significantly over time.

The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions

for stock options granted after the Spin-Off:

Grant Year
2021
2020
2019

Options
Granted

Risk-Free Interest
Rate

Expected Life

(a)

Expected
(b)
Volatility

Dividend Yield

454 
693 
667 

1.1 %
0.5 %
1.6 %

6.5
6.5
6.5

38.4 %
35.9 %
34.6 %

Weighted
Average Fair
Value of Options
13.84 
11.05 
5.70 

— % $
— % $
— % $

(a)

(b)

Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected
option life of 6.5 years for the options granted.
Because the Company’s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.

The following table represents the employee stock option activity during the year ended December 31, 2021:

December 31, 2020
Granted
Exercised
Forfeited/ Expired

December 31, 2021

Number of
Options
Outstanding

Weighted
Average
Exercise Price

Number of
Options Vested

Weighted
Average
Exercise Price
of Options
Vested

1,982  $
454  $
(115) $
(79) $
2,242  $

17.48 
35.01 
7.67 
21.81 

21.38 

615  $

7.52 

840  $

12.28 

The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2021 is as follows:

Options
Outstanding
Vested
Unvested
Exercised

$

December 31, 2021

14,749 
10,221 
4,528 
3,248 

The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. There
were 1,402 unvested and outstanding options at December 31, 2021. The weighted average contractual life for options outstanding, vested and expected to vest at
December 31, 2021 was 7.39 years.

77

Table of Contents

Restricted Stock

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

Under the Pennant Plans, the Company granted Restricted Stock to Pennant employees, Ensign employees, and to non-employee directors. All awards
generally vest between three to five years. A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31,
2021, is presented below:

December 31, 2020
Granted
Vested
Forfeited

December 31, 2021

13. LEASES

Non-Vested Restricted
Awards

Weighted Average
Grant Date Fair Value
14.80 
39.82 
16.20 
14.13 

15.00 

1,635  $
20 
(157)
(5)
1,493  $

The  Company’s  independent  operating  subsidiaries  lease  54  senior  living  communities  and  its  administrative  offices  under  non-cancelable  operating
leases,  most  of  which  have  initial  lease  terms  ranging  from  five  to  21  years.  The  Company’s  independent  operating  subsidiaries  also  lease  the  administrative
offices of 88 home health and hospice agencies which generally range from one to seven years. Most of these leases contain renewal options, most involve rent
increases  and  none  contain  purchase  options.  The  lease  term  excludes  lease  renewals  because  the  renewal  rents  are  not  at  a  bargain,  there  are  no  economic
penalties for the Company to renew the lease, and it is not reasonably certain that the Company will exercise the extension options. As of December 31, 2021, the
Company’s  independent  operating  subsidiaries  leased  32  communities  from  subsidiaries  of  Ensign  (“Ensign  Leases”)  under  a  master  lease  arrangement.  The
existing leases with subsidiaries of Ensign are for initial terms of between 14 to 20 years. In addition to rent, each of the operating companies are required to pay
the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other
services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the
leased properties and the business conducted on the leased properties; (4) all community maintenance and repair costs; and (5) all fees in connection with any
licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties.

Fifteen of the Company’s affiliated senior living communities, excluding the communities that are operated under the Ensign Leases (as defined herein),
are  operated  under  two  separate  master  lease  arrangements.  Under  these  master  leases,  a  breach  at  a  single  community  could  subject  one  or  more  of  the  other
communities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under
several of the Company’s leases and master leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the
master lease without the consent of the landlord.

The components of operating lease cost, are as follows:

Operating lease costs:
Facility rent—cost of services
Office rent—cost of services
Sublease income

Rent—cost of services

General and administrative expense
Variable lease cost

(a)

2021

Year Ended December 31,
2020

2019

$

$

$
$

35,958  $
4,905 
— 
40,863  $

276  $
6,248  $

35,562  $
3,772 
(143)
39,191  $

295 
5,330 

32,011 
2,964 
— 
34,975 

162 
4,608 

(a)

Represents variable lease cost for operating leases, which costs include property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple
net lease, and which is included in cost of services for the years ended December 31, 2021, 2020 and 2019.

78

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The following table shows the lease maturity analysis for all leases as of December 31, 2021:

Year
2022
2023
2024
2025
2026
Thereafter
Total lease payments

Less: present value adjustments
Present value of total lease liabilities

Less: current lease liabilities

Long-term operating lease liabilities

Amount

38,929 
37,978 
36,906 
35,778 
35,078 
320,664 
505,333 
(201,462)
303,871 
(16,118)
287,753 

$

$

Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present
value of lease payments, the Company used its incremental borrowing rate based on the information available at each lease’s commencement date to determine
each lease's operating lease liability. As of December 31, 2021, the weighted average remaining lease term is 14.1 years and the weighted average discount rate is
7.9%.

14. INCOME TAXES

The provision for income tax expense for the years ended December 31, 2021, 2020 and 2019 is summarized as follows:

Current:

Federal
State

Total current

Deferred:
Federal
State

Total deferred

Total income tax expense

2021

Year Ended December 31,
2020

2019

$

$

1,768  $
566 
2,334 

(1,360)
(392)
(1,752)

582  $

5,058  $
1,478 
6,536 

(3,348)
(838)
(4,186)
2,350  $

562 
278 
840 

1,070 
175 
1,245 
2,085 

79

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2021, 2020

and 2019, respectively, is comprised as follows:

(c)

Income tax expense at statutory rate
State income taxes - net of federal benefit
Non-deductible meals and entertainment
Non-deductible equity compensation
Section 162(m) limitation
Non-deductible accrued bonus
Other non-deductible expenses
Transaction costs
Tax credits
Deductible equity compensation
Noncontrolling interest
Other adjustments

(b)

(a)

Total income tax provision

(d)

2021

Year Ended December 31,
2020

2019

21.0 %
3.9 
1.8 
19.4 
2.1 
2.7 
0.7 
— 
— 
(34.1)
5.0 
(1.2)
21.3 %

21.0 %
2.7 
0.3 
— 
— 
— 
0.1 
— 
— 
(10.8)
0.3 
(0.5)
13.1 %

21.0 %
6.8 
1.8 
— 
— 
— 
0.8 
41.2 
(1.6)
(30.0)
— 
(0.4)
39.6 %

(a)

(b)

(c)

(d)

The Company's completion of the Spin-Off in the year ended December 31, 2019 resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which
increased the effective tax rate significantly and affected all items that were impacted by this exclusion.
During  the  year  ended  December  31,  2021,  employees  exercised  stock  options  representing  approximately  115  shares.  During  the  year  ended  December  31,  2020,  employees  exercised  stock
options  representing  approximately  239  shares.  During  the  year  ended  December  31,  2019,  employees  exercised  stock  options  representing  approximately  100  shares  and  had  restricted  stock
awards vest representing 960 shares. These exercises and vestings resulted in tax benefits that reduced the Company's effective tax rate significantly in all three years.
During the year ended December 31, 2021, approximately $2,528 of the share-based compensation expense related to restricted stock did not result in a deferred tax asset because it will be subject
to future limitation under IRC Section 162(m).
Certain items in the prior year have been reclassified to conform with the current year presentation.

Prior to the date of the Spin-Off, the Company's operations were included in Ensign’s U.S. federal and state income tax returns and all income taxes were
paid by subsidiaries of Ensign. Additionally, prior to the date of the Spin-Off, income tax expense and other income tax related information contained in these
Consolidated and Combined Financial Statements for the year ended 2019 were presented on a separate tax return approach. Under this approach, the provision for
income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company were a
stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts were
reasonable. However, the Company's Consolidated and Combined Financial Statements or the year ended 2019 may not necessarily reflect the Company’s income
tax expense or tax payments in the future, or what its tax amounts would have been if the Company had been a stand-alone company during the periods presented.

80

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

The Company’s deferred tax assets and liabilities for the years ended December 31, 2021 and 2020 are summarized below.

Deferred tax assets (liabilities):
Accrued expenses
Allowance for doubtful accounts
State taxes
Lease liabilities
Insurance
Gross deferred tax assets
Less: valuation allowance
Net deferred tax assets
Depreciation and amortization
Prepaid expenses
Right of use asset
State taxes

Total deferred tax liabilities

Net deferred tax assets (liabilities)

Year Ended December 31,
2020
2021

$

$

9,829  $
1,728 
— 
79,575 
953 
92,085 
(25)
92,060 
(8,432)
(907)
(78,656)
(217)
(88,212)

3,848  $

8,181 
875 
147 
80,979 
277 
90,459 
(15)
90,444 
(7,512)
(780)
(80,055)
— 
(88,347)
2,097 

During the year ended December 31, 2020, the Company utilized all of its net operating loss ("NOL") carryforwards for federal income tax purposes. As
of December 31, 2021, the Company has $614 of NOL carryforwards in various states, which are available to reduce future state taxable income, if any. The state
NOL carryforwards, if not utilized, will expire in years ending between December 31, 2030 and December 31, 2040. The Company believes that it is more likely
than not that the benefit from the state NOL carryforwards in jurisdictions where we do not file a consolidated return will not be realized. In recognition of this
risk, as of December 31, 2021, the Company has provided a valuation allowance of $25 on the deferred tax assets related to these states for the tax effect of the
NOL carryforwards that will not be realized.

The federal statutes of limitations on the Company’s 2017, 2016, and 2015 income tax years lapsed during the third quarter of 2021, 2020, and 2019,
respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2021 and 2020
had no impact on the Company’s unrecognized tax benefits.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

Balance at January 1
Additions for tax positions of prior years
Reductions for tax positions related to the current year

Balance at December 31

2021

Year Ended December 31,
2020

2019

$

—  $
188 
(123)

65  $

—  $
— 
— 
—  $

— 
— 
— 
— 

None of unrecognized tax benefits net of their state benefits would affect the Company’s effective tax rate for the years ended December 31, 2021 and
2020. The  Company  classifies  interest  and/or  penalties  on  income  tax  liabilities  or  refunds  as  additional  income  tax  expense  or  income.  Such  amounts  are  not
material.

15. COMMITMENTS AND CONTINGENCIES

Regulatory Matters - The Company provides services in complex and highly regulated industries. The Company’s compliance with applicable federal,

state and local laws and regulations governing these industries may be subject to

81

 
Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

governmental review and adverse findings may result in significant regulatory action, which could include sanctions, damages, fines, penalties (many of which
may not be covered by insurance), and even exclusion from government programs. The Company is a party to various regulatory and other governmental audits
and investigations in the ordinary course of business and cannot predict the ultimate outcome of any federal or state regulatory survey, audit or investigation. While
governmental audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The
Department  of  Justice,  CMS,  or  other  federal  and  state  enforcement  and  regulatory  agencies  may  conduct  additional  investigations  related  to  the  Company's
businesses. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations.

Cost-Containment  Measures  -  Government  and  third  party  payors  have  instituted  cost-containment  measures  designed  to  limit  payments  made  to
providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the
Company.

Indemnities - From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against
third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior
operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer
agreements, in which the Company agrees to indemnify past operators of agencies and communities the Company acquires against certain liabilities arising from
the transfer of the operation and/or the operation thereof after the transfer, (iii) certain Ensign lending agreements, and (iv) certain agreements with management,
directors and employees, under which the subsidiaries of the Company may be required to indemnify such persons for liabilities arising out of their employment
relationships.  The  terms  of  such  obligations  vary  by  contract  and,  in  most  instances,  a  specific  or  maximum  dollar  amount  is  not  explicitly  stated  therein.
Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no
liabilities have been recorded for these obligations on the Company’s combined balance sheets for any of the periods presented.

Litigation  -  The  Company’s  businesses  involve  a  significant  risk  of  liability  given  the  age  and  health  of  the  patients  and  residents  served  by  its
independent operating subsidiaries. The Company, its operating companies, and others in the industry may be subject to a number of claims and lawsuits, including
professional  liability  claims,  alleging  that  services  provided  have  resulted  in  personal  injury,  elder  abuse,  wrongful  death  or  other  related  claims.  Healthcare
litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to
these claims in the ordinary course of business, including potential claims related to patient care and treatment, professional negligence and class actions, as well
as employment related claims. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in
their  prosecution  of  these  claims,  this  could  materially  adversely  affect  the  Company’s  business,  financial  condition,  results  of  operations  and  cash  flows.  In
addition,  the  defense  of  these  lawsuits  may  result  in  significant  legal  costs,  regardless  of  the  outcome,  and  can  result  in  large  settlement  amounts  or  damage
awards.

In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the False Claims Act (the “FCA”)
and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide
the  basis  for  exclusion  from  federally  funded  healthcare  programs.  Such  exclusions  could  have  a  correlative  negative  impact  on  the  Company’s  financial
performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations.

In  2009,  Congress  passed  the  Fraud  Enforcement  and  Recovery  Act  ("FERA")  which  made  significant  changes  to  the  FCA,  expanding  the  types  of
activities subject to prosecution and whistleblower liability. Following changes by FERA, healthcare providers face significant penalties for the knowing retention
of government overpayments, even if no false claim was involved. Providers can now be liable for knowingly and improperly avoiding or decreasing an obligation
to pay money or property to the government, including the retention of any government overpayment. The Patient Protection and Affordable Care Act of 2010 (the
“ACA”) supplemented FERA by imposing an affirmative obligation on healthcare providers to return an overpayment to CMS within 60 days of “identification”
or  the  date  any  corresponding  cost  report  is  due,  whichever  is  later.  Retention  of  any  overpayment  beyond  this  period  may  create  liability  under  the  FCA.  In
addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus,
there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company

and its operating companies are subjected to, alleged to be liable for, or agree to a settlement

82

Table of Contents

THE PENNANT GROUP, INC.
NOTES TO CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS - (Continued)

of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, the Company’s business, financial
condition and results of operations and cash flows could be materially and adversely affected. Among other things, any settlement or litigation could involve the
payment  of  substantial  sums  to  settle  any  alleged  civil  violations,  and  may  also  include  the  assumption  of  specific  procedural  and  financial  obligations  by  the
Company or its independent operating subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government.

Medicare Revenue Recoupments - The Company is subject to probe reviews relating to Medicare services, billings and potential overpayments by Unified
Program Integrity Contractors (UPIC), Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC),
Supplemental  Medical  Review  Contractors  (SMRC)  and  Medicaid  Integrity  Contributors  (MIC)  programs,  each  of  the  foregoing  collectively  referred  to  as
“Reviews.” As  of  December  31,  2021,  eight  of  the  Company’s  independent  operating  subsidiaries  had  Reviews  scheduled,  on  appeal  or  in  dispute  resolution
process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If an operation fails an initial or
subsequent Review, the operation could then be subject to extended Review, suspension of payment, or extrapolation of the identified error rate to all billing in the
same time period. As of December 31, 2021, and through the filing of this Annual Report on Form 10-K, the Company’s independent operating subsidiaries have
responded to the Reviews that are currently ongoing, on appeal or in dispute resolution process and the Company has no probable or estimable contingencies.

One hospice provider number is subject to a Medicare payment suspension imposed by a Uniform Program Integrity Contractor (UPIC). As of December
31,  2021  the  UPIC  requested  for  review  42  patient  records  covering  a  4-month  period  to  determine  whether,  in  its  view,  a  Medicare  overpayment  was  made.
Subsequent  to  December  31,  2021  the  UPIC  expanded  upon  its  initial  request  to  cover  an  additional  60  patient  records  over  an  additional  6-month  period.
Medicare payments to that provider number are suspended pending the conclusion of the UPIC’s review. The payments suspended as of December 31, 2021 total
$3,700. The suspended amounts represent all Medicare payments due to the provider number since the start of the suspension and are not an overpayment finding.
If the UPIC concludes that an overpayment exists, it will recover the overpayment from the suspended funds and release the excess funds, if any, to the provider.
The UPIC has not specified when the payment suspension will end or when it will reach an over-payment determination.

Concentrations

Credit Risk - The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain
governmental  programs,  primarily  Medicare  and  Medicaid.  These  receivables  represent  the  only  significant  concentration  of  credit  risk  for  the  Company.  The
Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has
been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s
gross receivables from the Medicare and Medicaid programs accounted for approximately 78.6% and 75.7% of its total gross accounts receivable as of December
31, 2021 and December 31, 2020, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 62.6%, 60.1%, and 55.6%
of the Company's revenue for the years ended December 31, 2021, 2020 and 2019, respectively.

16. SUBSEQUENT EVENT

On  January  27,  2022,  affiliates  of  the  Company,  entered  into  certain  operations  transfer  agreements  (collectively,  the  “Transfer  Agreements”)  with
affiliates of Ensign, providing for the transfer of the operations of certain senior living communities (the “Transaction”). The Transfer Agreements require one of
the  transferors  to  place  in  escrow  $6,500  to  cover  post-closing  capital  expenditures  and  operating  losses  related  to  one  of  the  communities.  The  closing  of  the
Transaction  is  anticipated  to  occur  in  the  first  half  of  2022,  subject  to  receipt  of  applicable  regulatory  approvals  and  satisfaction  of  other  customary  closing
conditions set forth in the Transfer Agreements. As such, management determined that the long-lived assets for the impacted communities were impaired and the
Company recognized a non-cash charge of $2,613 in its operating results for the year ended December 31, 2021, included in the transaction.

83

As of December 31, 2021, The Pennant Group, Inc. has registered one class of securities under Section 12 of the Securities Exchange Act of 1934, as

DESCRIPTION OF SECURITIES

EXHIBIT 4.1

amended (the “Exchange Act”).

Description of Common Stock

The following description of our Common Stock (as defined below) is a summary and does not purport to be complete. It is subject to and qualified in its
entirety by reference to our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our Amended and Restated By-laws (the
“Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part. We encourage you to read
our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporate Law (the “DGCL”), for additional information.

Authorized Capital Shares

Our authorized capital shares consist of 100,000,000 shares of common stock, $0.001 par value per share (“Common Stock”), and 1,000,000 shares of

preferred stock, $0.001 par value per share (“Preferred Stock”).

We  have  outstanding  shares  of  Common  Stock.  The  outstanding  shares  of  our  Common  Stock  are  fully  paid  and  non-assessable.  This  means  the  full
purchase price for the outstanding shares of Common Stock has been paid and the holders of such shares will not be assessed any additional amounts for such
shares. Any additional shares of Common Stock that the Company may issue in the future will also be fully paid and non-assessable.

Voting Rights

Each  share  of  Common  Stock  is  entitled  to  one  vote  on  all  matters  submitted  to  a  vote  of  the  stockholders,  including  the  election  of  directors.  Our
Common Stock does not have cumulative voting rights. This means a holder of a single share of Common Stock cannot cast more than one vote for each position
to be filled on the Board of Directors. It also means the holders of a majority of the shares of Common Stock entitled to vote in the election of directors can elect
all directors standing for election and the holders of the remaining shares will not be able to elect any directors.

Dividend Rights

Subject to the rights of holders of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends, if any, as
may be declared from time to time by the Board of Directors in its discretion out of funds legally available for the payment of dividends. Delaware law allows a
corporation to pay dividends only out of surplus, as determined under the DGCL.

Liquidation Rights

Upon  the  liquidation,  dissolution  or  winding  up  of  the  Company,  the  holders  of  Common  Stock  are  entitled  to  receive  ratably  the  net  assets  of  the
Company  legally  available  for  distribution  after  we  have  paid  or  provided  for  all  of  our  liabilities  and  all  of  the  preferential  amounts  to  which  any  holders  of
Preferred Stock, if any, may be entitled.

Other Rights and Preferences

Our Common Stock has no sinking fund or redemption provisions or pre-emptive, conversion or exchange rights.

Stockholder Action by Written Consent

Our  Certificate  of  Incorporation  and  Bylaws  prohibit  stockholder  action  by  written  consent  except  when  the  action  to  be  taken  has  previously  been

approved by our Board of Directors.

Exclusive Jurisdiction of Certain Actions

Our Certificate of Incorporation provides that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of
the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (1) derivative action or proceeding brought on behalf of
the Company, (2) action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the Company to the Company or our
stockholders,  or  any  claim  for  aiding  and  abetting  any  such  alleged  breach,  (3)  action  asserting  a  claim  against  the  Company  or  any  director  or  officer  of  the
Company arising pursuant to any provision of the DGCL or the Certificate of Incorporation or our Bylaws, or (4) action asserting a claim against us or any director
or officer of the Company governed by the internal affairs doctrine except for, as to each of (1) through (4) above, any claim (A) as to which the Court of Chancery
determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal
jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than
the Court of Chancery, or (C) arising under the federal securities laws, including the Securities Act of 1933, as amended, as to which the Court of Chancery and the
federal  district  court  for  the  District  of  Delaware  shall  concurrently  be  the  sole  and  exclusive  forums.  Notwithstanding  the  foregoing,  the  provisions  of  this
paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the
United States of America shall be the sole and exclusive forum. The foregoing may have the effect of discouraging lawsuits against the Company’s directors and
officers.

Listing

The Common Stock is traded on The Nasdaq Global Select Market under the trading symbol “PNTG.”

The following is a list of subsidiaries of The Pennant Group, Inc. as of December 31, 2021:

List of Subsidiaries of The Pennant Group, Inc.

Exhibit 21.1

Subsidiary
2410 Stillhouse Senior Living, Inc.
Alpowa Healthcare, Inc.
Arches Home Care, Inc.
Autumn Ridge Senior Living, Inc.
Beach City Senior Living LLC
Bear River Healthcare LLC
Black Mountain Healthcare LLC
Brenwood Park Senior Living, Inc.
Brookhollow Senior Living LLC
Brown Road Senior Housing LLC
Bruce Neenah Senior Living, Inc.
Cactus Heights Healthcare LLC
Canyon Healthcare, Inc.
Care Continuum Solutions LLC
Capitol Healthcare, Inc.
CCS Holding LLC
Cedar Senior Living, Inc.
Clark Fork Healthcare LLC
Clear Creek Healthcare, Inc.
Connected Healthcare, Inc.
Copper Basin Healthcare, Inc.
Cornerstone Healthcare, Inc.
Cornerstone Service Center, Inc.
Crown Point Healthcare LLC
Custom Care Healthcare, Inc.
De Soto Senior Living, Inc.
Denmark Senior Living, Inc.
Eagle Pass Senior Living LLC
Elkhorn Healthcare LLC
Emblem Healthcare, Inc.
Emerald Healthcare, Inc.
Eureka Healthcare, Inc.
Exemplar Healthcare, Inc.
Finding Home Healthcare, Inc.
Glacier Peak Healthcare, Inc.
Go Assisted, Inc.
Granite Healthcare, Inc.

Jurisdiction
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Delaware
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Granite Hills Senior Living, Inc.
Great Lakes Healthcare, Inc.
Great Plains Healthcare, Inc.
Green Bay Senior Living, Inc.
Heartland Healthcare, Inc.
Hummingbird Healthcare LLC
iCare Private Duty, Inc.
Indigo Healthcare LLC
Iron Bridge Healthcare, Inc.
Jameson Senior Living, Inc.
Jentilly Healthcare LLC
Joshua Tree Healthcare, Inc.
Kenosha Senior Living, Inc.
Keystone Hospice Care, Inc.
Lake Pointe Senior Living, Inc.
Lemon Senior Living LLC
Lowes Senior Living, Inc.
Madison Senior Living, Inc.
Manitowoc Senior Living, Inc.
McFarland Senior Living, Inc.
Mesa Grande Senior Living, Inc.
Mesa Springs Senior Living LLC
Mission Inn Senior Living LLC
Mohave Healthcare, Inc.
Monument Healthcare, Inc.
Moss Bay Senior Living, Inc.
Mountain Peak Home Care, Inc.
Mountain Vista Senior Living, Inc.
Oceano Senior Living, Inc.
Oceanside Healthcare, Inc.
Orange Senior Living, Inc.
Orangewood Senior Living, Inc.
Orchard Prairie Healthcare LLC
Painted Sky Healthcare, Inc.
Paragon Healthcare, Inc.
Park Point Healthcare LLC
Peaceful Heart Healthcare LLC
Pearl Senior Living, Inc.
Pecan Bayou Healthcare LLC
Pennant Services, Inc.
Pinnacle Senior Living LLC
Pinnacle Service Center LLC
Pleasant Run Senior Living, Inc.

Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Prairie View Healthcare, Inc.
Primrose Senior Living, Inc.
Prospect Senior Living, Inc.
Racine Senior Living, Inc.
Rancho Bernardo Healthcare LLC
Red Rock Healthcare, Inc.
Riverview Village Senior Living, Inc.
Rock Garden Healthcare LLC
Rockbrook Senior Living, Inc.
Rogue River Healthcare LLC
Rolling Hills Healthcare, Inc.
Rosenburg Senior Living, Inc.
Sacramento River Healthcare LLC
Saguaro Senior Living, Inc.
San Gabriel Senior Living, Inc.
Sand Lily Healthcare, Inc.
Sandstone Senior Living, Inc.
Sentinel Healthcare LLC
Sheboygan Senior Living, Inc.
Silver Lake Healthcare, Inc.
Somers Kenosha Senior Living, Inc.
South Bay Healthcare, Inc.
South Plains Healthcare, Inc.
Southern Pines Healthcare LLC
Spanish Meadows Healthcare LLC
Spokane Healthcare, Inc.
Spring Valley Assisted Living, Inc.
Star Valley Healthcare, Inc.
Stevens Point Senior Living, Inc.
Stoughton Senior Living, Inc.
Summerlin Healthcare, Inc.
Sun Peak Healthcare LLC
Sycamore Senior Living, Inc.
Symbol Healthcare, Inc.
Terrace Court Senior Living, Inc.
Teton Healthcare, Inc.
The Pennant Group, Inc.
Thomas Road Senior Housing, Inc.
Thousand Peaks Healthcare, Inc.
Total Healtcare Services LLC
Triumph Healthcare LLC
Twin Falls Senior Living LLC
Two Rivers Senior Living, Inc.

Nevada
Nevada
Nevada
Nevada
Delaware
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Delaware
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Vesper Healthcare, Inc.
Victoria Ventura Assisted Living Community, Inc.
Virgin River Healthcare, Inc.
Whitewater Healthcare LLC
Whitetank Mountain Healthcare LLC
Willow Creek Senior Living, Inc.
Wisconsin Rapids Senior Living, Inc.

Nevada
Nevada
Nevada
Nevada
Nevada
Nevada
Nevada

  
  
  
  
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-233937 on Form S-8 of our reports dated February 28, 2022, relating to the
financial statements of The Pennant Group, Inc. and the effectiveness of the Pennant Group, Inc.’s internal control over financial reporting appearing in this
Annual Report on Form 10-K for the year ended December 31, 2021.

EXHIBIT 23.1

/s/ DELOITTE & TOUCHE LLP

Boise, Idaho
February 28, 2022

I, Daniel H Walker, certify that:

EXHIBIT 31.1

1.

I have reviewed this annual report on Form 10-K of The Pennant Group, Inc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the

statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness

of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely

to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over

financial reporting.

Date: February 28, 2022

/s/ DANIEL H WALKER

Name:  Daniel H Walker

Title:  

Chairman and Chief Executive Officer (Principal
Executive Officer)

 
 
   
 
 
 
 
 
 
 
I, Jennifer L. Freeman, certify that:

EXHIBIT 31.2

1.

I have reviewed this annual report on Form 10-K of The Pennant Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the

statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness

of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely

to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over

financial reporting.

Date: February 28, 2022

/s/ JENNIFER L. FREEMAN
Name: 

Title:  

Jennifer L. Freeman
Chief Financial Officer (Principal Financial
Officer, Principal Accounting Officer and Duly
Authorized Officer)

 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In  connection  with  the  Annual  Report  of  The  Pennant  Group,  Inc.  (the  Company)  on  Form  10-K  for  the  period  ended  December  31,  2021,  as  filed  with  the
Securities and Exchange Commission on the date hereof (the Report), I, Daniel H Walker, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

EXHIBIT 32.1

2   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ DANIEL H WALKER
Name:  

Title:  

Daniel H Walker
Chairman and Chief Executive Officer (Principal
Executive Officer)

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.

February 28, 2022

 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.2

In  connection  with  the  Annual  Report  of  The  Pennant  Group,  Inc.  (the  Company)  on  Form  10-K  for  the  period  ended  December  31,  2021,  as  filed  with  the
Securities  and  Exchange  Commission  on  the  date  hereof  (the  Report),  I,  Jennifer  L.  Freeman,  Chief  Financial  Officer  of  the  Company,  certify,  pursuant  to  18
U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ JENNIFER L. FREEMAN
Name: 

Title:  

Jennifer L. Freeman 
Chief Financial Officer (Principal Financial
Officer, Principal Accounting Officer and Duly
Authorized Officer)

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.

February 28, 2022